PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
12909723-0	2003	The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells.	13-hydroxy-9,11-octadecadienoic acid	30-62	peroxisome proliferator activator receptor delta	Mus musculus	78-88
12909723-8	2003	Our current study shows that (i) 13-S-HODE binds to PPAR-delta, decreases PPAR-delta activation, and down-regulates PPAR-delta expression in colorectal cancer cells; (ii) the induction of 15-LOX-1 expression is a critical step in NSAID down-regulation of PPAR-delta and the resultant induction of apoptosis; and (iii) PPAR-delta is an important signaling receptor for 13-S-HODE-induced apoptosis.	13-hydroxy-9,11-octadecadienoic acid	33-42	peroxisome proliferator activator receptor delta	Mus musculus	52-62
12909723-8	2003	Our current study shows that (i) 13-S-HODE binds to PPAR-delta, decreases PPAR-delta activation, and down-regulates PPAR-delta expression in colorectal cancer cells; (ii) the induction of 15-LOX-1 expression is a critical step in NSAID down-regulation of PPAR-delta and the resultant induction of apoptosis; and (iii) PPAR-delta is an important signaling receptor for 13-S-HODE-induced apoptosis.	13-hydroxy-9,11-octadecadienoic acid	33-42	peroxisome proliferator activator receptor delta	Mus musculus	74-84
12909723-8	2003	Our current study shows that (i) 13-S-HODE binds to PPAR-delta, decreases PPAR-delta activation, and down-regulates PPAR-delta expression in colorectal cancer cells; (ii) the induction of 15-LOX-1 expression is a critical step in NSAID down-regulation of PPAR-delta and the resultant induction of apoptosis; and (iii) PPAR-delta is an important signaling receptor for 13-S-HODE-induced apoptosis.	13-hydroxy-9,11-octadecadienoic acid	33-42	peroxisome proliferator activator receptor delta	Mus musculus	74-84
12909723-8	2003	Our current study shows that (i) 13-S-HODE binds to PPAR-delta, decreases PPAR-delta activation, and down-regulates PPAR-delta expression in colorectal cancer cells; (ii) the induction of 15-LOX-1 expression is a critical step in NSAID down-regulation of PPAR-delta and the resultant induction of apoptosis; and (iii) PPAR-delta is an important signaling receptor for 13-S-HODE-induced apoptosis.	13-hydroxy-9,11-octadecadienoic acid	33-42	peroxisome proliferator activator receptor delta	Mus musculus	74-84
12909723-8	2003	Our current study shows that (i) 13-S-HODE binds to PPAR-delta, decreases PPAR-delta activation, and down-regulates PPAR-delta expression in colorectal cancer cells; (ii) the induction of 15-LOX-1 expression is a critical step in NSAID down-regulation of PPAR-delta and the resultant induction of apoptosis; and (iii) PPAR-delta is an important signaling receptor for 13-S-HODE-induced apoptosis.	13-hydroxy-9,11-octadecadienoic acid	33-42	peroxisome proliferator activator receptor delta	Mus musculus	74-84
12909723-10	2003	Our findings indicate that the down-regulation of PPAR-delta by 15-LOX-1 through 13-S-HODE is an apoptotic signaling pathway that is activated by NSAIDs.	13-hydroxy-9,11-octadecadienoic acid	81-90	peroxisome proliferator activator receptor delta	Mus musculus	50-60
12842194-0	2003	Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle.	Fatty Acids	87-97	peroxisome proliferator activator receptor delta	Mus musculus	35-83
12842194-5	2003	The rise of PPARdelta is accompanied by parallel up-regulations of fatty acid translocase/CD36 (FAT/CD36) and heart fatty acid binding protein (H-FABP), while refeeding promotes down-regulation of both genes.	Fatty Acids	67-77	peroxisome proliferator activator receptor delta	Mus musculus	12-21
12842194-5	2003	The rise of PPARdelta is accompanied by parallel up-regulations of fatty acid translocase/CD36 (FAT/CD36) and heart fatty acid binding protein (H-FABP), while refeeding promotes down-regulation of both genes.	heart fatty acid	110-126	peroxisome proliferator activator receptor delta	Mus musculus	12-21
12842194-7	2003	Differentiated C2C12 cells responds to 2-bromopalmitate or synthetic PPARdelta agonist by induction of genes involved in lipid metabolism and increment of fatty acid oxidation.	Fatty Acids	155-165	peroxisome proliferator activator receptor delta	Mus musculus	69-78
12842194-9	2003	These data strongly support a role for PPARdelta in the regulation of fatty acid oxidation in skeletal muscle and in adaptive response of this tissue to lipid catabolism.	Fatty Acids	70-80	peroxisome proliferator activator receptor delta	Mus musculus	39-48
12740443-4	2003	Natural and synthetic PPARgamma agonists, including the thiazolidinedione rosiglitazone (Ro), modestly induced the expression of a surprisingly small number of genes, several of which were also induced by a specific PPARdelta agonist.	thiazolidinedione rosiglitazone	56-87	peroxisome proliferator activator receptor delta	Mus musculus	216-225
12740443-4	2003	Natural and synthetic PPARgamma agonists, including the thiazolidinedione rosiglitazone (Ro), modestly induced the expression of a surprisingly small number of genes, several of which were also induced by a specific PPARdelta agonist.	Rosiglitazone	89-91	peroxisome proliferator activator receptor delta	Mus musculus	216-225
12740443-7	2003	At high concentrations, Ro inhibited induction of lipopolysaccharide target genes in PPARgamma-deficient macrophages, at least in part by activating PPARdelta.	Rosiglitazone	24-26	peroxisome proliferator activator receptor delta	Mus musculus	149-158
12705865-2	2003	We show here that targeted activation of PPARdelta in adipose tissue specifically induces expression of genes required for fatty acid oxidation and energy dissipation, which in turn leads to improved lipid profiles and reduced adiposity.	Fatty Acids	123-133	peroxisome proliferator activator receptor delta	Mus musculus	41-50
12705865-6	2003	In vitro, activation of PPARdelta in adipocytes and skeletal muscle cells promotes fatty acid oxidation and utilization.	Fatty Acids	83-93	peroxisome proliferator activator receptor delta	Mus musculus	24-33
12554792-3	2003	nTZDpa bound potently to PPARgamma with high selectivity vs. PPARalpha or PPARdelta.	nTzDpa	0-6	peroxisome proliferator activator receptor delta	Mus musculus	74-83
12061550-3	2002	Here we report that the ascochlorin derivative, 4-O-carboxymethyl ascochlorin (AS-6) acts as a potent activator of the nuclear hormone receptor, PPARgamma, although it does not activate the related receptors, PPARalpha, PPARdelta or RARalpha.	ascochlorin	24-35	peroxisome proliferator activator receptor delta	Mus musculus	220-229
12862494-3	2003	While PPARbeta expression is undetectable in unchallenged and healthy adult interfollicular mouse skin, it is robustly re-activated in stress situations, such as upon phorbol ester treatment, hair plucking and cutaneous wounding.	Phorbol Esters	167-180	peroxisome proliferator activator receptor delta	Mus musculus	6-14
12056592-8	2002	These data suggest that PPARbeta is involved in maintaining FA and phospholipid levels in adult female mouse brain and provide strong evidence that suggests a role for PPARbeta in brain peroxisomal acyl-CoA utilization.	Phospholipids	67-79	peroxisome proliferator activator receptor delta	Mus musculus	24-32
11779158-3	2002	PPARdelta is activated by unsaturated fatty acids, PGI2, and by synthetic ligands.	Fatty Acids, Unsaturated	26-49	peroxisome proliferator activator receptor delta	Mus musculus	0-9
11779158-3	2002	PPARdelta is activated by unsaturated fatty acids, PGI2, and by synthetic ligands.	Epoprostenol	51-55	peroxisome proliferator activator receptor delta	Mus musculus	0-9
12061550-3	2002	Here we report that the ascochlorin derivative, 4-O-carboxymethyl ascochlorin (AS-6) acts as a potent activator of the nuclear hormone receptor, PPARgamma, although it does not activate the related receptors, PPARalpha, PPARdelta or RARalpha.	4-O-carboxymethylascochlorin	79-83	peroxisome proliferator activator receptor delta	Mus musculus	220-229
10991946-0	2000	Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation.	Fatty Acids	80-90	peroxisome proliferator activator receptor delta	Mus musculus	15-63
11069900-0	2001	Peroxisome proliferator-activated receptor delta (PPARdelta )-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling.	Cyclic AMP	148-152	peroxisome proliferator activator receptor delta	Mus musculus	0-48
11069900-0	2001	Peroxisome proliferator-activated receptor delta (PPARdelta )-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling.	Cyclic AMP	148-152	peroxisome proliferator activator receptor delta	Mus musculus	50-59
11069900-4	2001	We demonstrate that treatment of NIH-3T3 fibroblasts overexpressing PPARdelta with standard adipogenic inducers led to induction of PPARgamma2 expression and terminal adipocyte differentiation in a manner that was strictly dependent on simultaneous administration of a PPARdelta ligand and methylisobutylxanthine (MIX) or other cAMP elevating agents.	1-Methyl-3-isobutylxanthine	290-312	peroxisome proliferator activator receptor delta	Mus musculus	68-77
11069900-4	2001	We demonstrate that treatment of NIH-3T3 fibroblasts overexpressing PPARdelta with standard adipogenic inducers led to induction of PPARgamma2 expression and terminal adipocyte differentiation in a manner that was strictly dependent on simultaneous administration of a PPARdelta ligand and methylisobutylxanthine (MIX) or other cAMP elevating agents.	1-Methyl-3-isobutylxanthine	290-312	peroxisome proliferator activator receptor delta	Mus musculus	269-278
11069900-4	2001	We demonstrate that treatment of NIH-3T3 fibroblasts overexpressing PPARdelta with standard adipogenic inducers led to induction of PPARgamma2 expression and terminal adipocyte differentiation in a manner that was strictly dependent on simultaneous administration of a PPARdelta ligand and methylisobutylxanthine (MIX) or other cAMP elevating agents.	Cyclic AMP	328-332	peroxisome proliferator activator receptor delta	Mus musculus	68-77
11069900-4	2001	We demonstrate that treatment of NIH-3T3 fibroblasts overexpressing PPARdelta with standard adipogenic inducers led to induction of PPARgamma2 expression and terminal adipocyte differentiation in a manner that was strictly dependent on simultaneous administration of a PPARdelta ligand and methylisobutylxanthine (MIX) or other cAMP elevating agents.	Cyclic AMP	328-332	peroxisome proliferator activator receptor delta	Mus musculus	269-278
11378687-14	2001	These structure-activity relationships indicate that PPAR-delta may be a potential mediator of VPA-induced differentiation of F9 cells and may possibly be involved in the mechanism of teratogenicity of VPA in vivo.	Valproic Acid	95-98	peroxisome proliferator activator receptor delta	Mus musculus	53-63
11284737-7	2001	Only the PPARdelta/alpha agonist GW2433 is able to up-regulate the gene encoding L-FABP in the intestine of PPARalpha-null mice.	GW 2433	33-39	peroxisome proliferator activator receptor delta	Mus musculus	9-18
11241737-11	2001	In the enriched cultures, the total number of OLs increases significantly in the PPAR delta agonist-treated groups, but BrdU immunostaining does not show an increased proliferation of cells.	N-biotin-C-Co4(mu3-O)4(Py)4(H2O)4-beta-alanine	46-49	peroxisome proliferator activator receptor delta	Mus musculus	81-91
10991946-2	2000	Ectopic expression of the nuclear receptors PPARgamma or PPARdelta promotes adipogenesis in fibroblastic cells exposed to thiazolidinediones or long-chain fatty acids.	Thiazolidinediones	122-140	peroxisome proliferator activator receptor delta	Mus musculus	57-66
10991946-2	2000	Ectopic expression of the nuclear receptors PPARgamma or PPARdelta promotes adipogenesis in fibroblastic cells exposed to thiazolidinediones or long-chain fatty acids.	long-chain fatty acids	144-166	peroxisome proliferator activator receptor delta	Mus musculus	57-66
10991946-4	2000	Overexpression of PPARdelta enhanced fatty acid induction of the adipose-related genes for fatty acid translocase, adipocyte lipid binding protein, and PPARgamma and fatty acid effects on terminal differentiation.	Fatty Acids	37-47	peroxisome proliferator activator receptor delta	Mus musculus	18-27
10991946-4	2000	Overexpression of PPARdelta enhanced fatty acid induction of the adipose-related genes for fatty acid translocase, adipocyte lipid binding protein, and PPARgamma and fatty acid effects on terminal differentiation.	Fatty Acids	91-101	peroxisome proliferator activator receptor delta	Mus musculus	18-27
10991946-7	2000	These data demonstrate that PPARdelta plays a central role in fatty acid-controlled differentiation of preadipose cells.	Fatty Acids	62-72	peroxisome proliferator activator receptor delta	Mus musculus	28-37
10926831-0	2000	Peroxisome-proliferator-activated receptor delta mediates the effects of long-chain fatty acids on post-confluent cell proliferation.	long-chain fatty acids	73-95	peroxisome proliferator activator receptor delta	Mus musculus	0-48
10969080-14	2000	In addition, inhibition of p38 led to decreased decidualization suggesting that an intracrine prostanoid pathway consisting of Cox-2, prostacyclin, and PPARdelta is required for maintenance of early pregnancy.	Prostaglandins	94-104	peroxisome proliferator activator receptor delta	Mus musculus	152-161
11108658-4	2000	The PPARgamma and PPARdelta activators troglitazone and bezafibrate, respectively, exerted little, if any, inhibitory activity.	Troglitazone	39-51	peroxisome proliferator activator receptor delta	Mus musculus	18-27
10926831-4	2000	We have recently demonstrated that PPARdelta, once activated by fatty acids, drives the expression of a limited set of genes, including that encoding PPARgamma, thereby inducing adipose differentiation.	Fatty Acids	64-75	peroxisome proliferator activator receptor delta	Mus musculus	35-44
10926831-6	2000	We show here that PPARdelta is directly implicated in fatty acid-induced cell proliferation.	Fatty Acids	54-64	peroxisome proliferator activator receptor delta	Mus musculus	18-27
10926831-7	2000	Ectopic expression of PPARdelta renders 3T3C2 cells capable of responding to treatment with long-chain fatty acids by a resumption of mitosis, and this effect is limited to a few days after confluence.	long-chain fatty acids	92-114	peroxisome proliferator activator receptor delta	Mus musculus	22-31
10926831-9	2000	Furthermore, the use of a mutated inactive PPARdelta demonstrated that transcriptional activity of the nuclear receptor is required to mediate fatty acid-induced proliferation.	Fatty Acids	143-153	peroxisome proliferator activator receptor delta	Mus musculus	43-52
10926831-10	2000	These data demonstrate that PPARdelta, as a transcription factor, is directly implicated in fatty acid-induced proliferation, and this could explain the hyperplastic development of adipose tissue that occurs in high-fat-fed animals.	Fatty Acids	92-102	peroxisome proliferator activator receptor delta	Mus musculus	28-37
10675550-5	2000	Carbaprostacyclin, a PPARbeta ligand, also inhibited cytokine production, whereas PPARalpha ligands did not.	carboprostacyclin	0-17	peroxisome proliferator activator receptor delta	Mus musculus	21-29
10818235-3	2000	Here we show that treatment of insulin resistant db/db mice with the PPARdelta agonist L-165041, at doses that had no effect on either glucose or triglycerides, raised total plasma cholesterol concentrations.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	87-95	peroxisome proliferator activator receptor delta	Mus musculus	69-78
10818235-3	2000	Here we show that treatment of insulin resistant db/db mice with the PPARdelta agonist L-165041, at doses that had no effect on either glucose or triglycerides, raised total plasma cholesterol concentrations.	Cholesterol	181-192	peroxisome proliferator activator receptor delta	Mus musculus	69-78
10818235-7	2000	These data suggest both that PPARdelta is involved in the regulation of cholesterol metabolism in db/db mice and that PPARdelta ligands could potentially have therapeutic value.	Cholesterol	72-83	peroxisome proliferator activator receptor delta	Mus musculus	29-38
10866668-6	2000	The hyperplastic response observed in the epidermis after TPA application was significantly greater in the PPARbeta-null mice than in controls.	Tetradecanoylphorbol Acetate	58-61	peroxisome proliferator activator receptor delta	Mus musculus	107-115
10195695-4	1999	Likewise, topical treatment of mouse skin with PMA results in increased PPARbeta mRNA expression in the epidermis.	Tetradecanoylphorbol Acetate	47-50	peroxisome proliferator activator receptor delta	Mus musculus	72-80
10385625-0	1999	Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta.	Epoprostenol	26-38	peroxisome proliferator activator receptor delta	Mus musculus	85-94
10385625-4	1999	Several lines of evidence suggest that the effects of PGI2 are mediated by its activation of the nuclear hormone receptor PPARdelta, demonstrating the first reported biologic function of this receptor signaling pathway.	Epoprostenol	54-58	peroxisome proliferator activator receptor delta	Mus musculus	122-131
10511291-3	1999	Among fatty acids, prostacyclin produced from arachidonic acid enhances the expression of both C/EBPs through cell surface IP receptor and presumably activates PPARdelta.	Fatty Acids	6-17	peroxisome proliferator activator receptor delta	Mus musculus	160-169
10511291-3	1999	Among fatty acids, prostacyclin produced from arachidonic acid enhances the expression of both C/EBPs through cell surface IP receptor and presumably activates PPARdelta.	Epoprostenol	19-31	peroxisome proliferator activator receptor delta	Mus musculus	160-169
10511291-3	1999	Among fatty acids, prostacyclin produced from arachidonic acid enhances the expression of both C/EBPs through cell surface IP receptor and presumably activates PPARdelta.	Arachidonic Acid	46-62	peroxisome proliferator activator receptor delta	Mus musculus	160-169
10037770-3	1999	Here we characterized novel, non-thiazolidinedione agonists for PPARgamma and PPARdelta that were identified by radioligand binding assays.	2,4-thiazolidinedione	33-50	peroxisome proliferator activator receptor delta	Mus musculus	78-87
34774619-0	2021	Dimethyl itaconate attenuates palmitate-induced insulin resistance in skeletal muscle cells through the AMPK/FGF21/PPARdelta-mediated suppression of inflammation.	dimethyl itaconate	0-18	peroxisome proliferator activator receptor delta	Mus musculus	115-124
34774619-8	2021	AMPK phosphorylation, as well as PPARdelta and myokine FGF21 expression, were enhanced in C2C12 myocytes by DITA treatment.	dimethyl itaconate	108-112	peroxisome proliferator activator receptor delta	Mus musculus	33-42
34774619-10	2021	SIGNIFICANCE: In sum, DITA suppresses inflammation through the AMPK/FGF21/PPARdelta signaling, thereby alleviating insulin resistance in palmitate-treated C2C12 myocytes.	dimethyl itaconate	22-26	peroxisome proliferator activator receptor delta	Mus musculus	74-83
34649350-3	2021	Activation of PPARdelta by the specific ligand GW501516 led to a dose-dependent decrease in ferroptotic cell death triggered by xCT deficiency, along with decreased levels of intracellular iron accumulation and lipid peroxidation.	GW 501516	47-55	peroxisome proliferator activator receptor delta	Mus musculus	14-23
34454927-6	2021	At transcription level, beta-elemene augmented the mRNA expression of fatty acid oxidation-associated genes, such as peroxisome proliferator-activated receptor-beta (PPARbeta).	beta-elemene	24-36	peroxisome proliferator activator receptor delta	Mus musculus	117-164
34454927-6	2021	At transcription level, beta-elemene augmented the mRNA expression of fatty acid oxidation-associated genes, such as peroxisome proliferator-activated receptor-beta (PPARbeta).	Fatty Acids	70-80	peroxisome proliferator activator receptor delta	Mus musculus	117-164
34649350-3	2021	Activation of PPARdelta by the specific ligand GW501516 led to a dose-dependent decrease in ferroptotic cell death triggered by xCT deficiency, along with decreased levels of intracellular iron accumulation and lipid peroxidation.	Iron	189-193	peroxisome proliferator activator receptor delta	Mus musculus	14-23
34649350-4	2021	These effects of GW501516 were abolished by PPARdelta-targeting small interfering RNA (siRNA) and the PPARdelta inhibitor GSK0660, indicating that PPARdelta inhibits xCT deficiency-induced ferroptosis.	GW 501516	17-25	peroxisome proliferator activator receptor delta	Mus musculus	44-53
34649350-4	2021	These effects of GW501516 were abolished by PPARdelta-targeting small interfering RNA (siRNA) and the PPARdelta inhibitor GSK0660, indicating that PPARdelta inhibits xCT deficiency-induced ferroptosis.	GW 501516	17-25	peroxisome proliferator activator receptor delta	Mus musculus	102-111
34649350-4	2021	These effects of GW501516 were abolished by PPARdelta-targeting small interfering RNA (siRNA) and the PPARdelta inhibitor GSK0660, indicating that PPARdelta inhibits xCT deficiency-induced ferroptosis.	GW 501516	17-25	peroxisome proliferator activator receptor delta	Mus musculus	147-156
34649350-5	2021	In addition, GW501516-activated PPARdelta time- and dose-dependently upregulated catalase expression at both the mRNA and protein levels.	GW 501516	13-21	peroxisome proliferator activator receptor delta	Mus musculus	32-41
34649350-7	2021	Consistently, the effects of GW501516 on ferroptosis of xCT-deficient MEFs were counteracted in the presence of 3-amino-1,2,4-triazole, a specific inhibitor of catalase, suggesting that catalase is essential for the effect of PPARdelta on ferroptosis triggered by xCT deficiency.	GW 501516	29-37	peroxisome proliferator activator receptor delta	Mus musculus	226-235
34649350-7	2021	Consistently, the effects of GW501516 on ferroptosis of xCT-deficient MEFs were counteracted in the presence of 3-amino-1,2,4-triazole, a specific inhibitor of catalase, suggesting that catalase is essential for the effect of PPARdelta on ferroptosis triggered by xCT deficiency.	Amitrole	112-134	peroxisome proliferator activator receptor delta	Mus musculus	226-235
34649350-8	2021	GW501516-activated PPARdelta stabilized peroxisomes through catalase upregulation by targeting peroxisomal hydrogen peroxide-mediated lysosomal rupture, which led to ferroptosis of xCT-deficient MEFs.	GW 501516	0-8	peroxisome proliferator activator receptor delta	Mus musculus	19-28
34649350-8	2021	GW501516-activated PPARdelta stabilized peroxisomes through catalase upregulation by targeting peroxisomal hydrogen peroxide-mediated lysosomal rupture, which led to ferroptosis of xCT-deficient MEFs.	Hydrogen Peroxide	107-124	peroxisome proliferator activator receptor delta	Mus musculus	19-28
34380027-1	2021	Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) activates AMP-activated protein kinase (AMPK) and plays a crucial role in glucose and lipid metabolism.	Glucose	145-152	peroxisome proliferator activator receptor delta	Mus musculus	0-69
34397170-7	2021	Importantly, MAPC exposure to the PPARdelta antagonist in the presence of a COX-2 inhibitor indomethacin before administration significantly reduced the efficacy of PPARdelta antagonized MAPCs in the aGvHD humanized mouse model.	mapc	13-17	peroxisome proliferator activator receptor delta	Mus musculus	34-43
34397170-7	2021	Importantly, MAPC exposure to the PPARdelta antagonist in the presence of a COX-2 inhibitor indomethacin before administration significantly reduced the efficacy of PPARdelta antagonized MAPCs in the aGvHD humanized mouse model.	mapc	13-17	peroxisome proliferator activator receptor delta	Mus musculus	165-174
34397170-7	2021	Importantly, MAPC exposure to the PPARdelta antagonist in the presence of a COX-2 inhibitor indomethacin before administration significantly reduced the efficacy of PPARdelta antagonized MAPCs in the aGvHD humanized mouse model.	Indomethacin	92-104	peroxisome proliferator activator receptor delta	Mus musculus	165-174
34397170-7	2021	Importantly, MAPC exposure to the PPARdelta antagonist in the presence of a COX-2 inhibitor indomethacin before administration significantly reduced the efficacy of PPARdelta antagonized MAPCs in the aGvHD humanized mouse model.	mapcs	187-192	peroxisome proliferator activator receptor delta	Mus musculus	34-43
34397170-7	2021	Importantly, MAPC exposure to the PPARdelta antagonist in the presence of a COX-2 inhibitor indomethacin before administration significantly reduced the efficacy of PPARdelta antagonized MAPCs in the aGvHD humanized mouse model.	mapcs	187-192	peroxisome proliferator activator receptor delta	Mus musculus	165-174
33538151-10	2021	EPA induced the up-regulation of genes downstream of PPARdelta, such as carnitine palmitoyltransferase-1alpha and angiopoietin-like protein 4 (Angptl4), in mature/immature neutrophils in vitro and inhibited enhanced mobilization in mice fed with FFD in vivo.	Eicosapentaenoic Acid	0-3	peroxisome proliferator activator receptor delta	Mus musculus	53-62
33538151-12	2021	Collectively, PPARdelta signaling in BM mature/immature neutrophils induced by dietary fatty acids negatively regulates mobilization, at least partially, via Angptl4 production.	dietary fatty acids	79-98	peroxisome proliferator activator receptor delta	Mus musculus	14-23
35093536-6	2022	PPARdelta, rather than PPARalpha or PPARgamma, is involved in the anti-ROS effect of BBR, as evidenced by the siRNA transfection and specific antagonist treatment data.	Reactive Oxygen Species	71-74	peroxisome proliferator activator receptor delta	Mus musculus	0-9
35605662-7	2022	The suppressive effect of seladelpar on Cyp7a1 expression was blocked by a JNK inhibitor as well as in the absence of Fgf21, indicating that Fgf21 plays an indispensable role in PPARdelta-mediated downregulation of Cyp7a1.	Seladelpar	26-36	peroxisome proliferator activator receptor delta	Mus musculus	178-187
35562376-5	2022	Furthermore, PPARdelta ligand activation by a high-fat diet or GW501516 (a highly selective, synthetic PPARdelta ligand) in mutant KRASG12D (KRASmu) pancreatic epithelial cells strongly accelerates PanIN progression to PDAC.	GW 501516	63-71	peroxisome proliferator activator receptor delta	Mus musculus	13-22
35562376-5	2022	Furthermore, PPARdelta ligand activation by a high-fat diet or GW501516 (a highly selective, synthetic PPARdelta ligand) in mutant KRASG12D (KRASmu) pancreatic epithelial cells strongly accelerates PanIN progression to PDAC.	GW 501516	63-71	peroxisome proliferator activator receptor delta	Mus musculus	103-112
35093536-0	2022	Novel mechanistic insight on the neuroprotective effect of berberine: The role of PPARdelta for antioxidant action.	Berberine	59-68	peroxisome proliferator activator receptor delta	Mus musculus	82-91
35605662-0	2022	Selective PPARdelta agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway.	Seladelpar	28-38	peroxisome proliferator activator receptor delta	Mus musculus	10-19
35605662-1	2022	Peroxisome proliferator-activated receptor delta (PPARdelta) agonists have been shown to exert beneficial effects in liver disease and reduce total bile acid levels.	Bile Acids and Salts	148-157	peroxisome proliferator activator receptor delta	Mus musculus	0-48
35605662-1	2022	Peroxisome proliferator-activated receptor delta (PPARdelta) agonists have been shown to exert beneficial effects in liver disease and reduce total bile acid levels.	Bile Acids and Salts	148-157	peroxisome proliferator activator receptor delta	Mus musculus	50-59
35605662-2	2022	The mechanism(s) whereby PPARdelta agonism reduces bile acid levels are, however, unknown, and therefore the aim of the current study was to investigate the molecular pathways responsible for reducing bile acid synthesis in hepatocytes following treatment with the selective PPARdelta agonist, seladelpar.	Bile Acids and Salts	51-60	peroxisome proliferator activator receptor delta	Mus musculus	25-34
35605662-2	2022	The mechanism(s) whereby PPARdelta agonism reduces bile acid levels are, however, unknown, and therefore the aim of the current study was to investigate the molecular pathways responsible for reducing bile acid synthesis in hepatocytes following treatment with the selective PPARdelta agonist, seladelpar.	Bile Acids and Salts	51-60	peroxisome proliferator activator receptor delta	Mus musculus	275-284
35605662-2	2022	The mechanism(s) whereby PPARdelta agonism reduces bile acid levels are, however, unknown, and therefore the aim of the current study was to investigate the molecular pathways responsible for reducing bile acid synthesis in hepatocytes following treatment with the selective PPARdelta agonist, seladelpar.	Bile Acids and Salts	201-210	peroxisome proliferator activator receptor delta	Mus musculus	25-34
35605662-2	2022	The mechanism(s) whereby PPARdelta agonism reduces bile acid levels are, however, unknown, and therefore the aim of the current study was to investigate the molecular pathways responsible for reducing bile acid synthesis in hepatocytes following treatment with the selective PPARdelta agonist, seladelpar.	Bile Acids and Salts	201-210	peroxisome proliferator activator receptor delta	Mus musculus	275-284
35093536-6	2022	PPARdelta, rather than PPARalpha or PPARgamma, is involved in the anti-ROS effect of BBR, as evidenced by the siRNA transfection and specific antagonist treatment data.	Berberine	85-88	peroxisome proliferator activator receptor delta	Mus musculus	0-9
35093536-9	2022	Collectively, our results indicate that BBR confers neuroprotective effects by activating PPARdelta to scavenge ROS, providing a novel mechanistic insight for the antioxidant action of BBR.	Berberine	40-43	peroxisome proliferator activator receptor delta	Mus musculus	90-99
35093536-9	2022	Collectively, our results indicate that BBR confers neuroprotective effects by activating PPARdelta to scavenge ROS, providing a novel mechanistic insight for the antioxidant action of BBR.	Reactive Oxygen Species	112-115	peroxisome proliferator activator receptor delta	Mus musculus	90-99
35093536-9	2022	Collectively, our results indicate that BBR confers neuroprotective effects by activating PPARdelta to scavenge ROS, providing a novel mechanistic insight for the antioxidant action of BBR.	Berberine	185-188	peroxisome proliferator activator receptor delta	Mus musculus	90-99
35163565-7	2022	As the PPARD mice aged from 10 weeks to 35 weeks and 55 weeks, we observed significant changes in levels of the metabolites inosine monophosphate (p = 0.0054), adenosine monophosphate (p = 0.009), UDP-glucose (p = 0.0006), and oxypurinol (p = 0.039).	Inosine Monophosphate	124-145	peroxisome proliferator activator receptor delta	Mus musculus	7-12
35163565-7	2022	As the PPARD mice aged from 10 weeks to 35 weeks and 55 weeks, we observed significant changes in levels of the metabolites inosine monophosphate (p = 0.0054), adenosine monophosphate (p = 0.009), UDP-glucose (p = 0.0006), and oxypurinol (p = 0.039).	Adenosine	160-169	peroxisome proliferator activator receptor delta	Mus musculus	7-12
35163565-7	2022	As the PPARD mice aged from 10 weeks to 35 weeks and 55 weeks, we observed significant changes in levels of the metabolites inosine monophosphate (p = 0.0054), adenosine monophosphate (p = 0.009), UDP-glucose (p = 0.0006), and oxypurinol (p = 0.039).	Glucose	201-208	peroxisome proliferator activator receptor delta	Mus musculus	7-12
35163565-7	2022	As the PPARD mice aged from 10 weeks to 35 weeks and 55 weeks, we observed significant changes in levels of the metabolites inosine monophosphate (p = 0.0054), adenosine monophosphate (p = 0.009), UDP-glucose (p = 0.0006), and oxypurinol (p = 0.039).	Oxypurinol	227-237	peroxisome proliferator activator receptor delta	Mus musculus	7-12
35163565-9	2022	Liquid chromatography-mass spectrometry-based measurement of fatty acid levels showed lower linoleic acid, palmitic acid, oleic acid, and steric acid levels in 55-week-old PPARD mice than in 10-week-old PPARD mice, supporting fatty acid oxidation as a bioenergy source for PPARD-expressing gastric tumors.	Fatty Acids	61-71	peroxisome proliferator activator receptor delta	Mus musculus	172-177
35163565-9	2022	Liquid chromatography-mass spectrometry-based measurement of fatty acid levels showed lower linoleic acid, palmitic acid, oleic acid, and steric acid levels in 55-week-old PPARD mice than in 10-week-old PPARD mice, supporting fatty acid oxidation as a bioenergy source for PPARD-expressing gastric tumors.	Fatty Acids	61-71	peroxisome proliferator activator receptor delta	Mus musculus	203-208
35163565-9	2022	Liquid chromatography-mass spectrometry-based measurement of fatty acid levels showed lower linoleic acid, palmitic acid, oleic acid, and steric acid levels in 55-week-old PPARD mice than in 10-week-old PPARD mice, supporting fatty acid oxidation as a bioenergy source for PPARD-expressing gastric tumors.	Fatty Acids	61-71	peroxisome proliferator activator receptor delta	Mus musculus	273-278
35163565-9	2022	Liquid chromatography-mass spectrometry-based measurement of fatty acid levels showed lower linoleic acid, palmitic acid, oleic acid, and steric acid levels in 55-week-old PPARD mice than in 10-week-old PPARD mice, supporting fatty acid oxidation as a bioenergy source for PPARD-expressing gastric tumors.	stearic acid	138-149	peroxisome proliferator activator receptor delta	Mus musculus	172-177
35163565-9	2022	Liquid chromatography-mass spectrometry-based measurement of fatty acid levels showed lower linoleic acid, palmitic acid, oleic acid, and steric acid levels in 55-week-old PPARD mice than in 10-week-old PPARD mice, supporting fatty acid oxidation as a bioenergy source for PPARD-expressing gastric tumors.	Fatty Acids	226-236	peroxisome proliferator activator receptor delta	Mus musculus	172-177
33646450-0	2021	PPAR-delta activation reduces cisplatin-induced apoptosis via inhibiting p53/Bax/caspase-3 pathway without modulating autophagy in murine renal proximal tubular cells.	Cisplatin	30-39	peroxisome proliferator activator receptor delta	Mus musculus	0-10
35198077-7	2022	PPARdelta directly bound to the oxygen-dependent degradation domain of HIF1alpha at the ligand-dependent domain of PPARdelta.	Oxygen	32-38	peroxisome proliferator activator receptor delta	Mus musculus	0-9
35198077-7	2022	PPARdelta directly bound to the oxygen-dependent degradation domain of HIF1alpha at the ligand-dependent domain of PPARdelta.	Oxygen	32-38	peroxisome proliferator activator receptor delta	Mus musculus	115-124
33646450-3	2021	Thus, PPAR-delta may protect against cisplatin-induced kidney injury.	Cisplatin	37-46	peroxisome proliferator activator receptor delta	Mus musculus	6-16
33646450-4	2021	METHODS: We examined the protective effects of PPAR-delta activation on cisplatin-induced cellular injury and their detailed mechanisms in a murine renal proximal tubular (mProx) cell line using GW0742, an authentic PPAR-delta activator.	Cisplatin	72-81	peroxisome proliferator activator receptor delta	Mus musculus	47-57
33646450-9	2021	The inhibitory effect of GW0742 on cisplatin-induced caspase-3 activation was significantly diminished by silencing of the PPAR-delta gene expression.	GW0742	25-31	peroxisome proliferator activator receptor delta	Mus musculus	123-133
33932312-0	2021	gamma-Oryzanol improves exercise endurance and muscle strength by upregulating PPARdelta and ERRgamma activity in aged mice.	gamma-oryzanol	0-14	peroxisome proliferator activator receptor delta	Mus musculus	79-88
33646450-9	2021	The inhibitory effect of GW0742 on cisplatin-induced caspase-3 activation was significantly diminished by silencing of the PPAR-delta gene expression.	Cisplatin	35-44	peroxisome proliferator activator receptor delta	Mus musculus	123-133
33646450-11	2021	CONCLUSION: Our results indicate that GW0742 may serve as a candidate agent to mitigate cisplatin nephrotoxicity via inhibiting the mitochondrial apoptotic pathway considerably depending on PPAR-delta, without modulating autophagy.	GW0742	38-44	peroxisome proliferator activator receptor delta	Mus musculus	190-200
34019979-0	2021	Butyrate Protects Endothelial Function Through PPARdelta/miR-181b Signaling.	Butyrates	0-8	peroxisome proliferator activator receptor delta	Mus musculus	47-56
34019979-8	2021	Global and endothelial-specific knockout of PPARdelta eliminated the protective effects of butyrate against IL-1beta-impairment to EDRs.	Butyrates	91-99	peroxisome proliferator activator receptor delta	Mus musculus	44-53
34019979-9	2021	Butyrate abolished IL-1beta-induced reactive oxygen species (ROS) production in endothelial cells while the inhibitory effect was incapacitated by genetic deletion of PPARdelta or pharmacological inhibition of PPARdelta.	Butyrates	0-8	peroxisome proliferator activator receptor delta	Mus musculus	210-219
34019979-10	2021	IL-1beta increased NADPH oxidase 2 (NOX2) mRNA and protein expressions in endothelial cells, which were prevented by butyrate treatment, and the effects of butyrate were blunted following pharmacological inhibition of PPARdelta.	Butyrates	117-125	peroxisome proliferator activator receptor delta	Mus musculus	218-227
34019979-10	2021	IL-1beta increased NADPH oxidase 2 (NOX2) mRNA and protein expressions in endothelial cells, which were prevented by butyrate treatment, and the effects of butyrate were blunted following pharmacological inhibition of PPARdelta.	Butyrates	156-164	peroxisome proliferator activator receptor delta	Mus musculus	218-227
34019979-13	2021	To conclude, butyrate prevents endothelial dysfunction in atherosclerosis by reducing endothelial NOX2 expression and ROS production via the PPARdelta/miR-181b pathway.	Butyrates	13-21	peroxisome proliferator activator receptor delta	Mus musculus	141-150
33932312-4	2021	The expression and activity of PPARdelta and ERRgamma were increased in skeletal muscle of gamma-oryzanol supplemented mice.	gamma-oryzanol	91-105	peroxisome proliferator activator receptor delta	Mus musculus	31-40
33932312-8	2021	Collectively, gamma-oryzanol attenuates muscle weakness pathway and increases oxidative capacity by increasing PPARdelta and ERRgamma activity, which contribute to enhance strength and improve oxidative capacity in muscles, consequently enhancing exercise capacity in aged mice.	gamma-oryzanol	14-28	peroxisome proliferator activator receptor delta	Mus musculus	111-120
33932312-9	2021	Particularly, gamma-oryzanol directly bind to PPARdelta.	gamma-oryzanol	14-28	peroxisome proliferator activator receptor delta	Mus musculus	46-55
33932312-10	2021	CONCLUSIONS: These are the first findings showing that gamma-oryzanol enhances skeletal muscle function in aged mice by regulating PPARdelta and ERRgamma activity without muscle gain.	gamma-oryzanol	55-69	peroxisome proliferator activator receptor delta	Mus musculus	131-140
33596122-3	2021	Peroxisome-proliferator activated receptors (PPARs), in particular PPARdelta and PPARgamma, are involved in the regulation of lipids and carbohydrates and, along adenosine-monophosphate (AMP)-activated protein kinase (AMPK) and protein kinase B (Akt/PKB), are implicated in translocation of glucose transporter 4 (GLUT4).	Carbohydrates	137-150	peroxisome proliferator activator receptor delta	Mus musculus	67-76
32703610-0	2021	PPARdelta and its ligand erucic acid may act anti-tumoral, neuroprotective, and myelin protective in neuroblastoma, glioblastoma, and Parkinson"s disease.	erucic acid	25-36	peroxisome proliferator activator receptor delta	Mus musculus	0-9
32703610-4	2021	PPARdelta ligand-activation via oleic acid and GW501516, or overexpression of PPARdelta, elicits profound antitumor actions in neuroblastoma and melanoma.	Oleic Acid	32-42	peroxisome proliferator activator receptor delta	Mus musculus	0-9
32703610-4	2021	PPARdelta ligand-activation via oleic acid and GW501516, or overexpression of PPARdelta, elicits profound antitumor actions in neuroblastoma and melanoma.	GW 501516	47-55	peroxisome proliferator activator receptor delta	Mus musculus	0-9
33732230-3	2021	Here, we specifically investigated the role of PPAR-delta in microglia during EAE by using mice where excision of a floxed Ppard allele was driven by expression of a tamoxifen (TAM)-inducible CX3C chemokine receptor 1 promoter-Cre recombinase transgene (Cx3cr1 CreERT2: Ppard fl/fl).	Tamoxifen	166-175	peroxisome proliferator activator receptor delta	Mus musculus	123-128
33732230-3	2021	Here, we specifically investigated the role of PPAR-delta in microglia during EAE by using mice where excision of a floxed Ppard allele was driven by expression of a tamoxifen (TAM)-inducible CX3C chemokine receptor 1 promoter-Cre recombinase transgene (Cx3cr1 CreERT2: Ppard fl/fl).	Tamoxifen	177-180	peroxisome proliferator activator receptor delta	Mus musculus	123-128
33732230-4	2021	We observed that by 30 days of TAM treatment, Cx3cr1 CreERT2: Ppard fl/fl mice exhibited Cre-mediated deletion primarily in microglia and this was accompanied by efficient knockdown of Ppard expression in these cells.	Tamoxifen	31-34	peroxisome proliferator activator receptor delta	Mus musculus	62-67
33732230-4	2021	We observed that by 30 days of TAM treatment, Cx3cr1 CreERT2: Ppard fl/fl mice exhibited Cre-mediated deletion primarily in microglia and this was accompanied by efficient knockdown of Ppard expression in these cells.	Tamoxifen	31-34	peroxisome proliferator activator receptor delta	Mus musculus	185-190
33732230-5	2021	Upon induction of EAE, TAM-treated Cx3cr1 CreERT2: Ppard fl/fl mice presented with an exacerbated course of disease compared to TAM-treated Ppard fl/fl controls.	Tamoxifen	23-26	peroxisome proliferator activator receptor delta	Mus musculus	51-56
33732230-5	2021	Upon induction of EAE, TAM-treated Cx3cr1 CreERT2: Ppard fl/fl mice presented with an exacerbated course of disease compared to TAM-treated Ppard fl/fl controls.	Tamoxifen	23-26	peroxisome proliferator activator receptor delta	Mus musculus	140-145
33732230-5	2021	Upon induction of EAE, TAM-treated Cx3cr1 CreERT2: Ppard fl/fl mice presented with an exacerbated course of disease compared to TAM-treated Ppard fl/fl controls.	Tamoxifen	128-131	peroxisome proliferator activator receptor delta	Mus musculus	140-145
33732230-6	2021	Histopathological and magnetic resonance (MR) studies on the spinal cord and brains of EAE mice revealed increased Iba-1 immunoreactivity, axonal injury and CNS tissue loss in the TAM-treated Cx3cr1 CreERT2: Ppard fl/fl group compared to controls.	Tamoxifen	180-183	peroxisome proliferator activator receptor delta	Mus musculus	208-213
33732230-8	2021	In addition, Ppard-deficient microglia exhibited increased expression of genes associated with reactive oxygen species generation, phagocytosis and lipid clearance, M2-activation, and promotion of inflammation.	Oxygen	104-110	peroxisome proliferator activator receptor delta	Mus musculus	13-18
32703610-10	2021	In the rotenone PD model in rats, PPARdelta ligand GW501516 saves dopaminergic neurons during injury induced by chemical toxins and improves behavioral functioning in PD via alleviation of endoplasmic reticulum stress.	Rotenone	7-15	peroxisome proliferator activator receptor delta	Mus musculus	34-43
32703610-10	2021	In the rotenone PD model in rats, PPARdelta ligand GW501516 saves dopaminergic neurons during injury induced by chemical toxins and improves behavioral functioning in PD via alleviation of endoplasmic reticulum stress.	GW 501516	51-59	peroxisome proliferator activator receptor delta	Mus musculus	34-43
32703610-11	2021	PPARdelta agonists also reduce the NLRP3 inflammasome-associated neural inflammation in the MPTP PD model in mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	92-96	peroxisome proliferator activator receptor delta	Mus musculus	0-9
33190845-10	2021	Mechanistically, this prodepressant property of TWIST1 was mediated, at least in part, through the repression of miR-214-PPAR-delta signaling and mitochondrial function, which was also mimicked by genetic and pharmacological inhibition of PPAR-delta.	prodepressant	22-35	peroxisome proliferator activator receptor delta	Mus musculus	121-131
33190845-10	2021	Mechanistically, this prodepressant property of TWIST1 was mediated, at least in part, through the repression of miR-214-PPAR-delta signaling and mitochondrial function, which was also mimicked by genetic and pharmacological inhibition of PPAR-delta.	prodepressant	22-35	peroxisome proliferator activator receptor delta	Mus musculus	239-249
33596122-0	2021	alpha-amyrin induce GLUT4 translocation mediated by AMPK and PPARdelta/gamma in C2C12 myoblasts.	beta-amyrin	0-12	peroxisome proliferator activator receptor delta	Mus musculus	61-70
33596122-1	2021	alpha-amyrin, a natural pentacyclic triterpene, have anti-hyperglycemic effect in mice and dual PPARdelta/gamma action in 3T3-L1 adipocytes, and potential in the control of type 2 diabetes (T2D).	beta-amyrin	0-12	peroxisome proliferator activator receptor delta	Mus musculus	96-105
33596122-3	2021	Peroxisome-proliferator activated receptors (PPARs), in particular PPARdelta and PPARgamma, are involved in the regulation of lipids and carbohydrates and, along adenosine-monophosphate (AMP)-activated protein kinase (AMPK) and protein kinase B (Akt/PKB), are implicated in translocation of glucose transporter 4 (GLUT4).	Adenosine	162-171	peroxisome proliferator activator receptor delta	Mus musculus	67-76
33596122-5	2021	The work"s objective was to determine the action of alpha-amyrin in PPARdelta, PPARgamma, AMPK, and Akt/PKB in C2C12 myoblasts.	beta-amyrin	52-64	peroxisome proliferator activator receptor delta	Mus musculus	68-77
32553670-0	2021	The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice.	Seladelpar	33-43	peroxisome proliferator activator receptor delta	Mus musculus	14-24
32553670-0	2021	The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice.	Ethanol	52-59	peroxisome proliferator activator receptor delta	Mus musculus	14-24
33308300-4	2020	Calpain-3-deficient mice were also treated with PPAR-delta agonist (GW501516) to assess mitochondrial function and membrane repair.	GW 501516	68-76	peroxisome proliferator activator receptor delta	Mus musculus	48-58
32553670-0	2021	The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice.	Bile Acids and Salts	120-129	peroxisome proliferator activator receptor delta	Mus musculus	14-24
32553670-3	2021	Here, we evaluated the effect of the selective PPAR-delta agonist seladelpar (MBX-8025) on gut barrier function and bile acid metabolism in a mouse model of ethanol-induced liver disease.	Seladelpar	66-76	peroxisome proliferator activator receptor delta	Mus musculus	47-57
32553670-11	2021	Data from this study demonstrates that seladelpar prevents and treats ethanol-induced liver damage in mice by direct PPARdelta agonism in both the liver and the intestine.	Seladelpar	39-49	peroxisome proliferator activator receptor delta	Mus musculus	117-126
32553670-11	2021	Data from this study demonstrates that seladelpar prevents and treats ethanol-induced liver damage in mice by direct PPARdelta agonism in both the liver and the intestine.	Ethanol	70-77	peroxisome proliferator activator receptor delta	Mus musculus	117-126
32863184-9	2020	While data show that PPARdelta levels were increased by the drug metformin, PPARdelta was not necessary for metformin-induced protection from light damage.	Metformin	65-74	peroxisome proliferator activator receptor delta	Mus musculus	21-30
33318871-0	2021	Endogenous hydrogen sulfide improves vascular remodeling through PPARdelta/SOCS3 signaling.	Hydrogen Sulfide	11-27	peroxisome proliferator activator receptor delta	Mus musculus	65-74
32961442-0	2020	Procyanidin B2 mitigates endothelial endoplasmic reticulum stress through a PPARdelta-Dependent mechanism.	procyanidin B2	0-14	peroxisome proliferator activator receptor delta	Mus musculus	76-85
32961442-9	2020	The protective effect of PCB2 on vasodilation was abolished in the aortas pretreated with GSK0660 or those from the EC-specific PPARdelta knockout mice.	procyanidin B2	25-29	peroxisome proliferator activator receptor delta	Mus musculus	128-137
32961442-10	2020	Moreover, the protective effects of PCB2 on ER stress and endothelial dysfunction required the inter-dependent actions of PPARdelta and AMPK.	procyanidin B2	36-40	peroxisome proliferator activator receptor delta	Mus musculus	122-131
32697599-7	2020	Treatment of primary mouse skeletal muscle cells or C2C12 cells with PPARdelta activators GW501516 and AICAR increased Lin28a expression.	GW 501516	90-98	peroxisome proliferator activator receptor delta	Mus musculus	69-78
32697599-7	2020	Treatment of primary mouse skeletal muscle cells or C2C12 cells with PPARdelta activators GW501516 and AICAR increased Lin28a expression.	AICA ribonucleotide	103-108	peroxisome proliferator activator receptor delta	Mus musculus	69-78
32697599-11	2020	PGC1alpha-mediated induction of Lin28a expression was blocked by PPARdelta inhibitor GSK0660.	GSK0660	85-92	peroxisome proliferator activator receptor delta	Mus musculus	65-74
32562818-0	2020	ZLY032, the first-in-class dual FFA1/PPARdelta agonist, improves glucolipid metabolism and alleviates hepatic fibrosis.	zly032	0-6	peroxisome proliferator activator receptor delta	Mus musculus	37-46
32562818-2	2020	Based on their synergetic mechanisms, we have previously identified the first-in-class dual FFA1/PPARdelta agonist ZLY032.	zly032	115-121	peroxisome proliferator activator receptor delta	Mus musculus	97-106
32562818-6	2020	These results suggest that the dual FFA1/PPARdelta agonists such as ZLY032 may be useful for the treatment of metabolic disorders.	zly032	68-74	peroxisome proliferator activator receptor delta	Mus musculus	41-50
32480174-3	2020	The modeling study revealed that compound 6 binds well to the binding pockets of PPARalpha and PPARdelta, which formed multiple hydrogen bonds with key residues related to the activation of PPARalpha and PPARdelta.	Hydrogen	128-136	peroxisome proliferator activator receptor delta	Mus musculus	95-104
32480174-3	2020	The modeling study revealed that compound 6 binds well to the binding pockets of PPARalpha and PPARdelta, which formed multiple hydrogen bonds with key residues related to the activation of PPARalpha and PPARdelta.	Hydrogen	128-136	peroxisome proliferator activator receptor delta	Mus musculus	204-213
33318871-7	2021	Results: The deficiency of endogenous H2S generated vascular remodeling with aggravated active and passive contraction, thicken aortic walls, collagen deposition, increased phosphorylation of STAT3, decreased production of PPARdelta and SOCS3 in aortas, which were reversed by NaHS.	Deuterium	38-41	peroxisome proliferator activator receptor delta	Mus musculus	223-232
33318871-8	2021	PPG inhibited expression of PPARdelta and SOCS3, stimulated the phosphorylation of STAT3, increased inflammatory molecules production and proliferation rate of VSMCs which could all be corrected by NaHS supply.	ppg	0-3	peroxisome proliferator activator receptor delta	Mus musculus	28-37
33318871-9	2021	PPARdelta agonist GW501516 offered protections similar to NaHS in PPG treated VSMCs.	GW 501516	18-26	peroxisome proliferator activator receptor delta	Mus musculus	0-9
33318871-10	2021	Aggravated active and passive contraction in PPG mice aortas, upregulated p-STAT3 and inflammatory molecules, downregulated SOCS3 and phenotype transformation in PPG treated VSMCs could be corrected by PPARdelta agonist GW501516 treatment.	GW 501516	220-228	peroxisome proliferator activator receptor delta	Mus musculus	202-211
33318871-11	2021	On the contrary, PPARdelta antagonist GSK0660 exhibited opposite effects on vascular contraction in aortas, expressions of p-STAT3 and SOCS3 in VSMCs compared with GW501516.	GSK0660	38-45	peroxisome proliferator activator receptor delta	Mus musculus	17-26
33318871-11	2021	On the contrary, PPARdelta antagonist GSK0660 exhibited opposite effects on vascular contraction in aortas, expressions of p-STAT3 and SOCS3 in VSMCs compared with GW501516.	GW 501516	164-172	peroxisome proliferator activator receptor delta	Mus musculus	17-26
33318871-12	2021	Conclusion: In a word, endogenous H2S protected against vascular remodeling through preserving PPARdelta/SOCS3 anti-inflammatory signaling pathway.	Deuterium	34-37	peroxisome proliferator activator receptor delta	Mus musculus	95-104
32001235-12	2020	These data indicate that omentin-1 protects against high glucose-induced vascular-endothelial dysfunction through inhibiting ER stress and oxidative stress and increasing NO production via activation of AMPK/PPARdelta pathway.	Glucose	57-64	peroxisome proliferator activator receptor delta	Mus musculus	208-217
32093891-4	2020	We focused on oleic acid, an omega-9 monounsaturated fatty acid, as a factor that activates PPARdelta.	Oleic Acid	14-24	peroxisome proliferator activator receptor delta	Mus musculus	92-101
32093891-4	2020	We focused on oleic acid, an omega-9 monounsaturated fatty acid, as a factor that activates PPARdelta.	omega-9 monounsaturated fatty acid	29-63	peroxisome proliferator activator receptor delta	Mus musculus	92-101
32093891-5	2020	In this study, we examined the effects of oleic acid on the muscle fiber type of C2C12 myotubes and its relationship with PPARdelta.	Oleic Acid	42-52	peroxisome proliferator activator receptor delta	Mus musculus	122-131
32093891-7	2020	To confirm the relationship between PPARdelta activation and oleic acid-induced MyHC1 increase, we examined the effects of oleic acid in PPARdelta knockdown C2C12 myoblasts.	Oleic Acid	61-71	peroxisome proliferator activator receptor delta	Mus musculus	36-45
32093891-7	2020	To confirm the relationship between PPARdelta activation and oleic acid-induced MyHC1 increase, we examined the effects of oleic acid in PPARdelta knockdown C2C12 myoblasts.	Oleic Acid	123-133	peroxisome proliferator activator receptor delta	Mus musculus	137-146
32093891-8	2020	We found that oleic acid supplementation increased the mRNA expression of MyHC1 in PPARdelta-knockdown C2C12 cells.	Oleic Acid	14-24	peroxisome proliferator activator receptor delta	Mus musculus	83-92
32093891-9	2020	Our data suggest that oleic acid increases type 1 fiber levels in C2C12 myotubes in a PPARdelta-independent manner.	Oleic Acid	22-32	peroxisome proliferator activator receptor delta	Mus musculus	86-95
32224867-4	2020	PPARdelta antagonists such as GSK3787 exist, but would benefit from delivery to joints to avoid side effects.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	30-37	peroxisome proliferator activator receptor delta	Mus musculus	0-9
32001235-0	2020	Omentin-1 protects against high glucose-induced endothelial dysfunction via the AMPK/PPARdelta signaling pathway.	Glucose	32-39	peroxisome proliferator activator receptor delta	Mus musculus	85-94
31008686-6	2019	In this study, the effects of GW0742 (a selective PPAR-delta agonist) on hippocampal synaptic transmission, plasticity, and spatial memory were investigated in the db/db mouse model of T2DM.	GW0742	30-36	peroxisome proliferator activator receptor delta	Mus musculus	50-60
32014571-2	2020	The present study revealed CPU025 is a potent FFA1 agonist (EC50 = 38.7 nM) with moderate agonistic activity on PPARdelta (EC50 = 625.6 nM), and promotes insulin secretion at a glucose-dependent manner.	cpu025	27-33	peroxisome proliferator activator receptor delta	Mus musculus	112-121
32099540-9	2020	In spontaneously hypertensive rats, alpha 1-adrenergic receptor stimulation affected mitochondrial oxidative phosphorylation and ATP production by activating PPARdelta, AMPK, and PGC-1alpha and the relevant biologic functions of multiple organs, suggesting organ crosstalk.	Adenosine Triphosphate	129-132	peroxisome proliferator activator receptor delta	Mus musculus	158-167
31625071-0	2020	Erucic acid, a nutritional PPARdelta-ligand may influence Huntington"s disease pathogenesis.	erucic acid	0-11	peroxisome proliferator activator receptor delta	Mus musculus	27-36
31625071-2	2020	PPARdelta directly involves in the pathogenesis of HD and treatment with a brain-permeable PPARdelta-agonist (KD3010) alleviates its severity in mice.	4-(2,6-dimethyl-4-(4-trifluoromethoxyphenyl)piperazine-1-sulfonyl)indan-2-carboxylic acid	110-116	peroxisome proliferator activator receptor delta	Mus musculus	0-9
31625071-2	2020	PPARdelta directly involves in the pathogenesis of HD and treatment with a brain-permeable PPARdelta-agonist (KD3010) alleviates its severity in mice.	4-(2,6-dimethyl-4-(4-trifluoromethoxyphenyl)piperazine-1-sulfonyl)indan-2-carboxylic acid	110-116	peroxisome proliferator activator receptor delta	Mus musculus	91-100
31625071-3	2020	Erucic acid (EA) is also a PPARdelta-ligand omega9 fatty acid which is highly consumed in Asian countries through ingesting cruciferous vegetables such as rapeseed (Brassica napus) and indian mustard (Brassica juncea).	erucic acid	0-11	peroxisome proliferator activator receptor delta	Mus musculus	27-36
31625071-3	2020	Erucic acid (EA) is also a PPARdelta-ligand omega9 fatty acid which is highly consumed in Asian countries through ingesting cruciferous vegetables such as rapeseed (Brassica napus) and indian mustard (Brassica juncea).	erucic acid	13-15	peroxisome proliferator activator receptor delta	Mus musculus	27-36
31625071-3	2020	Erucic acid (EA) is also a PPARdelta-ligand omega9 fatty acid which is highly consumed in Asian countries through ingesting cruciferous vegetables such as rapeseed (Brassica napus) and indian mustard (Brassica juncea).	omega9 fatty acid	44-61	peroxisome proliferator activator receptor delta	Mus musculus	27-36
31919912-9	2020	Our results indicated PPARdelta activation by fatty acid resulted in the activation of myeloid DCs and subsequent polarization of T lymphocytes, which contributed to atherosclerosis in Apoe-/- mice.	Fatty Acids	46-56	peroxisome proliferator activator receptor delta	Mus musculus	22-31
31578267-1	2019	Peroxisome proliferator-activated receptor (PPAR)-delta is a fatty acid-activated transcription factor that regulates metabolic homeostasis, cell growth, and differentiation.	Fatty Acids	61-71	peroxisome proliferator activator receptor delta	Mus musculus	0-55
31730422-7	2019	Kirenol markedly increased adenosine triphosphate production and mitochondrial activity by stimulating the expression of markers of mitochondrial biogenesis and upregulating the AMPK/SIRT1/PGC-1alpha/PPARdelta signaling pathway in L6 myotubes.	kirenol	0-7	peroxisome proliferator activator receptor delta	Mus musculus	200-209
31735914-9	2019	In addition, the overexpression or silencing of peroxisome proliferator-activated receptor delta (PPARdelta) significantly influenced 15-d-PGJ2-induced phenotypic conversion.	15-deoxyprostaglandin J2	134-143	peroxisome proliferator activator receptor delta	Mus musculus	48-96
31735914-9	2019	In addition, the overexpression or silencing of peroxisome proliferator-activated receptor delta (PPARdelta) significantly influenced 15-d-PGJ2-induced phenotypic conversion.	15-deoxyprostaglandin J2	134-143	peroxisome proliferator activator receptor delta	Mus musculus	98-107
31781179-0	2019	Corrigendum to "Caffeoylquinic Acid-Rich Extract of Aster glehni F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPARdelta and Adiponectin in ApoE KO Mice".	caffeoylquinic acid	16-35	peroxisome proliferator activator receptor delta	Mus musculus	139-148
31635041-5	2019	24 mice were assigned to groups according to an 8-week exercise training program and/or an 8-week treatment with 3 mg/kg/day of GW0742, a PPARbeta/delta agonist.	GW0742	128-134	peroxisome proliferator activator receptor delta	Mus musculus	138-146
31635041-6	2019	Our results show metabolic changes of peripheral lymphoid tissues with PPARbeta/delta agonist (increase in fatty acid oxidation gene expression) or exercise (increase in AMPK activity) and a potentiating effect of the combination of both on the percentage of anti-inflammatory Foxp3+ T cells.	Fatty Acids	107-117	peroxisome proliferator activator receptor delta	Mus musculus	71-79
31464308-0	2019	Gymnemic acid alleviates inflammation and insulin resistance via PPARdelta- and NFkappaB-mediated pathways in db/db mice.	gymnemic acid	0-13	peroxisome proliferator activator receptor delta	Mus musculus	65-74
31464308-4	2019	Furthermore, GA treatment accelerated lipid transport and promoted fatty acid oxidation, which reduced lipid accumulation and inhibited expression of inflammatory cytokines, including those involved in the proliferator-activated receptor delta (PPARdelta)- and nuclear factor kappaB (NFkappaB)-mediated signaling pathways.	gymnemic acid	13-15	peroxisome proliferator activator receptor delta	Mus musculus	245-254
31150647-0	2019	Metformin inhibits PPARdelta agonist-mediated tumor growth by reducing Glut1 and SLC1A5 expressions of cancer cells.	Metformin	0-9	peroxisome proliferator activator receptor delta	Mus musculus	19-28
30885780-1	2019	BACKGROUND & AIMS: The peroxisome proliferator-activated receptor delta (PPARD) regulates cell metabolism, proliferation, and inflammation and has been associated with gastric and other cancers.	Adenosine Monophosphate	12-15	peroxisome proliferator activator receptor delta	Mus musculus	27-75
31464308-7	2019	In summary, we demonstrated in db/db mice that GA induces fatty acid oxidation, and alleviates inflammation and IR in liver, skeletal muscle and adipose tissue through PPARdelta- and NFkappaB-mediated signaling pathways.	gymnemic acid	47-49	peroxisome proliferator activator receptor delta	Mus musculus	168-177
31144304-0	2019	PPARdelta agonist prevents endothelial dysfunction via induction of dihydrofolate reductase gene and activation of tetrahydrobiopterin salvage pathway.	sapropterin	115-134	peroxisome proliferator activator receptor delta	Mus musculus	0-9
31144304-9	2019	KEY RESULTS: The PPARdelta agonist GW501516 increased DHFR and BH4 levels in endothelial cells (ECs).	GW 501516	35-43	peroxisome proliferator activator receptor delta	Mus musculus	17-26
31144304-9	2019	KEY RESULTS: The PPARdelta agonist GW501516 increased DHFR and BH4 levels in endothelial cells (ECs).	sapropterin	63-66	peroxisome proliferator activator receptor delta	Mus musculus	17-26
31144304-10	2019	The effect was blocked by PPARdelta antagonist GSK0660.	GSK0660	47-54	peroxisome proliferator activator receptor delta	Mus musculus	26-35
31144304-19	2019	CONCLUSION AND IMPLICATIONS: PPARdelta prevented endothelial dysfunction by increasing DHFR and activating the BH4 salvage pathway.	sapropterin	111-114	peroxisome proliferator activator receptor delta	Mus musculus	29-38
31153636-7	2019	PPAR-delta agonist GW501516 partially rescued the insulin resistance induced by miR-29a.	GW 501516	19-27	peroxisome proliferator activator receptor delta	Mus musculus	0-10
30885780-1	2019	BACKGROUND & AIMS: The peroxisome proliferator-activated receptor delta (PPARD) regulates cell metabolism, proliferation, and inflammation and has been associated with gastric and other cancers.	Adenosine Monophosphate	12-15	peroxisome proliferator activator receptor delta	Mus musculus	77-82
30850637-7	2019	The downstream targets of PPARalpha, PPARdelta, and RELA in this network significantly overlapped with telmisartan-induced differentially expressed genes (DEGs), which were verified in palmitate-treated Hepa1c1c7 cell line.	Telmisartan	103-114	peroxisome proliferator activator receptor delta	Mus musculus	37-46
31038173-8	2019	Furthermore, these effects were mimicked by repeated systemic administration of a PPARdelta antagonist, GSK0660 (1 or 3 mg/kg i.p.	GSK0660	104-111	peroxisome proliferator activator receptor delta	Mus musculus	82-91
29458111-0	2019	PPARdelta modulation rescues mitochondrial fatty acid oxidation defects in the mdx model of muscular dystrophy.	Fatty Acids	43-53	peroxisome proliferator activator receptor delta	Mus musculus	0-9
30902749-3	2019	In an earlier study, we showed that free fatty acids increase transcription of small ubiquitin-like modifier (SUMO) specific protease 2 (SENP2) in skeletal muscle, and that SENP2 stimulates expression of FAO-associated enzymes by deSUMOylating peroxisome proliferator-activated receptors, PPARdelta and PPARgamma.	Fatty Acids	41-52	peroxisome proliferator activator receptor delta	Mus musculus	289-298
30612307-7	2019	Cinnamic acid mediated protection of the nigrostriatal system and locomotor activities in WT and PPARbeta (-/-), but not PPARalpha (-/-) mice from MPTP intoxication suggests that cinnamic acid requires the involvement of PPARalpha in protecting dopaminergic neurons in this model of PD.	cinnamic acid	0-13	peroxisome proliferator activator receptor delta	Mus musculus	97-105
30850637-7	2019	The downstream targets of PPARalpha, PPARdelta, and RELA in this network significantly overlapped with telmisartan-induced differentially expressed genes (DEGs), which were verified in palmitate-treated Hepa1c1c7 cell line.	Palmitates	185-194	peroxisome proliferator activator receptor delta	Mus musculus	37-46
30679176-7	2019	Treatment with PPARD agonist GW501516 enhanced colorectal cancer tumorigenesis in ApcDelta580 mice, whereas treatment with PPARD antagonist GSK3787 suppressed tumorigenesis.	GW 501516	29-37	peroxisome proliferator activator receptor delta	Mus musculus	15-20
30679176-7	2019	Treatment with PPARD agonist GW501516 enhanced colorectal cancer tumorigenesis in ApcDelta580 mice, whereas treatment with PPARD antagonist GSK3787 suppressed tumorigenesis.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	140-147	peroxisome proliferator activator receptor delta	Mus musculus	123-128
30605833-0	2019	Discovery of first-in-class thiazole-based dual FFA1/PPARdelta agonists as potential anti-diabetic agents.	Thiazoles	28-36	peroxisome proliferator activator receptor delta	Mus musculus	53-62
30814493-0	2019	PPARdelta attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation.	Fatty Acids	66-76	peroxisome proliferator activator receptor delta	Mus musculus	0-9
30602573-1	2019	Background: Reversal of alcohol-induced peroxisome proliferator-activated receptor (PPAR) alpha (PPARalpha) and PPARdelta dysfunction has been reported to decrease the severity of alcoholic steatohepatitis (ASH).	Alcohols	24-31	peroxisome proliferator activator receptor delta	Mus musculus	112-121
30602573-5	2019	Results: C57BL/6 mice on ethanol diet showed AT dysfunction, disrupted intestinal barrier, and ASH, which was accompanied by alcohol-mediated decrease in PPARalpha, PPARdelta, and autophagy levels in intestine, liver, and AT.	Ethanol	25-32	peroxisome proliferator activator receptor delta	Mus musculus	165-174
30602573-5	2019	Results: C57BL/6 mice on ethanol diet showed AT dysfunction, disrupted intestinal barrier, and ASH, which was accompanied by alcohol-mediated decrease in PPARalpha, PPARdelta, and autophagy levels in intestine, liver, and AT.	Alcohols	125-132	peroxisome proliferator activator receptor delta	Mus musculus	165-174
30602573-6	2019	Chronic treatment with elafibranor attenuated AT apoptosis and inflammation by restoration of tissue PPARalpha, PPARdelta, and autophagy levels.	2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid	23-34	peroxisome proliferator activator receptor delta	Mus musculus	112-121
30605833-3	2019	In this study, we hybrid FFA1 agonist AM-4668 with PPARdelta agonist GW501516, leading to the identification of orally bioavailable dual agonist 32, which revealed high selectivity over other PPARs.	GW 501516	69-77	peroxisome proliferator activator receptor delta	Mus musculus	51-60
30204243-6	2018	Administration of the PPARdelta ligand GW501516 inhibited tumor growth in xenograft model mice bearing MDA-MB-231 cells stably expressing wild-type PPARdelta, but not those expressing dominant-negative PPARdelta, by interfering with c-Myc function through protein-protein interaction.	GW 501516	39-47	peroxisome proliferator activator receptor delta	Mus musculus	22-31
30391747-3	2019	In addition, PPARdelta agonist GW501516 enhanced pro-inflammatory gene expressions (COX-2, IL-6, IL-8 and MCP-1) in inflamed colon.	GW 501516	31-39	peroxisome proliferator activator receptor delta	Mus musculus	13-22
30391747-5	2019	These findings revealed a new mechanism of PPARdelta agonist GW501516-mediated colitis-associated colorectal cancer.	GW 501516	61-69	peroxisome proliferator activator receptor delta	Mus musculus	43-52
30987865-3	2019	Treatment of mice fed a high-fat diet with the PPARbeta/delta agonist GW501516 increased the hepatic expression of Vldlr.	GW 501516	70-78	peroxisome proliferator activator receptor delta	Mus musculus	47-55
30987865-7	2019	Overall, these findings provide new effects by which PPARbeta/delta regulate VLDLR levels and may influence serum triglyceride levels and NAFLD development.	Triglycerides	114-126	peroxisome proliferator activator receptor delta	Mus musculus	53-61
30453390-0	2019	PPARbeta/delta-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1DeltaE9 astrocytes.	GW0742	23-29	peroxisome proliferator activator receptor delta	Mus musculus	0-8
30453390-0	2019	PPARbeta/delta-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1DeltaE9 astrocytes.	Fatty Acids	57-67	peroxisome proliferator activator receptor delta	Mus musculus	0-8
30453390-5	2019	The impairment was corrected by treatment with a synthetic peroxisome proliferator activated receptor delta (PPARbeta/delta) agonist GW0742 which acts to regulate an array of genes governing cellular metabolism.	GW0742	133-139	peroxisome proliferator activator receptor delta	Mus musculus	59-107
30453390-5	2019	The impairment was corrected by treatment with a synthetic peroxisome proliferator activated receptor delta (PPARbeta/delta) agonist GW0742 which acts to regulate an array of genes governing cellular metabolism.	GW0742	133-139	peroxisome proliferator activator receptor delta	Mus musculus	109-117
30453390-10	2019	Collectively, these data suggest that PPARbeta/delta-agonism alleviates AD related deficits through increasing fatty acid oxidation in astrocytes and improves cognition in a transgenic mouse model of AD.	Fatty Acids	111-121	peroxisome proliferator activator receptor delta	Mus musculus	38-46
30503839-8	2019	Experiments on isolated arteries also showed that the effect of resveratrol or SIRT1 activator CAY10602 was inhibited by PPARdelta antagonist GSK0660.	Resveratrol	64-75	peroxisome proliferator activator receptor delta	Mus musculus	121-130
30503839-8	2019	Experiments on isolated arteries also showed that the effect of resveratrol or SIRT1 activator CAY10602 was inhibited by PPARdelta antagonist GSK0660.	CAY10602	95-103	peroxisome proliferator activator receptor delta	Mus musculus	121-130
30503839-8	2019	Experiments on isolated arteries also showed that the effect of resveratrol or SIRT1 activator CAY10602 was inhibited by PPARdelta antagonist GSK0660.	GSK0660	142-149	peroxisome proliferator activator receptor delta	Mus musculus	121-130
30503839-9	2019	Resveratrol increased PPARdelta transcriptional activity in endothelial cells.	Resveratrol	0-11	peroxisome proliferator activator receptor delta	Mus musculus	22-31
30227151-0	2018	The PPARdelta agonist GW0742 restores neuroimmune function by regulating Tim-3 and Th17/Treg-related signaling in the BTBR autistic mouse model.	GW0742	22-28	peroxisome proliferator activator receptor delta	Mus musculus	4-13
30503839-0	2019	Resveratrol ameliorates endothelial dysfunction in diabetic and obese mice through sirtuin 1 and peroxisome proliferator-activated receptor delta.	Resveratrol	0-11	peroxisome proliferator activator receptor delta	Mus musculus	97-145
30503839-7	2019	Oral treatment with resveratrol treatment improves endothelial function in high fat diet fed wild type Ppard-wt but not in PPARdelta knockout Ppard-mut mice.	Resveratrol	20-31	peroxisome proliferator activator receptor delta	Mus musculus	103-108
29388693-10	2018	These results indicate that PPARdelta attenuates LPS-triggered neuroinflammation by enhancing SOCS1-mediated inhibition of JAK2/STAT1 signaling, thereby inhibiting neurotoxicity associated with glutamate release.	Glutamic Acid	194-203	peroxisome proliferator activator receptor delta	Mus musculus	28-37
29580823-0	2018	GW0742 (PPAR-beta agonist) attenuates hepatic endoplasmic reticulum stress by improving hepatic energy metabolism in high-fat diet fed mice.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	8-17
29580823-3	2018	This study aimed to investigate the effects of GW0742 (PPAR-beta agonist) on hepatic energy metabolism and ER stress in a murine diet-induced obesity model.	GW0742	47-53	peroxisome proliferator activator receptor delta	Mus musculus	55-64
30213948-11	2018	In the current study, we report for the first time that METRNL alleviates inflammation and insulin resistance and induces fatty acid oxidation through AMPK or PPARdelta-dependent signaling in skeletal muscle.	Fatty Acids	122-132	peroxisome proliferator activator receptor delta	Mus musculus	159-168
29873587-3	2018	Furthermore, administration of GFE to high-fat diet-induced obese mice lowered the total blood cholesterol levels, upregulated the expression of PPARdelta-target genes in skeletal muscles and improved glucose intolerance.	1-(3,4-dichlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine	31-34	peroxisome proliferator activator receptor delta	Mus musculus	145-154
30142312-0	2018	Erucic acid, a component of Lorenzo"s oil and PPAR-delta ligand modifies C6 glioma growth and toxicity of doxorubicin.	erucic acid	0-11	peroxisome proliferator activator receptor delta	Mus musculus	46-56
30142312-0	2018	Erucic acid, a component of Lorenzo"s oil and PPAR-delta ligand modifies C6 glioma growth and toxicity of doxorubicin.	Doxorubicin	106-117	peroxisome proliferator activator receptor delta	Mus musculus	46-56
30142312-3	2018	OBJECTIVE: One of the ligands of PPAR-delta is erucic acid (EA), an edible omega-9 fatty acid consumed more by Asian populations and exists highly in Chinese womens milk.	erucic acid	47-58	peroxisome proliferator activator receptor delta	Mus musculus	33-43
30142312-3	2018	OBJECTIVE: One of the ligands of PPAR-delta is erucic acid (EA), an edible omega-9 fatty acid consumed more by Asian populations and exists highly in Chinese womens milk.	erucic acid	60-62	peroxisome proliferator activator receptor delta	Mus musculus	33-43
30142312-3	2018	OBJECTIVE: One of the ligands of PPAR-delta is erucic acid (EA), an edible omega-9 fatty acid consumed more by Asian populations and exists highly in Chinese womens milk.	Oleic Acid	75-93	peroxisome proliferator activator receptor delta	Mus musculus	33-43
30213948-8	2018	siRNA-mediated suppression of AMPK and PPARdelta abrogated the suppressive effects of METRNL on palmitate-induced inflammation and insulin resistance.	Palmitates	96-105	peroxisome proliferator activator receptor delta	Mus musculus	39-48
29388693-0	2018	Activation of PPARdelta attenuates neurotoxicity by inhibiting lipopolysaccharide-triggered glutamate release in BV-2 microglial cells.	Glutamic Acid	92-101	peroxisome proliferator activator receptor delta	Mus musculus	14-23
29388693-3	2018	Here, we show that peroxisome proliferator-activated receptor delta (PPARdelta) modulates neurotoxicity by inhibiting glutamate release in lipopolysaccharide (LPS)-activated BV-2 microglial cells.	Glutamic Acid	118-127	peroxisome proliferator activator receptor delta	Mus musculus	19-67
29388693-3	2018	Here, we show that peroxisome proliferator-activated receptor delta (PPARdelta) modulates neurotoxicity by inhibiting glutamate release in lipopolysaccharide (LPS)-activated BV-2 microglial cells.	Glutamic Acid	118-127	peroxisome proliferator activator receptor delta	Mus musculus	69-78
29388693-4	2018	Activation of PPARdelta by GW501516, a specific PPARdelta agonist, inhibited glutamate release in BV-2 cells.	GW 501516	27-35	peroxisome proliferator activator receptor delta	Mus musculus	14-23
29388693-4	2018	Activation of PPARdelta by GW501516, a specific PPARdelta agonist, inhibited glutamate release in BV-2 cells.	GW 501516	27-35	peroxisome proliferator activator receptor delta	Mus musculus	48-57
29388693-4	2018	Activation of PPARdelta by GW501516, a specific PPARdelta agonist, inhibited glutamate release in BV-2 cells.	Glutamic Acid	77-86	peroxisome proliferator activator receptor delta	Mus musculus	14-23
29388693-4	2018	Activation of PPARdelta by GW501516, a specific PPARdelta agonist, inhibited glutamate release in BV-2 cells.	Glutamic Acid	77-86	peroxisome proliferator activator receptor delta	Mus musculus	48-57
29388693-5	2018	This effect of GW501516 was significantly blocked by shRNA-mediated knockdown of PPARdelta and by treatment with GSK0660, a specific PPARdelta antagonist, indicating that PPARdelta is associated with blockade of glutamate release.	GW 501516	15-23	peroxisome proliferator activator receptor delta	Mus musculus	81-90
29388693-5	2018	This effect of GW501516 was significantly blocked by shRNA-mediated knockdown of PPARdelta and by treatment with GSK0660, a specific PPARdelta antagonist, indicating that PPARdelta is associated with blockade of glutamate release.	GW 501516	15-23	peroxisome proliferator activator receptor delta	Mus musculus	133-142
29388693-5	2018	This effect of GW501516 was significantly blocked by shRNA-mediated knockdown of PPARdelta and by treatment with GSK0660, a specific PPARdelta antagonist, indicating that PPARdelta is associated with blockade of glutamate release.	GW 501516	15-23	peroxisome proliferator activator receptor delta	Mus musculus	133-142
29388693-5	2018	This effect of GW501516 was significantly blocked by shRNA-mediated knockdown of PPARdelta and by treatment with GSK0660, a specific PPARdelta antagonist, indicating that PPARdelta is associated with blockade of glutamate release.	Glutamic Acid	212-221	peroxisome proliferator activator receptor delta	Mus musculus	133-142
29388693-5	2018	This effect of GW501516 was significantly blocked by shRNA-mediated knockdown of PPARdelta and by treatment with GSK0660, a specific PPARdelta antagonist, indicating that PPARdelta is associated with blockade of glutamate release.	Glutamic Acid	212-221	peroxisome proliferator activator receptor delta	Mus musculus	133-142
29388693-6	2018	Additionally, GW501516-activated PPARdelta suppressed generation of reactive oxygen species and expression of gp91phox, a functional subunit of NADPH oxidase 2, in BV-2 cells stimulated with LPS.	GW 501516	14-22	peroxisome proliferator activator receptor delta	Mus musculus	33-42
29388693-6	2018	Additionally, GW501516-activated PPARdelta suppressed generation of reactive oxygen species and expression of gp91phox, a functional subunit of NADPH oxidase 2, in BV-2 cells stimulated with LPS.	Reactive Oxygen Species	68-91	peroxisome proliferator activator receptor delta	Mus musculus	33-42
29693165-8	2018	The results confirmed that silencing miR-29a induced a decrease in glucose transport and affected lipid metabolism in PA-treated C2C12 cells, and therefore may be involved in insulin resistance by targeting PPARdelta in skeletal muscle.	Palmitic Acid	118-120	peroxisome proliferator activator receptor delta	Mus musculus	207-216
29233935-6	2018	Finally, GW501516-activated PPARdelta improved insulin signaling and glucose intolerance in mice fed a high-fat diet through its interaction with TCPTP45.	GW 501516	9-17	peroxisome proliferator activator receptor delta	Mus musculus	28-37
29409330-7	2018	The bacterial therapy led to up-regulation of lipolytic transcription factors, such as peroxisome proliferator-activated receptor (PPAR)-alpha, PPAR-delta, and their regulated gene products in fatty acid metabolism and glucose uptake, such as acyl-CoA oxidase, carnitine palmitoyl-transferase-1, uncoupling protein-3 and glucose transporter-4.	Fatty Acids	193-203	peroxisome proliferator activator receptor delta	Mus musculus	144-154
29409330-7	2018	The bacterial therapy led to up-regulation of lipolytic transcription factors, such as peroxisome proliferator-activated receptor (PPAR)-alpha, PPAR-delta, and their regulated gene products in fatty acid metabolism and glucose uptake, such as acyl-CoA oxidase, carnitine palmitoyl-transferase-1, uncoupling protein-3 and glucose transporter-4.	Glucose	219-226	peroxisome proliferator activator receptor delta	Mus musculus	144-154
29367760-0	2018	ROS release by PPARbeta/delta-null fibroblasts reduces tumor load through epithelial antioxidant response.	ros	0-3	peroxisome proliferator activator receptor delta	Mus musculus	15-23
29367760-5	2018	The pre-treatment of FSPCre-Pparb/d-/- and Pparb/dfl/fl with antioxidant N-acetyl-cysteine prior DSS-induced tumorigenesis resulted in lower tumor load.	Acetylcysteine	73-90	peroxisome proliferator activator receptor delta	Mus musculus	21-48
29367760-9	2018	Therefore, our results establish a role for fibroblast PPARbeta/delta in epithelial-mesenchymal communication for ROS homeostasis.	ros	114-117	peroxisome proliferator activator receptor delta	Mus musculus	55-63
29697010-2	2018	We hypothesized that the PPAR-beta/delta-agonist GW0742 improves long-term outcome after sepsis caused by cecal ligation and puncture (CLP).	GW0742	49-55	peroxisome proliferator activator receptor delta	Mus musculus	25-34
29233935-6	2018	Finally, GW501516-activated PPARdelta improved insulin signaling and glucose intolerance in mice fed a high-fat diet through its interaction with TCPTP45.	Glucose	69-76	peroxisome proliferator activator receptor delta	Mus musculus	28-37
29295852-8	2018	We found that the protective effect of COX-2 on renal vascular function was associated with prostacyclin signaling through PPARbeta/delta (peroxisome proliferator-activated receptor-beta/delta).	Epoprostenol	92-104	peroxisome proliferator activator receptor delta	Mus musculus	123-186
29067487-12	2018	Interestingly, non-adipogenic epigenetic profiles can be reverted in NIH-3T3 cells as 5-azacytidine treatment increased Zfp423 mRNA levels (p < 0.01), reduced DNA methylation at a specific CpG site (p < 0.01), decreased nucleosome occupancy (NUC1, NUC2: p < 0.001) and induced adipocyte differentiation (p < 0.05).	Azacitidine	86-99	peroxisome proliferator activator receptor delta	Mus musculus	248-252
29351550-11	2018	CONCLUSIONS: This work provides evidence that the PPAR-beta/delta agonist ameliorated metabolic disorders through enhanced beta-oxidation and better tolerance to glucose, whereas the PPAR-alpha agonism was confirmed as a promising therapeutic target for treating metabolic diseases via beige cell induction and enhanced thermogenesis.	Glucose	162-169	peroxisome proliferator activator receptor delta	Mus musculus	50-59
29160120-3	2018	We hypothesized that PPARdelta activation by the novel orally administered lipophilic PPARdelta agonist SAR145 may improve short- and long-term outcome after focal brain ischemia.	sar145	104-110	peroxisome proliferator activator receptor delta	Mus musculus	21-30
29312829-10	2018	These effects of formononetin were dramatically attenuated in cells treated with small interfering RNA (siRNA) against PPARdelta or with GSK0660, a specific inhibitor of PPARdelta, indicating that PPARdelta is involved in formononetin-mediated SIRT1 expression.	formononetin	17-29	peroxisome proliferator activator receptor delta	Mus musculus	170-179
29312829-13	2018	Furthermore, modulation of SIRT1 expression by transfection of SIRT1- or PPARdelta-targeting siRNA significantly counteracted the inhibitory effects of formononetin on LPS-induced HMGB1 acetylation, which was responsible for HMGB1 release.	formononetin	152-164	peroxisome proliferator activator receptor delta	Mus musculus	73-82
29312829-14	2018	Discussion: This study shows for the first time that formononetin inhibits HMGB1 release by decreasing HMGB1 acetylation via upregulating SIRT1 in a PPARdelta-dependent manner.	formononetin	53-65	peroxisome proliferator activator receptor delta	Mus musculus	149-158
29806482-8	2018	Furthermore, MBP-luci mice demonstrated enhanced luciferase signal and remyelination in the cuprizone model after treatment with a peroxisome proliferator activated receptor-delta selective agonist and quetiapine.	Cuprizone	92-101	peroxisome proliferator activator receptor delta	Mus musculus	131-179
29312829-0	2018	Formononetin inhibits lipopolysaccharide-induced release of high mobility group box 1 by upregulating SIRT1 in a PPARdelta-dependent manner.	formononetin	0-12	peroxisome proliferator activator receptor delta	Mus musculus	113-122
29312829-9	2018	In addition, formononetin significantly induced mRNA and protein expression of SIRT1 in a peroxisome proliferator-activated receptor delta (PPARdelta)-dependent manner.	formononetin	13-25	peroxisome proliferator activator receptor delta	Mus musculus	90-138
29312829-9	2018	In addition, formononetin significantly induced mRNA and protein expression of SIRT1 in a peroxisome proliferator-activated receptor delta (PPARdelta)-dependent manner.	formononetin	13-25	peroxisome proliferator activator receptor delta	Mus musculus	140-149
29312829-10	2018	These effects of formononetin were dramatically attenuated in cells treated with small interfering RNA (siRNA) against PPARdelta or with GSK0660, a specific inhibitor of PPARdelta, indicating that PPARdelta is involved in formononetin-mediated SIRT1 expression.	formononetin	17-29	peroxisome proliferator activator receptor delta	Mus musculus	119-128
29312829-10	2018	These effects of formononetin were dramatically attenuated in cells treated with small interfering RNA (siRNA) against PPARdelta or with GSK0660, a specific inhibitor of PPARdelta, indicating that PPARdelta is involved in formononetin-mediated SIRT1 expression.	formononetin	17-29	peroxisome proliferator activator receptor delta	Mus musculus	170-179
29160120-3	2018	We hypothesized that PPARdelta activation by the novel orally administered lipophilic PPARdelta agonist SAR145 may improve short- and long-term outcome after focal brain ischemia.	sar145	104-110	peroxisome proliferator activator receptor delta	Mus musculus	86-95
29404484-0	2017	The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.	Seladelpar	71-81	peroxisome proliferator activator receptor delta	Mus musculus	14-62
29212711-0	2017	PPARdelta activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis.	Bexarotene	24-34	peroxisome proliferator activator receptor delta	Mus musculus	0-9
29212711-3	2017	We recently determined that transcriptional dysregulation of PPARdelta contributes to Huntington"s disease (HD), a progressive neurodegenerative disorder resulting from a CAG-polyglutamine repeat expansion in the huntingtin gene.	polyglutamine	175-188	peroxisome proliferator activator receptor delta	Mus musculus	61-70
29212711-4	2017	We documented that the PPARdelta agonist KD3010 is an effective therapy for HD in a mouse model.	4-(2,6-dimethyl-4-(4-trifluoromethoxyphenyl)piperazine-1-sulfonyl)indan-2-carboxylic acid	41-47	peroxisome proliferator activator receptor delta	Mus musculus	23-32
29212711-9	2017	To determine the basis for PPARdelta neuroprotection, we evaluated metabolic function and noted markedly impaired oxidative metabolism in HD neurons, which was rescued by bexarotene or KD3010.	Bexarotene	171-181	peroxisome proliferator activator receptor delta	Mus musculus	27-36
29212711-9	2017	To determine the basis for PPARdelta neuroprotection, we evaluated metabolic function and noted markedly impaired oxidative metabolism in HD neurons, which was rescued by bexarotene or KD3010.	4-(2,6-dimethyl-4-(4-trifluoromethoxyphenyl)piperazine-1-sulfonyl)indan-2-carboxylic acid	185-191	peroxisome proliferator activator receptor delta	Mus musculus	27-36
29070884-0	2017	Telmisartan Activates PPARdelta to Improve Symptoms of Unpredictable Chronic Mild Stress-Induced Depression in Mice.	Telmisartan	0-11	peroxisome proliferator activator receptor delta	Mus musculus	22-31
29070884-3	2017	Telmisartan was recently shown to activate PPARdelta expression; therefore, the effectiveness of telmisartan in treating depression was investigated.	Telmisartan	0-11	peroxisome proliferator activator receptor delta	Mus musculus	43-52
29070884-5	2017	Telmisartan also reversed the decrease in PPARdelta and 5-HTT levels in the hippocampus of depression-like mice.	Telmisartan	0-11	peroxisome proliferator activator receptor delta	Mus musculus	42-51
29070884-6	2017	Administration of PPARdelta antagonist GSK0660 and direct infusion of sh-PPARdelta into the brain blocked the effects of telmisartan on the improvement of depression-like behavior in these mice.	GSK0660	39-46	peroxisome proliferator activator receptor delta	Mus musculus	18-27
29070884-6	2017	Administration of PPARdelta antagonist GSK0660 and direct infusion of sh-PPARdelta into the brain blocked the effects of telmisartan on the improvement of depression-like behavior in these mice.	Telmisartan	121-132	peroxisome proliferator activator receptor delta	Mus musculus	18-27
29070884-6	2017	Administration of PPARdelta antagonist GSK0660 and direct infusion of sh-PPARdelta into the brain blocked the effects of telmisartan on the improvement of depression-like behavior in these mice.	Telmisartan	121-132	peroxisome proliferator activator receptor delta	Mus musculus	73-82
29070884-7	2017	Moreover, telmisartan enhanced the expression of PPARdelta and 5HTT in H19-7 cells.	Telmisartan	10-21	peroxisome proliferator activator receptor delta	Mus musculus	49-58
29070884-8	2017	In conclusion, the obtained results suggest that telmisartan improves symptoms of stress-induced depression in animals under chronic stress through activation of PPARdelta.	Telmisartan	49-60	peroxisome proliferator activator receptor delta	Mus musculus	162-171
29031719-10	2017	NLR family pyrin domain containing 3 (Nlrp3) inflammasome activation by PA in the presence of lipopolysaccharide is also increased in Stat6-/- macrophages and to a lesser extent, in Ppardelta/gamma-/- macrophages.	Palmitic Acid	72-74	peroxisome proliferator activator receptor delta	Mus musculus	182-191
29404484-3	2017	Seladelpar (MBX-8025), a selective PPAR-delta agonist, improves atherogenic dyslipidemia.	Seladelpar	0-10	peroxisome proliferator activator receptor delta	Mus musculus	35-45
29031719-9	2017	Deletion of Stat6 or Ppardelta/Ppargamma increases the susceptibility of macrophages to PA-induced cell death.	Palmitic Acid	88-90	peroxisome proliferator activator receptor delta	Mus musculus	21-30
29037332-2	2017	We hypothesized that increasing PUFA intake in mice would increase peroxisome proliferator activated receptor delta (PPARdelta) expression and activity, and we sought to examine the effect of different PUFA-enriched oils on muscle PPARdelta expression.	Fatty Acids, Unsaturated	32-36	peroxisome proliferator activator receptor delta	Mus musculus	117-126
29037332-9	2017	The effect of DHSA on PPARdelta and stearoyl-CoA desaturase-1 expression mimicked that of the CSO-fed mice.	dihydrosterculic acid	14-18	peroxisome proliferator activator receptor delta	Mus musculus	22-31
29037332-10	2017	Taken together, these data suggest that DHSA from CSO may be an effective means to increase PPARdelta expression with concomitant suppression of liver stearoyl-CoA desaturase-1 activity.	dihydrosterculic acid	40-44	peroxisome proliferator activator receptor delta	Mus musculus	92-101
29037332-10	2017	Taken together, these data suggest that DHSA from CSO may be an effective means to increase PPARdelta expression with concomitant suppression of liver stearoyl-CoA desaturase-1 activity.	Cottonseed Oil	50-53	peroxisome proliferator activator receptor delta	Mus musculus	92-101
27584056-0	2016	A PPARdelta-selective antagonist ameliorates IMQ-induced psoriasis-like inflammation in mice.	Imiquimod	45-48	peroxisome proliferator activator receptor delta	Mus musculus	2-11
28467934-0	2017	PPARdelta Promotes Running Endurance by Preserving Glucose.	Glucose	51-58	peroxisome proliferator activator receptor delta	Mus musculus	0-9
28467934-4	2017	In addition to stimulating fatty acid metabolism in sedentary mice, PPARdelta activation potently suppresses glucose catabolism and does so without affecting either muscle fiber type or mitochondrial content.	Fatty Acids	27-37	peroxisome proliferator activator receptor delta	Mus musculus	68-77
28467934-5	2017	By preserving systemic glucose levels, PPARdelta acts to delay the onset of hypoglycemia and extends running time by ~100 min in treated mice.	Glucose	23-30	peroxisome proliferator activator receptor delta	Mus musculus	39-48
28467934-6	2017	Collectively, these results identify a bifurcated PPARdelta program that underlies glucose sparing and highlight the potential of PPARdelta-targeted exercise mimetics in the treatment of metabolic disease, dystrophies, and, unavoidably, the enhancement of athletic performance.	Glucose	83-90	peroxisome proliferator activator receptor delta	Mus musculus	50-59
28404991-2	2017	Activation of PPARdelta stimulates fatty acid oxidation in adipose tissue and skeletal muscle and improves dyslipidemia in mice and humans.	Fatty Acids	35-45	peroxisome proliferator activator receptor delta	Mus musculus	14-23
28404991-5	2017	Furthermore, absence of intestinal PPARdelta abolished the ability of PPARdelta agonist GW501516 to increase plasma levels of HDL-cholesterol.	GW 501516	88-96	peroxisome proliferator activator receptor delta	Mus musculus	35-44
28404991-5	2017	Furthermore, absence of intestinal PPARdelta abolished the ability of PPARdelta agonist GW501516 to increase plasma levels of HDL-cholesterol.	GW 501516	88-96	peroxisome proliferator activator receptor delta	Mus musculus	70-79
28404991-5	2017	Furthermore, absence of intestinal PPARdelta abolished the ability of PPARdelta agonist GW501516 to increase plasma levels of HDL-cholesterol.	Cholesterol	130-141	peroxisome proliferator activator receptor delta	Mus musculus	70-79
28242713-2	2017	We tested whether GW0742, a peroxisome proliferator activator receptor beta/delta (PPARbeta/delta) agonist, ameliorates disease activity and cardiovascular complications in a female mouse model of lupus.	GW0742	18-24	peroxisome proliferator activator receptor delta	Mus musculus	83-91
28242713-9	2017	All these effects of GW0742 were inhibited by PPARbeta/delta blockade with GSK0660.	GW0742	21-27	peroxisome proliferator activator receptor delta	Mus musculus	46-54
28242713-9	2017	All these effects of GW0742 were inhibited by PPARbeta/delta blockade with GSK0660.	GSK0660	75-82	peroxisome proliferator activator receptor delta	Mus musculus	46-54
29201040-0	2017	Caffeoylquinic Acid-Rich Extract of Aster glehni F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPARdelta and Adiponectin in ApoE KO Mice.	caffeoylquinic acid	0-19	peroxisome proliferator activator receptor delta	Mus musculus	123-132
29201040-8	2017	glehni treatment; this effect was suppressed in the presence of the PPARdelta antagonist, GSK0660.	glehni	0-6	peroxisome proliferator activator receptor delta	Mus musculus	68-77
27930695-0	2016	Coordinated Activation of VEGF/VEGFR-2 and PPARdelta Pathways by a Multi-Component Chinese Medicine DHI Accelerated Recovery from Peripheral Arterial Disease in Type 2 Diabetic Mice.	dehydrosoyasaponin I	100-103	peroxisome proliferator activator receptor delta	Mus musculus	43-52
27930695-9	2016	A cross talk between ischemia-induced angiogenesis and glucose tolerance pathways was analyzed by Ingenuity Pathway Analysis (IPA) which suggested an interaction of VEGF-A/VEGFR-2 and peroxisome proliferator-activated receptor delta (PPARdelta)/peroxisome proliferator-activated receptor gamma (PPARgamma) genes.	Glucose	55-62	peroxisome proliferator activator receptor delta	Mus musculus	184-232
27930695-9	2016	A cross talk between ischemia-induced angiogenesis and glucose tolerance pathways was analyzed by Ingenuity Pathway Analysis (IPA) which suggested an interaction of VEGF-A/VEGFR-2 and peroxisome proliferator-activated receptor delta (PPARdelta)/peroxisome proliferator-activated receptor gamma (PPARgamma) genes.	Glucose	55-62	peroxisome proliferator activator receptor delta	Mus musculus	234-243
27930695-10	2016	We confirmed that upregulation of VEGF-A/VEGFR-2 by DHI promoted PPARdelta gene expression in both type 2 diabetic mice.	dehydrosoyasaponin I	52-55	peroxisome proliferator activator receptor delta	Mus musculus	65-74
27930695-11	2016	Our findings demonstrated that a multi-component Chinese medicine DHI effectively increased blood flow recovery after tissue ischemia in diabetic mice by promoting angiogenesis and improving glucose tolerance through a concomitant activation of VEGF-A/VEGFR-2 and PPARdelta signaling pathways.	dehydrosoyasaponin I	66-69	peroxisome proliferator activator receptor delta	Mus musculus	264-273
27765815-3	2016	Because peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) modulates ethanol-induced hepatic effects, the present study examined alterations in gene expression that may contribute to this disease.	Ethanol	89-96	peroxisome proliferator activator receptor delta	Mus musculus	8-55
27765815-3	2016	Because peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) modulates ethanol-induced hepatic effects, the present study examined alterations in gene expression that may contribute to this disease.	Ethanol	89-96	peroxisome proliferator activator receptor delta	Mus musculus	63-71
27765815-4	2016	Chronic ethanol treatment causes increased hepatic CYP2B10 expression inPparbeta/delta+/+ mice but not in Pparbeta/delta-/- mice.	Ethanol	8-15	peroxisome proliferator activator receptor delta	Mus musculus	72-80
27765815-6	2016	PPARgamma co-activator 1alpha, a co-activator of both CAR and PPARbeta/delta, was up-regulated in Pparbeta/delta+/+ liver following ethanol exposure, but not in Pparbeta/delta-/- liver.	Ethanol	132-139	peroxisome proliferator activator receptor delta	Mus musculus	62-70
27765815-6	2016	PPARgamma co-activator 1alpha, a co-activator of both CAR and PPARbeta/delta, was up-regulated in Pparbeta/delta+/+ liver following ethanol exposure, but not in Pparbeta/delta-/- liver.	Ethanol	132-139	peroxisome proliferator activator receptor delta	Mus musculus	98-106
27765815-7	2016	Functional mapping of the Cyp2b10 promoter and ChIP assays revealed that PPARbeta/delta-dependent modulation of SP1 promoter occupancy up-regulated Cyp2b10 expression in response to ethanol.	Ethanol	182-189	peroxisome proliferator activator receptor delta	Mus musculus	73-81
27765815-9	2016	Ligand activation of PPARbeta/delta attenuates ethanol-induced Cyp2b10 expression in Pparbeta/delta+/+ liver but not in Pparbeta/delta-/- liver.	Ethanol	47-54	peroxisome proliferator activator receptor delta	Mus musculus	21-29
27765815-9	2016	Ligand activation of PPARbeta/delta attenuates ethanol-induced Cyp2b10 expression in Pparbeta/delta+/+ liver but not in Pparbeta/delta-/- liver.	Ethanol	47-54	peroxisome proliferator activator receptor delta	Mus musculus	85-93
27765815-10	2016	Strikingly, Cyp2b10 suppression by ligand activation of PPARbeta/delta following ethanol treatment occurred in hepatocytes and was mediated by paracrine signaling from Kupffer cells.	Ethanol	81-88	peroxisome proliferator activator receptor delta	Mus musculus	56-64
27939528-9	2017	Differential effects of GW0742 observed during the regeneration were associated with variations of PPARbeta pathway activity.	GW0742	24-30	peroxisome proliferator activator receptor delta	Mus musculus	99-107
27818230-0	2017	Effect of PPAR-beta/delta agonist GW0742 treatment in the acute phase response and blood-brain barrier permeability following brain injury.	GW0742	34-40	peroxisome proliferator activator receptor delta	Mus musculus	10-19
27818230-5	2017	In the present study, we determined for the first time, the effects of GW0742, a PPAR-beta/delta agonist on the APR following brain injury and assessed the effects on BBB permeability and tight junction integrity via claudin-5, occludin, and zona occludens-1 expression.	GW0742	71-77	peroxisome proliferator activator receptor delta	Mus musculus	81-90
27913621-8	2017	Finally, we have provided in vivo evidence showing that activation of PPARdelta by agonist L165041 in mice increased hepatic LPCAT3 mRNA abundance and LPCAT enzymatic activity, which is associated with increased incorporations of arachidonate into liver phosphatidylcholine and phosphatidylethanolamine.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	91-98	peroxisome proliferator activator receptor delta	Mus musculus	70-79
27913621-8	2017	Finally, we have provided in vivo evidence showing that activation of PPARdelta by agonist L165041 in mice increased hepatic LPCAT3 mRNA abundance and LPCAT enzymatic activity, which is associated with increased incorporations of arachidonate into liver phosphatidylcholine and phosphatidylethanolamine.	Arachidonic Acid	230-242	peroxisome proliferator activator receptor delta	Mus musculus	70-79
27913621-8	2017	Finally, we have provided in vivo evidence showing that activation of PPARdelta by agonist L165041 in mice increased hepatic LPCAT3 mRNA abundance and LPCAT enzymatic activity, which is associated with increased incorporations of arachidonate into liver phosphatidylcholine and phosphatidylethanolamine.	Phosphatidylcholines	254-273	peroxisome proliferator activator receptor delta	Mus musculus	70-79
27913621-8	2017	Finally, we have provided in vivo evidence showing that activation of PPARdelta by agonist L165041 in mice increased hepatic LPCAT3 mRNA abundance and LPCAT enzymatic activity, which is associated with increased incorporations of arachidonate into liver phosphatidylcholine and phosphatidylethanolamine.	phosphatidylethanolamine	278-302	peroxisome proliferator activator receptor delta	Mus musculus	70-79
27913621-10	2017	Altogether, our new findings identify LPCAT3 as a direct PPARdelta target gene and suggest a novel function of PPARdelta in regulation of phospholipid metabolism through LPCAT3.	Phospholipids	138-150	peroxisome proliferator activator receptor delta	Mus musculus	57-66
27913621-10	2017	Altogether, our new findings identify LPCAT3 as a direct PPARdelta target gene and suggest a novel function of PPARdelta in regulation of phospholipid metabolism through LPCAT3.	Phospholipids	138-150	peroxisome proliferator activator receptor delta	Mus musculus	111-120
28214892-8	2017	Moreover, we found that baicalin induced PPARalpha and PPARbeta/delta expression in vivo and in vitro.	baicalin	24-32	peroxisome proliferator activator receptor delta	Mus musculus	55-63
26661245-6	2017	PPARdelta-siRNA abolished iloprost-augmented protein expression of ADAM10.	Iloprost	26-34	peroxisome proliferator activator receptor delta	Mus musculus	0-9
26661245-7	2017	In contrast, GW501516 (a selective agonist of PPARdelta) upregulated ADAM10 and increased production of sAPPalpha.	GW 501516	13-21	peroxisome proliferator activator receptor delta	Mus musculus	46-55
26964143-4	2016	METHODS: We either treated human MSCs (hMSCs) with the irreversible PPARbeta/delta antagonist (GSK3787) or derived MSCs from mice deficient for PPARbeta/delta (PPARbeta/delta-/- MSCs).	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	95-102	peroxisome proliferator activator receptor delta	Mus musculus	68-82
27736732-0	2016	Conjugated linoleic acid (CLA) promotes endurance capacity via peroxisome proliferator-activated receptor delta-mediated mechanism in mice.	Linoleic Acid	11-24	peroxisome proliferator activator receptor delta	Mus musculus	63-111
27736732-0	2016	Conjugated linoleic acid (CLA) promotes endurance capacity via peroxisome proliferator-activated receptor delta-mediated mechanism in mice.	Linoleic Acids, Conjugated	26-29	peroxisome proliferator activator receptor delta	Mus musculus	63-111
27736732-1	2016	Previously, it was reported that conjugated linoleic acid (CLA) with exercise training potentially improved endurance capacity via the peroxisome proliferator-activated receptor delta (PPARdelta)-mediated mechanism in mice.	Linoleic Acid	44-57	peroxisome proliferator activator receptor delta	Mus musculus	135-183
27736732-1	2016	Previously, it was reported that conjugated linoleic acid (CLA) with exercise training potentially improved endurance capacity via the peroxisome proliferator-activated receptor delta (PPARdelta)-mediated mechanism in mice.	Linoleic Acid	44-57	peroxisome proliferator activator receptor delta	Mus musculus	185-194
27736732-1	2016	Previously, it was reported that conjugated linoleic acid (CLA) with exercise training potentially improved endurance capacity via the peroxisome proliferator-activated receptor delta (PPARdelta)-mediated mechanism in mice.	Linoleic Acids, Conjugated	59-62	peroxisome proliferator activator receptor delta	Mus musculus	135-183
27736732-1	2016	Previously, it was reported that conjugated linoleic acid (CLA) with exercise training potentially improved endurance capacity via the peroxisome proliferator-activated receptor delta (PPARdelta)-mediated mechanism in mice.	Linoleic Acids, Conjugated	59-62	peroxisome proliferator activator receptor delta	Mus musculus	185-194
27736732-6	2016	Similarly, CLA treatment significantly increased expressions of sirtuin 1 and PPARgamma coactivator-1alpha, up-stream regulators of PPARdelta, in both sedentary and trained animals.	Linoleic Acids, Conjugated	11-14	peroxisome proliferator activator receptor delta	Mus musculus	132-141
27736732-7	2016	With respect to downstream markers of PPARdelta, CLA up-regulated the key biomarker needed to stimulate mitochondrial biogenesis, nuclear respiratory factor 1.	Linoleic Acids, Conjugated	49-52	peroxisome proliferator activator receptor delta	Mus musculus	38-47
27736732-9	2016	Taken together, it suggests that CLA improves endurance capacity independent of mild-intensity exercise via PPARdelta-mediated mechanism.	Linoleic Acids, Conjugated	33-36	peroxisome proliferator activator receptor delta	Mus musculus	108-117
27584056-4	2016	In the current study, we showed that PPARdelta was highly expressed in the skin of IMQ-induced psoriasis mice.	Imiquimod	83-86	peroxisome proliferator activator receptor delta	Mus musculus	37-46
27584056-6	2016	We found that PPARdelta was highly expressed in both psoriatic lesions and normal skin in IMQ-induced psoriasis mice.	Imiquimod	90-93	peroxisome proliferator activator receptor delta	Mus musculus	14-23
27584056-8	2016	The PPARdelta-selective antagonist GSK3787 ameliorated the observed inflammation in the skin of the experimental mice.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	35-42	peroxisome proliferator activator receptor delta	Mus musculus	4-13
27449753-0	2016	Paeonol protects against endoplasmic reticulum stress-induced endothelial dysfunction via AMPK/PPARdelta signaling pathway.	paeonol	0-7	peroxisome proliferator activator receptor delta	Mus musculus	95-104
27486236-8	2016	Of note, increased Fgf21 expression in mice fed a high-fat diet or hepatocytes exposed to palmitate was accompanied by reduced PPARbeta/delta and activation of the HRI-eIF2alpha-ATF4 pathway.	Palmitates	90-99	peroxisome proliferator activator receptor delta	Mus musculus	127-135
27449753-6	2016	Ex vivo treatment with paeonol (0.1muM) for 16h reversed the impaired endothelium-dependent relaxations in C57BJ/6J and PPARdelta wild type (WT) mouse aortas following incubation with tunicamycin (0.5mug/mL).	paeonol	23-30	peroxisome proliferator activator receptor delta	Mus musculus	120-129
27449753-7	2016	Elevated ER stress markers, oxidative stress and reduction of NO bioavailability induced by tunicamycin in HUVECs, C57BJ/6J and PPARdelta WT mouse aortas were reversed by paeonol treatment.	Tunicamycin	92-103	peroxisome proliferator activator receptor delta	Mus musculus	128-137
27449753-7	2016	Elevated ER stress markers, oxidative stress and reduction of NO bioavailability induced by tunicamycin in HUVECs, C57BJ/6J and PPARdelta WT mouse aortas were reversed by paeonol treatment.	paeonol	171-178	peroxisome proliferator activator receptor delta	Mus musculus	128-137
27449753-8	2016	These beneficial effects of paeonol were diminished in PPARdelta knockout (KO) mouse aortas.	paeonol	28-35	peroxisome proliferator activator receptor delta	Mus musculus	55-64
27449753-9	2016	Paeonol increased the expression of 5" adenosine monophosphate-activated protein kinase (AMPK) and PPARdelta expression and activity while restoring the decreased phosphorylation of eNOS.	paeonol	0-7	peroxisome proliferator activator receptor delta	Mus musculus	99-108
27449753-10	2016	The present study delineates that paeonol protects against tunicamycin-induced vascular endothelial dysfunction by inhibition of ER stress and oxidative stress, thus elevating NO bioavailability via the AMPK/PPARdelta signaling pathway.	paeonol	34-41	peroxisome proliferator activator receptor delta	Mus musculus	208-217
27449753-10	2016	The present study delineates that paeonol protects against tunicamycin-induced vascular endothelial dysfunction by inhibition of ER stress and oxidative stress, thus elevating NO bioavailability via the AMPK/PPARdelta signaling pathway.	Tunicamycin	59-70	peroxisome proliferator activator receptor delta	Mus musculus	208-217
27315062-0	2016	A Flavonoid Compound Promotes Neuronal Differentiation of Embryonic Stem Cells via PPAR-beta Modulating Mitochondrial Energy Metabolism.	Flavonoids	2-11	peroxisome proliferator activator receptor delta	Mus musculus	83-92
27650252-3	2016	The expression of peroxisome proliferator-activated receptor delta, a gene involved in fatty acid metabolism, was decreased in 10-week-old mice exposed to long photoperiod during 0-4 or 4-8 weeks of age.	Fatty Acids	87-97	peroxisome proliferator activator receptor delta	Mus musculus	18-66
27189971-9	2016	In conclusion, GW0742 exerted antihypertensive effects, restoring sympathetic tone and vascular structure and function in AngII-infused mice by PPARbeta activation in brain and vessels inhibiting AngII signaling as a result of RGS5 upregulation.	GW0742	15-21	peroxisome proliferator activator receptor delta	Mus musculus	144-152
27315062-6	2016	Treatment with PPAR-beta agonist L165041 alone or together with compound 4a significantly promoted neuronal differentiation, while antagonist GSK0660 blocked the neurogenesis-promoting effect of compound 4a.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	33-40	peroxisome proliferator activator receptor delta	Mus musculus	15-24
27315062-9	2016	In conclusion, we demonstrated that by modulating mitochondrial energy metabolism through Mfn2 and mitochondrial Ca2+, PPAR-beta took an important role in neuronal differentiation induced by flavonoid compound 4a.	Flavonoids	191-200	peroxisome proliferator activator receptor delta	Mus musculus	119-128
26864558-1	2016	Based on 3-(((4-(hexylamino)-2-methoxyphenyl)amino)sulfonyl)-2-thiophenecarboxylic acid methyl ester (ST247, compound 2), a recently described peroxisome proliferator-activated receptor (PPAR)beta/delta-selective inverse agonist, we designed and synthesized a series of structurally related ligands.	3-(((4-(hexylamino)-2-methoxyphenyl)amino)sulfonyl)-2-thiophenecarboxylic acid methyl ester	9-100	peroxisome proliferator activator receptor delta	Mus musculus	187-196
27179975-3	2016	In vivo, the PPARbeta/delta agonist GW0742 treatment prevented the LPS-induced reduction in aortic relaxation, the increase in vascular ROS production, the upregulation of NOX1, NOX2, p47(phox), and p22(phox) mRNA levels, and the endoplasmic reticulum (ER) stress markers in mice.	GW0742	36-42	peroxisome proliferator activator receptor delta	Mus musculus	13-21
27179975-3	2016	In vivo, the PPARbeta/delta agonist GW0742 treatment prevented the LPS-induced reduction in aortic relaxation, the increase in vascular ROS production, the upregulation of NOX1, NOX2, p47(phox), and p22(phox) mRNA levels, and the endoplasmic reticulum (ER) stress markers in mice.	Reactive Oxygen Species	136-139	peroxisome proliferator activator receptor delta	Mus musculus	13-21
27008868-2	2016	Recently, we showed that the administration of bezafibrate, a pan-PPAR agonist, increases the expression of PGC-1alpha and mitochondrial biogenesis, and improves phenotype and survival in R6/2 transgenic mouse model of HD.	Bezafibrate	47-58	peroxisome proliferator activator receptor delta	Mus musculus	66-70
26864581-0	2016	PPARdelta agonist GW0742 ameliorates Abeta1-42-induced hippocampal neurotoxicity in mice.	GW0742	18-24	peroxisome proliferator activator receptor delta	Mus musculus	0-9
26864581-3	2016	In the current study, the effect of GW0742, a selective PPARdelta agonist, on Abeta1-42-induced neurotoxicity was investigated in the hippocampus of mice.	GW0742	36-42	peroxisome proliferator activator receptor delta	Mus musculus	56-65
27053360-0	2016	Sodium Intake Regulates Glucose Homeostasis through the PPARdelta/Adiponectin-Mediated SGLT2 Pathway.	Sodium	0-6	peroxisome proliferator activator receptor delta	Mus musculus	56-65
27053360-4	2016	Here, we report that high sodium intake remarkably increased natriuresis in wild-type mice, but this effect was blunted in adipose-specific PPARdelta knockout mice and diabetic mice.	Sodium	26-32	peroxisome proliferator activator receptor delta	Mus musculus	140-149
27053360-5	2016	PPARdelta activation in perirenal fat by agonist or high sodium intake inhibited renal sodium-glucose cotransporter 2 (SGLT2) function, which is mediated by increased production of adipose adiponectin.	Sodium	57-63	peroxisome proliferator activator receptor delta	Mus musculus	0-9
27053360-8	2016	Our findings provide insights into the distinctive role of the PPARdelta/adiponectin/SGLT2 pathway in the regulation of sodium and glucose homeostasis.	Sodium	120-126	peroxisome proliferator activator receptor delta	Mus musculus	63-72
27179975-5	2016	The PPARbeta/delta antagonist GSK0660 abolished all these in vivo and in vitro protective effects induced by GW0742.	GSK0660	30-37	peroxisome proliferator activator receptor delta	Mus musculus	4-12
27179975-5	2016	The PPARbeta/delta antagonist GSK0660 abolished all these in vivo and in vitro protective effects induced by GW0742.	GW0742	109-115	peroxisome proliferator activator receptor delta	Mus musculus	4-12
27179975-9	2016	In conclusion, PPARbeta/delta activation restored the LPS-induced endothelial dysfunction by upregulation of UCP2, with the subsequent alleviation of ER stress and NADPH oxidase activity, thus reducing intracellular ROS production and increasing NO bioavailability.	Reactive Oxygen Species	216-219	peroxisome proliferator activator receptor delta	Mus musculus	15-23
26997622-10	2016	Our data show that combined pharmacological activation of AMPK and PPARdelta potentiates endurance in trained mice by transcriptional changes in muscle and liver, increased available energy substrates, delayed hypoglycemia through glycogen sparing accompanied by increased NEFA availability, and improved substrate shift from carbohydrate to fat.	Glycogen	231-239	peroxisome proliferator activator receptor delta	Mus musculus	67-76
26997622-3	2016	Balb/c mice were trained on a treadmill and administered both the AMPK activator AICAR and the PPARdelta agonist GW0742 for 4 weeks.	GW0742	113-119	peroxisome proliferator activator receptor delta	Mus musculus	95-104
26655383-0	2016	alpha-Lipoic acid up-regulates expression of peroxisome proliferator-activated receptor beta in skeletal muscle: involvement of the JNK signaling pathway.	Thioctic Acid	0-17	peroxisome proliferator activator receptor delta	Mus musculus	45-92
26655383-1	2016	We hypothesized that alpha-lipoic acid (alpha-LA) might interact with the transcriptional control of peroxisome proliferator-activated receptor (PPAR)beta in skeletal muscle.	Thioctic Acid	21-38	peroxisome proliferator activator receptor delta	Mus musculus	145-149
26655383-1	2016	We hypothesized that alpha-lipoic acid (alpha-LA) might interact with the transcriptional control of peroxisome proliferator-activated receptor (PPAR)beta in skeletal muscle.	Thioctic Acid	40-48	peroxisome proliferator activator receptor delta	Mus musculus	145-149
26655383-2	2016	Molecular mechanisms were investigated using differentiated C2C12 myotubes treated with alpha-LA and/or PPARbeta agonist GW0742.	GW0742	121-127	peroxisome proliferator activator receptor delta	Mus musculus	104-112
26655383-8	2016	Similarly to VWR training effect, PPARbeta expression increases (2-fold) in vastus lateralis of animals fed an alpha-LA-enriched diet.	Thioctic Acid	111-119	peroxisome proliferator activator receptor delta	Mus musculus	34-42
26322419-8	2016	Furthermore, the decrease in the expression of peroxisome proliferator-activated receptor (PPARdelta) induced by CSE stimulation could be rescued by SB216763.	SB 216763	149-157	peroxisome proliferator activator receptor delta	Mus musculus	91-100
26322419-13	2016	Taken together, our findings indicate that the reduced activity of WNT/beta-catenin signaling induced by CS may promote inflammatory cytokine production in airway epithelium and have an essential role in airway inflammation in COPD by PPARdelta/p38 MAPK pathway.	Cesium	105-107	peroxisome proliferator activator receptor delta	Mus musculus	235-244
26821916-6	2016	Meanwhile, the effects of lanatoside C were abolished using small interfering RNA (siRNA) inhibition of peroxisome proliferator-activated receptors beta/delta (PPARbeta/delta).	lanatoside C	26-38	peroxisome proliferator activator receptor delta	Mus musculus	160-168
26997622-10	2016	Our data show that combined pharmacological activation of AMPK and PPARdelta potentiates endurance in trained mice by transcriptional changes in muscle and liver, increased available energy substrates, delayed hypoglycemia through glycogen sparing accompanied by increased NEFA availability, and improved substrate shift from carbohydrate to fat.	Fatty Acids, Nonesterified	273-277	peroxisome proliferator activator receptor delta	Mus musculus	67-76
26997622-10	2016	Our data show that combined pharmacological activation of AMPK and PPARdelta potentiates endurance in trained mice by transcriptional changes in muscle and liver, increased available energy substrates, delayed hypoglycemia through glycogen sparing accompanied by increased NEFA availability, and improved substrate shift from carbohydrate to fat.	Carbohydrates	326-338	peroxisome proliferator activator receptor delta	Mus musculus	67-76
27117849-7	2016	Although palmitic acid (C16:0) and lauric acid (C12:0) significantly induced expression of both UCP3 and PDK4, capric acid (C10:0) upregulated only UCP3 expression via activation of peroxisome proliferator-activated receptor-delta.	Palmitic Acid	9-22	peroxisome proliferator activator receptor delta	Mus musculus	182-230
27150147-5	2016	Here, we demonstrate that treatment using a high-affinity PPARbeta/delta agonist, GW0742, reverses the lung tissue damage induced by elastase in emphysema-model mice and improves respiratory function.	GW0742	82-88	peroxisome proliferator activator receptor delta	Mus musculus	58-66
27117849-7	2016	Although palmitic acid (C16:0) and lauric acid (C12:0) significantly induced expression of both UCP3 and PDK4, capric acid (C10:0) upregulated only UCP3 expression via activation of peroxisome proliferator-activated receptor-delta.	lauric acid	35-46	peroxisome proliferator activator receptor delta	Mus musculus	182-230
27117849-7	2016	Although palmitic acid (C16:0) and lauric acid (C12:0) significantly induced expression of both UCP3 and PDK4, capric acid (C10:0) upregulated only UCP3 expression via activation of peroxisome proliferator-activated receptor-delta.	decanoic acid	111-122	peroxisome proliferator activator receptor delta	Mus musculus	182-230
26683793-10	2016	CONCLUSION: A novel PPARdelta agonist, PYPEP, suppressed atherosclerotic lesion progression by improving the serum lipoprotein profiles, including increased levels of ApoA-I and functional HDL particles, as well as a reduced non-HDL cholesterol level, in hApoB100/hCETP-dTg mice with human-like hypercholesterolemic dyslipidemia.	Cholesterol	233-244	peroxisome proliferator activator receptor delta	Mus musculus	20-29
25784542-5	2015	This increase promoted the recruitment of peroxisome proliferator-activated receptor (PPAR)delta and PPARgamma, through desumoylation of PPARs, to the promoters of the genes involved in fatty acid oxidation (FAO), such as carnitine-palmitoyl transferase-1 (CPT1b) and long-chain acyl-CoA synthetase 1 (ACSL1).	Fatty Acids	186-196	peroxisome proliferator activator receptor delta	Mus musculus	42-96
26642438-6	2016	In mouse models of HD, pharmacologic activation of PPAR-delta using the agonist KD3010 improved motor function, reduced neurodegeneration and increased survival.	4-(2,6-dimethyl-4-(4-trifluoromethoxyphenyl)piperazine-1-sulfonyl)indan-2-carboxylic acid	80-86	peroxisome proliferator activator receptor delta	Mus musculus	51-61
27738421-9	2016	Further, inhibition of PPARdelta abolished IL-15 induced increases in citrate synthase activity, ATP production, and overall mitochondrial activity.	Adenosine Triphosphate	97-100	peroxisome proliferator activator receptor delta	Mus musculus	23-32
26694920-7	2015	Enhanced PPARbeta/delta and PPARalpha expression and DNA binding induces expression of FA oxidation enzymes, increasing muscle carnitine and lowering tissue malonyl-CoA concentrations, thereby supporting intra-mitochondrial pathways of FA oxidation and enhancing mitochondrial respiration.	Carnitine	127-136	peroxisome proliferator activator receptor delta	Mus musculus	9-17
26694920-7	2015	Enhanced PPARbeta/delta and PPARalpha expression and DNA binding induces expression of FA oxidation enzymes, increasing muscle carnitine and lowering tissue malonyl-CoA concentrations, thereby supporting intra-mitochondrial pathways of FA oxidation and enhancing mitochondrial respiration.	Malonyl Coenzyme A	157-168	peroxisome proliferator activator receptor delta	Mus musculus	9-17
26253087-2	2015	We show that in MAECs (mouse aortic endothelial cells), the PPARbeta/delta (peroxisome- proliferator-activated receptor beta/delta) agonist GW0742 prevented the decreased A23187-stimulated NO production, phosphorylation of eNOS (endothelial nitric oxide synthase) at Ser1177 and increased intracellular ROS levels caused by exposure to palmitate in vitro.	Calcimycin	171-177	peroxisome proliferator activator receptor delta	Mus musculus	60-124
26253087-2	2015	We show that in MAECs (mouse aortic endothelial cells), the PPARbeta/delta (peroxisome- proliferator-activated receptor beta/delta) agonist GW0742 prevented the decreased A23187-stimulated NO production, phosphorylation of eNOS (endothelial nitric oxide synthase) at Ser1177 and increased intracellular ROS levels caused by exposure to palmitate in vitro.	Reactive Oxygen Species	303-306	peroxisome proliferator activator receptor delta	Mus musculus	60-124
26253087-2	2015	We show that in MAECs (mouse aortic endothelial cells), the PPARbeta/delta (peroxisome- proliferator-activated receptor beta/delta) agonist GW0742 prevented the decreased A23187-stimulated NO production, phosphorylation of eNOS (endothelial nitric oxide synthase) at Ser1177 and increased intracellular ROS levels caused by exposure to palmitate in vitro.	Palmitates	336-345	peroxisome proliferator activator receptor delta	Mus musculus	60-124
26253087-5	2015	The PPARbeta/delta antagonist GSK0660 abolished all of these protective effects induced by GW0742.	GSK0660	30-37	peroxisome proliferator activator receptor delta	Mus musculus	4-12
26253087-5	2015	The PPARbeta/delta antagonist GSK0660 abolished all of these protective effects induced by GW0742.	GW0742	91-97	peroxisome proliferator activator receptor delta	Mus musculus	4-12
26253087-9	2015	In conclusion, PPARbeta/delta activation restored the lipid-induced endothelial dysfunction by up-regulation of CPT-1, thus reducing DAG accumulation and the subsequent PKC-mediated ROS production and eNOS inhibition.	Diglycerides	133-136	peroxisome proliferator activator receptor delta	Mus musculus	15-23
26253087-9	2015	In conclusion, PPARbeta/delta activation restored the lipid-induced endothelial dysfunction by up-regulation of CPT-1, thus reducing DAG accumulation and the subsequent PKC-mediated ROS production and eNOS inhibition.	Reactive Oxygen Species	182-185	peroxisome proliferator activator receptor delta	Mus musculus	15-23
26255030-7	2015	Mono- and polyunsaturated FFA proved to be effective activators of PPARdelta compared to saturated palmitic acid; however, in combination with palmitic acid their effect on PPARdelta activation was blocked and stayed at the levels observed for palmitic acid alone.	Palmitic Acid	143-156	peroxisome proliferator activator receptor delta	Mus musculus	67-76
26255030-7	2015	Mono- and polyunsaturated FFA proved to be effective activators of PPARdelta compared to saturated palmitic acid; however, in combination with palmitic acid their effect on PPARdelta activation was blocked and stayed at the levels observed for palmitic acid alone.	Palmitic Acid	143-156	peroxisome proliferator activator receptor delta	Mus musculus	173-182
26255030-7	2015	Mono- and polyunsaturated FFA proved to be effective activators of PPARdelta compared to saturated palmitic acid; however, in combination with palmitic acid their effect on PPARdelta activation was blocked and stayed at the levels observed for palmitic acid alone.	Palmitic Acid	143-156	peroxisome proliferator activator receptor delta	Mus musculus	67-76
26255030-7	2015	Mono- and polyunsaturated FFA proved to be effective activators of PPARdelta compared to saturated palmitic acid; however, in combination with palmitic acid their effect on PPARdelta activation was blocked and stayed at the levels observed for palmitic acid alone.	Palmitic Acid	143-156	peroxisome proliferator activator receptor delta	Mus musculus	173-182
26362775-5	2015	RESULTS: We found that both CMS and LH resulted in a significant decrease in the PPARdelta expression in the hippocampi of mice, and this change was reversed by treatment with the antidepressant fluoxetine.	Fluoxetine	195-205	peroxisome proliferator activator receptor delta	Mus musculus	81-90
26111938-6	2015	Increasing BH4 bioavailability either exogenously by BH4 supplementation or endogenously by treatment with the selective peroxisome proliferator-activated receptor--delta activator GW501516 (2 mg/kg/day, 14 days) attenuated eNOS uncoupling and decreased superoxide anion production in cerebral microvessels of Tg2576 mice (p < 0.05).	sapropterin	11-14	peroxisome proliferator activator receptor delta	Mus musculus	121-170
26111938-6	2015	Increasing BH4 bioavailability either exogenously by BH4 supplementation or endogenously by treatment with the selective peroxisome proliferator-activated receptor--delta activator GW501516 (2 mg/kg/day, 14 days) attenuated eNOS uncoupling and decreased superoxide anion production in cerebral microvessels of Tg2576 mice (p < 0.05).	GW 501516	181-189	peroxisome proliferator activator receptor delta	Mus musculus	121-170
26111938-6	2015	Increasing BH4 bioavailability either exogenously by BH4 supplementation or endogenously by treatment with the selective peroxisome proliferator-activated receptor--delta activator GW501516 (2 mg/kg/day, 14 days) attenuated eNOS uncoupling and decreased superoxide anion production in cerebral microvessels of Tg2576 mice (p < 0.05).	Superoxides	254-270	peroxisome proliferator activator receptor delta	Mus musculus	121-170
26111938-6	2015	Increasing BH4 bioavailability either exogenously by BH4 supplementation or endogenously by treatment with the selective peroxisome proliferator-activated receptor--delta activator GW501516 (2 mg/kg/day, 14 days) attenuated eNOS uncoupling and decreased superoxide anion production in cerebral microvessels of Tg2576 mice (p < 0.05).	tg2576	310-316	peroxisome proliferator activator receptor delta	Mus musculus	121-170
26111938-12	2015	Supplementation of BH4 or activation of PPARdelta prevents detrimental effects of eNOS uncoupling by restoring bioavailability of BH4 and scavenging of .O2(-), respectively (b).	sapropterin	130-133	peroxisome proliferator activator receptor delta	Mus musculus	40-49
26111938-12	2015	Supplementation of BH4 or activation of PPARdelta prevents detrimental effects of eNOS uncoupling by restoring bioavailability of BH4 and scavenging of .O2(-), respectively (b).	Oxygen	153-155	peroxisome proliferator activator receptor delta	Mus musculus	40-49
26111938-13	2015	Activation of PPARdelta also increases expression of catalase thereby inactivating H2O2.	Hydrogen Peroxide	83-87	peroxisome proliferator activator receptor delta	Mus musculus	14-23
26443862-8	2015	The induction of LDLR expression by PPARdelta agonist was further observed in liver tissue of mice and hamsters treated with L165041.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	125-132	peroxisome proliferator activator receptor delta	Mus musculus	36-45
26508837-3	2015	GW0742, a selective peroxisome proliferator-activated receptor (PPAR)-delta agonist, has been shown to ameliorate metabolic abnormalities including IR in skeletal muscle in mice fed high-fructose corn syrup.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	20-75
26105792-1	2015	AIMS/HYPOTHESIS: We explored the effects of beta-aminoisobutyric acid (BAIBA) on hyperlipidaemic-condition-induced insulin resistance and inflammation as mediated through a signalling pathway involving AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor delta (PPARdelta).	3-aminoisobutyric acid	44-69	peroxisome proliferator activator receptor delta	Mus musculus	242-290
26105792-1	2015	AIMS/HYPOTHESIS: We explored the effects of beta-aminoisobutyric acid (BAIBA) on hyperlipidaemic-condition-induced insulin resistance and inflammation as mediated through a signalling pathway involving AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor delta (PPARdelta).	3-aminoisobutyric acid	44-69	peroxisome proliferator activator receptor delta	Mus musculus	292-301
26105792-1	2015	AIMS/HYPOTHESIS: We explored the effects of beta-aminoisobutyric acid (BAIBA) on hyperlipidaemic-condition-induced insulin resistance and inflammation as mediated through a signalling pathway involving AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor delta (PPARdelta).	3-aminoisobutyric acid	71-76	peroxisome proliferator activator receptor delta	Mus musculus	242-290
26105792-1	2015	AIMS/HYPOTHESIS: We explored the effects of beta-aminoisobutyric acid (BAIBA) on hyperlipidaemic-condition-induced insulin resistance and inflammation as mediated through a signalling pathway involving AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor delta (PPARdelta).	3-aminoisobutyric acid	71-76	peroxisome proliferator activator receptor delta	Mus musculus	292-301
26105792-8	2015	Furthermore, BAIBA treatment significantly induced AMPK phosphorylation and expression of PPARdelta in C2C12 myocytes and in skeletal muscle of mice.	3-aminoisobutyric acid	13-18	peroxisome proliferator activator receptor delta	Mus musculus	90-99
26105792-9	2015	Both compound C, an AMPK inhibitor, and Ppardelta (also known as Ppard) siRNA abrogated the inhibitory effects of BAIBA on palmitate-induced inflammation and insulin resistance.	Palmitates	123-132	peroxisome proliferator activator receptor delta	Mus musculus	40-49
26105792-9	2015	Both compound C, an AMPK inhibitor, and Ppardelta (also known as Ppard) siRNA abrogated the inhibitory effects of BAIBA on palmitate-induced inflammation and insulin resistance.	Palmitates	123-132	peroxisome proliferator activator receptor delta	Mus musculus	40-45
26105792-10	2015	BAIBA significantly induced the expression of genes associated with fatty acid oxidation, such as carnitine palmitoyltransferase 1 (Cpt1), acyl-CoA oxidase (Aco; also known as Acox1) and fatty acid binding protein 3 (Fabp3); this effect of BAIBA was significantly reduced by compound C and Ppardelta siRNA.	Fatty Acids	68-78	peroxisome proliferator activator receptor delta	Mus musculus	290-299
25976059-5	2015	Postweaning CLA supplementation in wild type animals, but not N2KO mice, may activate AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor-delta (PPARdelta) as well as promote desensitization of phosphatase and tensin homologue (PTEN) and sensitization of protein kinase B (AKT) at threonine 308 in gastrocnemius skeletal muscle, improving voluntary activity and glucose homeostasis.	Linoleic Acids, Conjugated	12-15	peroxisome proliferator activator receptor delta	Mus musculus	126-174
25976059-5	2015	Postweaning CLA supplementation in wild type animals, but not N2KO mice, may activate AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor-delta (PPARdelta) as well as promote desensitization of phosphatase and tensin homologue (PTEN) and sensitization of protein kinase B (AKT) at threonine 308 in gastrocnemius skeletal muscle, improving voluntary activity and glucose homeostasis.	Linoleic Acids, Conjugated	12-15	peroxisome proliferator activator receptor delta	Mus musculus	176-185
25648617-7	2015	CONCLUSION: These results strongly suggested that XRC is beneficial in EID treatment and that XRC may mediate its effects through regulation of the PGI2-PPARdelta signaling pathway.	Epoprostenol	148-152	peroxisome proliferator activator receptor delta	Mus musculus	153-162
25556996-6	2015	RESULTS: AVH and dilatation of dermal microvessels stimulated by vascular endothelial growth factor A, histamine, and thrombin are severely compromised in PPARbeta/delta-deficient mice.	Histamine	103-112	peroxisome proliferator activator receptor delta	Mus musculus	155-163
25943561-0	2015	A metabolomic study of the PPARdelta agonist GW501516 for enhancing running endurance in Kunming mice.	GW 501516	45-53	peroxisome proliferator activator receptor delta	Mus musculus	27-36
25943561-3	2015	This study utilized metabolomic profiling to examine the effects of GW501516, a PPARdelta agonist, on running endurance in mice.	GW 501516	68-76	peroxisome proliferator activator receptor delta	Mus musculus	80-89
25662586-1	2015	The peroxisome proliferator-activated receptor (PPAR)-beta/delta has emerged as a promising therapeutic target for treating dyslipidemia, including beneficial effects on HDL cholesterol (HDL-C).	Cholesterol	174-185	peroxisome proliferator activator receptor delta	Mus musculus	4-58
25648617-0	2015	Effect of Xianziyizhen Recipe Capsule on PGI2-PPARdelta Signaling Pathway in Embryo Implantation Dysfunction Mice.	Epoprostenol	41-45	peroxisome proliferator activator receptor delta	Mus musculus	46-55
25648617-1	2015	PROBLEM: We investigated the effect of Xianziyizhen recipe capsule (XRC), a kidney-tonifying herb, on the PGI2-PPARdelta signaling pathway at the maternal-fetal interface in embryo implantation dysfunction (EID) mice.	Epoprostenol	106-110	peroxisome proliferator activator receptor delta	Mus musculus	111-120
25648617-5	2015	RESULTS: The results showed that hydroxyurea and mifepristone-induced EID were associated with significantly lower PPARdelta and IL-11 mRNA levels in endometrium and reduced COX-2, PGI2, MMP-9, and TIMP-3 levels in endometrial glandular epithelium, compared with normal controls.	Hydroxyurea	33-44	peroxisome proliferator activator receptor delta	Mus musculus	115-124
25648617-5	2015	RESULTS: The results showed that hydroxyurea and mifepristone-induced EID were associated with significantly lower PPARdelta and IL-11 mRNA levels in endometrium and reduced COX-2, PGI2, MMP-9, and TIMP-3 levels in endometrial glandular epithelium, compared with normal controls.	Mifepristone	49-61	peroxisome proliferator activator receptor delta	Mus musculus	115-124
25728706-0	2015	PPARbeta/delta ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation.	Fructose	27-35	peroxisome proliferator activator receptor delta	Mus musculus	0-8
25728706-2	2015	Fructose intake for 8 weeks significantly increased body and liver weight, and hepatic triglyceride accumulation in PPARbeta/delta-deficient mice but not in wild-type mice.	Fructose	0-8	peroxisome proliferator activator receptor delta	Mus musculus	116-124
25728706-2	2015	Fructose intake for 8 weeks significantly increased body and liver weight, and hepatic triglyceride accumulation in PPARbeta/delta-deficient mice but not in wild-type mice.	Triglycerides	87-99	peroxisome proliferator activator receptor delta	Mus musculus	116-124
25728706-3	2015	Feeding PPARbeta/delta-deficient mice with fructose exacerbated glucose intolerance and led to macrophage infiltration, inflammation, enhanced mRNA and protein levels of CD36, and activation of the JNK pathway in white adipose tissue compared to those of water-fed PPARbeta/delta-deficient mice.	Fructose	43-51	peroxisome proliferator activator receptor delta	Mus musculus	8-16
25728706-3	2015	Feeding PPARbeta/delta-deficient mice with fructose exacerbated glucose intolerance and led to macrophage infiltration, inflammation, enhanced mRNA and protein levels of CD36, and activation of the JNK pathway in white adipose tissue compared to those of water-fed PPARbeta/delta-deficient mice.	Fructose	43-51	peroxisome proliferator activator receptor delta	Mus musculus	265-273
25728706-3	2015	Feeding PPARbeta/delta-deficient mice with fructose exacerbated glucose intolerance and led to macrophage infiltration, inflammation, enhanced mRNA and protein levels of CD36, and activation of the JNK pathway in white adipose tissue compared to those of water-fed PPARbeta/delta-deficient mice.	Glucose	64-71	peroxisome proliferator activator receptor delta	Mus musculus	8-16
25728706-3	2015	Feeding PPARbeta/delta-deficient mice with fructose exacerbated glucose intolerance and led to macrophage infiltration, inflammation, enhanced mRNA and protein levels of CD36, and activation of the JNK pathway in white adipose tissue compared to those of water-fed PPARbeta/delta-deficient mice.	Water	255-260	peroxisome proliferator activator receptor delta	Mus musculus	8-16
25728706-4	2015	Cultured adipocytes exposed to fructose also exhibited increased CD36 protein levels and this increase was prevented by the PPARbeta/delta activator GW501516.	Fructose	31-39	peroxisome proliferator activator receptor delta	Mus musculus	124-132
25728706-4	2015	Cultured adipocytes exposed to fructose also exhibited increased CD36 protein levels and this increase was prevented by the PPARbeta/delta activator GW501516.	GW 501516	149-157	peroxisome proliferator activator receptor delta	Mus musculus	124-132
25728706-7	2015	Protein levels of the well-known Nrf2 target gene NAD(P)H: quinone oxidoreductase 1 (Nqo1) were increased in water-fed PPARbeta/delta-null mice, suggesting that PPARbeta/delta deficiency increases Nrf2 activity; and this increase was exacerbated in fructose-fed PPARbeta/delta-deficient mice.	Water	109-114	peroxisome proliferator activator receptor delta	Mus musculus	119-127
25728706-7	2015	Protein levels of the well-known Nrf2 target gene NAD(P)H: quinone oxidoreductase 1 (Nqo1) were increased in water-fed PPARbeta/delta-null mice, suggesting that PPARbeta/delta deficiency increases Nrf2 activity; and this increase was exacerbated in fructose-fed PPARbeta/delta-deficient mice.	Water	109-114	peroxisome proliferator activator receptor delta	Mus musculus	161-169
25728706-7	2015	Protein levels of the well-known Nrf2 target gene NAD(P)H: quinone oxidoreductase 1 (Nqo1) were increased in water-fed PPARbeta/delta-null mice, suggesting that PPARbeta/delta deficiency increases Nrf2 activity; and this increase was exacerbated in fructose-fed PPARbeta/delta-deficient mice.	Water	109-114	peroxisome proliferator activator receptor delta	Mus musculus	161-169
25728706-7	2015	Protein levels of the well-known Nrf2 target gene NAD(P)H: quinone oxidoreductase 1 (Nqo1) were increased in water-fed PPARbeta/delta-null mice, suggesting that PPARbeta/delta deficiency increases Nrf2 activity; and this increase was exacerbated in fructose-fed PPARbeta/delta-deficient mice.	Fructose	249-257	peroxisome proliferator activator receptor delta	Mus musculus	161-169
25728706-7	2015	Protein levels of the well-known Nrf2 target gene NAD(P)H: quinone oxidoreductase 1 (Nqo1) were increased in water-fed PPARbeta/delta-null mice, suggesting that PPARbeta/delta deficiency increases Nrf2 activity; and this increase was exacerbated in fructose-fed PPARbeta/delta-deficient mice.	Fructose	249-257	peroxisome proliferator activator receptor delta	Mus musculus	161-169
25720738-5	2015	Among downstream biomarkers of PGC-1alpha, the CLA mixed isomer enhanced the expression of peroxisome proliferator-activated receptor-delta (PPARdelta).	Linoleic Acids, Conjugated	47-50	peroxisome proliferator activator receptor delta	Mus musculus	91-139
25720738-5	2015	Among downstream biomarkers of PGC-1alpha, the CLA mixed isomer enhanced the expression of peroxisome proliferator-activated receptor-delta (PPARdelta).	Linoleic Acids, Conjugated	47-50	peroxisome proliferator activator receptor delta	Mus musculus	141-150
25852474-11	2015	Finally, rosiglitazone, a PPARgamma ligand, increases PPARbeta/delta level, suggesting a possible cooperation between these two PPARs in the control of cell fate behavior.	Rosiglitazone	9-22	peroxisome proliferator activator receptor delta	Mus musculus	54-62
25662586-2	2015	In the current study, we determined the effects of the PPAR-beta/delta agonist GW0742 on HDL composition and the expression of liver HDL-related genes in mice and cultured human cells.	GW0742	79-85	peroxisome proliferator activator receptor delta	Mus musculus	55-64
25662586-6	2015	The GW0742-mediated effects on liver Pltp expression and serum enzyme activity were completely abolished in PPAR-beta/delta-deficient mice.	GW0742	4-10	peroxisome proliferator activator receptor delta	Mus musculus	108-117
25662586-8	2015	Collectively, our findings demonstrate a common transcriptional upregulation by GW0742-activated PPAR-beta/delta of Pltp expression in cultured cells and in mouse liver resulting in enhanced serum PLTP activity.	GW0742	80-86	peroxisome proliferator activator receptor delta	Mus musculus	97-106
25662586-9	2015	Our results also indicate that PPAR-beta/delta activation may modulate PLTP-mediated prebeta-HDL formation and macrophage cholesterol efflux.	Cholesterol	122-133	peroxisome proliferator activator receptor delta	Mus musculus	31-40
25849380-11	2015	Capsaicin increased the expression levels of p-CaM, Cx43, CaMKII, PPARdelta and HSL in mesenteric adipose tissues from WT mice fed a high-fat diet, db/db mice, as well as obese humans, but these effects of capsaicin were absent in TRPV1-/- mice.	Capsaicin	0-9	peroxisome proliferator activator receptor delta	Mus musculus	66-75
25713305-14	2015	Skeletal muscle dysfunction in HF is associated with impaired PPARdelta signaling and treatment with the PPARdelta agonist GW501516 corrects oxidative capacity and FA metabolism and improves exercise capacity in mice with LV dysfunction.	GW 501516	123-131	peroxisome proliferator activator receptor delta	Mus musculus	105-114
25523142-9	2015	Retinoids did not affect the glucocorticoid-induced short term phagocytosis of apoptotic cells, but were required for the glucocorticoid-induced enhancement of efferocytosis during prolonged clearance of apoptotic cells by promoting efficient LXR and PPARdelta upregulation.	Retinoids	0-9	peroxisome proliferator activator receptor delta	Mus musculus	251-260
25331977-5	2015	METHODS: Mouse chondrocytes and knee explants were treated with a pharmacologic agonist of PPARdelta (GW501516) to evaluate changes in gene expression, histologic features, and matrix glycosaminoglycan breakdown.	GW 501516	102-110	peroxisome proliferator activator receptor delta	Mus musculus	91-100
25331977-8	2015	RESULTS: In vitro, PPARdelta activation by GW501516 resulted in increased expression of several proteases in chondrocytes, as well as aggrecan degradation and glycosaminoglycan release in knee joint explants.	GW 501516	43-51	peroxisome proliferator activator receptor delta	Mus musculus	19-28
25592770-4	2015	Peroxisome proliferator activator receptor delta (PPARdelta) is a transcription factor with potent anti-inflammatory activation properties and PPARdelta agonism leads to reduction in brain Abeta levels in 5XFAD mice.	UNII-042A8N37WH	189-194	peroxisome proliferator activator receptor delta	Mus musculus	0-48
25592770-4	2015	Peroxisome proliferator activator receptor delta (PPARdelta) is a transcription factor with potent anti-inflammatory activation properties and PPARdelta agonism leads to reduction in brain Abeta levels in 5XFAD mice.	UNII-042A8N37WH	189-194	peroxisome proliferator activator receptor delta	Mus musculus	50-59
25592770-4	2015	Peroxisome proliferator activator receptor delta (PPARdelta) is a transcription factor with potent anti-inflammatory activation properties and PPARdelta agonism leads to reduction in brain Abeta levels in 5XFAD mice.	UNII-042A8N37WH	189-194	peroxisome proliferator activator receptor delta	Mus musculus	143-152
25592770-5	2015	This study was carried out to elucidate the involvement of microglial activation in the PPARdelta-mediated reduction of Abeta burden and subsequent outcome to neuronal survival in a 5XFAD mouse model of AD.	UNII-042A8N37WH	120-125	peroxisome proliferator activator receptor delta	Mus musculus	88-97
25592770-6	2015	METHODS: 5XFAD mice were orally treated with the PPARdelta agonist GW0742 for 2 weeks.	GW0742	67-73	peroxisome proliferator activator receptor delta	Mus musculus	49-58
25592770-14	2015	CONCLUSIONS: This study demonstrates that GW0742 treatment has a prominent anti-inflammatory effect in 5XFAD mice and suggests that PPARdelta agonists may have therapeutic utility in treating AD.	GW0742	42-48	peroxisome proliferator activator receptor delta	Mus musculus	132-141
24879443-11	2014	The present results suggest that fatty acids, preferably n-3 ones, are intracellularly transported by E-FABP to various targets, including mitochondria and nucleus, in which PPARbeta/delta may play functional roles in the transcriptional regulation of genes involved in the endochondral ossification.	Fatty Acids	33-44	peroxisome proliferator activator receptor delta	Mus musculus	174-182
25063273-4	2014	RESULTS: The PPARbeta/delta agonist GW501516 prevented lipid-induced ER stress in mouse and human myotubes and in skeletal muscle of mice fed a high-fat diet.	GW 501516	36-44	peroxisome proliferator activator receptor delta	Mus musculus	13-21
25164277-2	2014	GFT505 is a new dual agonist of the PPARalpha and PPARdelta isoforms, which improves lipid and glucose metabolism in type 2 diabetes mellitus (T2DM) and exerts hepatoprotective effects in mouse models of nonalcoholic fatty liver disease (NAFLD).	2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid	0-6	peroxisome proliferator activator receptor delta	Mus musculus	50-59
26604919-9	2015	Our results show that both PPARdelta and PPARalpha receptors are essential for GW501516-driven adipose tissue reduction and subsequently hepatic steatosis, with PPARalpha working downstream of PPARdelta.	GW 501516	79-87	peroxisome proliferator activator receptor delta	Mus musculus	27-36
26604919-9	2015	Our results show that both PPARdelta and PPARalpha receptors are essential for GW501516-driven adipose tissue reduction and subsequently hepatic steatosis, with PPARalpha working downstream of PPARdelta.	GW 501516	79-87	peroxisome proliferator activator receptor delta	Mus musculus	193-202
25279796-4	2014	PPARbeta(-/-) mice have reduced metabolic activity and are glucose intolerant.	Glucose	59-66	peroxisome proliferator activator receptor delta	Mus musculus	0-8
25279796-12	2014	Taken together, these data indicate that PPARbeta deficiency leads to glucose intolerance, decreased muscle function, and reduced bone strength.	Glucose	70-77	peroxisome proliferator activator receptor delta	Mus musculus	41-49
25330228-12	2014	The genes Decr2, Ppard and Agapt1 are more appealing candidates because of their involvement in lipid metabolism and down-regulation in carbohydrate-preferring animals.	Carbohydrates	136-148	peroxisome proliferator activator receptor delta	Mus musculus	17-22
24259440-4	2014	Since it was discovered that both PPARdelta agonists (GW1516) and AMPK activators (5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, known as AICAR) are very effective performance-enhancing substances in sedentary mice, the World Anti-doping Agency (WADA) included AICAR and GW1516 in the prohibited list of substances as metabolic modulators in the class "Hormone and metabolic modulators".	AICA ribonucleotide	148-153	peroxisome proliferator activator receptor delta	Mus musculus	34-43
24920036-6	2014	Subsequent immunoblotting experiments provided evidence for positive correlation of PPARD level and AKT and ERK signaling pathways upon GW501516 treatment.	GW 501516	136-144	peroxisome proliferator activator receptor delta	Mus musculus	84-89
24920036-7	2014	Furthermore, the stimulation of GW501516 increased trophoblast cell fusion gene syncytin-A (Syna), but not syncytin-B (Synb), expression, suggesting a potential role of Ppard activation in promoting cytotrophoblast differentiation.	GW 501516	32-40	peroxisome proliferator activator receptor delta	Mus musculus	169-174
24639079-4	2014	Pparbeta/delta-null keratinocytes exhibited decreased AHR occupancy and histone acetylation on the Cyp1a1 promoter in response to a PAH compared with wild-type keratinocytes.	Polycyclic Aromatic Hydrocarbons	132-135	peroxisome proliferator activator receptor delta	Mus musculus	0-8
24639079-5	2014	Bisulfite sequencing of the Cyp1a1 promoter and studies using a DNA methylation inhibitor suggest that PPARbeta/delta promotes demethylation of the Cyp1a1 promoter.	hydrogen sulfite	0-9	peroxisome proliferator activator receptor delta	Mus musculus	103-111
24639079-7	2014	Consistent with the lower AHR-dependent activities in Pparbeta/delta-null mice compared with wild-type mice, 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin tumorigenesis was inhibited in Pparbeta/delta-null mice compared with wild-type.	7,12-dimethylbenz[a	109-128	peroxisome proliferator activator receptor delta	Mus musculus	191-199
24639079-7	2014	Consistent with the lower AHR-dependent activities in Pparbeta/delta-null mice compared with wild-type mice, 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin tumorigenesis was inhibited in Pparbeta/delta-null mice compared with wild-type.	anthracene	129-139	peroxisome proliferator activator receptor delta	Mus musculus	54-62
24639079-7	2014	Consistent with the lower AHR-dependent activities in Pparbeta/delta-null mice compared with wild-type mice, 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin tumorigenesis was inhibited in Pparbeta/delta-null mice compared with wild-type.	9,10-Dimethyl-1,2-benzanthracene	141-145	peroxisome proliferator activator receptor delta	Mus musculus	54-62
24639079-7	2014	Consistent with the lower AHR-dependent activities in Pparbeta/delta-null mice compared with wild-type mice, 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin tumorigenesis was inhibited in Pparbeta/delta-null mice compared with wild-type.	9,10-Dimethyl-1,2-benzanthracene	141-145	peroxisome proliferator activator receptor delta	Mus musculus	191-199
24639079-9	2014	The mechanisms underlying this PPARbeta/delta-dependent reduction of AHR signaling by PAH are not due to alterations in the expression of AHR auxiliary proteins, ligand binding or AHR nuclear translocation between genotypes, but are likely influenced by PPARbeta/delta-dependent demethylation of AHR target gene promoters including Cyp1a1 that reduces AHR accessibility as shown by reduced promoter occupancy.	Polycyclic Aromatic Hydrocarbons	86-89	peroxisome proliferator activator receptor delta	Mus musculus	31-39
24639079-9	2014	The mechanisms underlying this PPARbeta/delta-dependent reduction of AHR signaling by PAH are not due to alterations in the expression of AHR auxiliary proteins, ligand binding or AHR nuclear translocation between genotypes, but are likely influenced by PPARbeta/delta-dependent demethylation of AHR target gene promoters including Cyp1a1 that reduces AHR accessibility as shown by reduced promoter occupancy.	Polycyclic Aromatic Hydrocarbons	86-89	peroxisome proliferator activator receptor delta	Mus musculus	254-262
24814977-9	2014	Treatment of mouse AML12 hepatocytes with the PPARbeta agonist (GW0742) decreased (14)C-18:2,n-6 in TGs but did not affect beta-oxidation.	GW0742	64-70	peroxisome proliferator activator receptor delta	Mus musculus	46-54
24259440-5	2014	Thiazolidinediones are PPARgamma agonists that can induce similar biological effects to those of PPARdelta and PPARdelta-AMPK agonists.	Thiazolidinediones	0-18	peroxisome proliferator activator receptor delta	Mus musculus	97-106
24814977-9	2014	Treatment of mouse AML12 hepatocytes with the PPARbeta agonist (GW0742) decreased (14)C-18:2,n-6 in TGs but did not affect beta-oxidation.	Carbon	86-87	peroxisome proliferator activator receptor delta	Mus musculus	46-54
24814977-9	2014	Treatment of mouse AML12 hepatocytes with the PPARbeta agonist (GW0742) decreased (14)C-18:2,n-6 in TGs but did not affect beta-oxidation.	Nitrogen	7-8	peroxisome proliferator activator receptor delta	Mus musculus	46-54
24814977-10	2014	These studies establish that Elovl5 activity regulates hepatic levels of FAs controlling PPARbeta activity, ATGL expression, and TG catabolism, but not FA oxidation.	ammonium ferrous sulfate	73-76	peroxisome proliferator activator receptor delta	Mus musculus	89-97
24698256-5	2014	Co-infusion of GW501516, an activator of PPARdelta, attenuated both the incidence and the severity of Ang II-induced AAA in apoE-deficient mice.	GW 501516	15-23	peroxisome proliferator activator receptor delta	Mus musculus	41-50
24958459-2	2014	Here, we show that PPARbeta/delta (peroxisome proliferator-activated receptor beta/delta) directly regulates CD300a in macrophages that express the immunoreceptor tyrosine based-inhibitory motif (ITIM)-containing receptor.	Tyrosine	163-171	peroxisome proliferator activator receptor delta	Mus musculus	19-88
24158519-8	2014	In aortae, GW1516 increased the expression of the PPARdelta-specific gene Adfp but not PPARalpha- or gamma-specific genes.	GW 501516	11-17	peroxisome proliferator activator receptor delta	Mus musculus	50-59
24644281-2	2014	We show that the endocannabinoid anandamide (AEA) can alter neuronal cell function both through its established role in activation of the G-protein-coupled receptor CB1, and by serving as a precursor for a potent agonist of the nuclear receptor PPARbeta/delta, in turn up-regulating multiple cognition-associated genes.	Endocannabinoids	17-32	peroxisome proliferator activator receptor delta	Mus musculus	245-259
24644281-2	2014	We show that the endocannabinoid anandamide (AEA) can alter neuronal cell function both through its established role in activation of the G-protein-coupled receptor CB1, and by serving as a precursor for a potent agonist of the nuclear receptor PPARbeta/delta, in turn up-regulating multiple cognition-associated genes.	anandamide	33-43	peroxisome proliferator activator receptor delta	Mus musculus	245-259
24644281-2	2014	We show that the endocannabinoid anandamide (AEA) can alter neuronal cell function both through its established role in activation of the G-protein-coupled receptor CB1, and by serving as a precursor for a potent agonist of the nuclear receptor PPARbeta/delta, in turn up-regulating multiple cognition-associated genes.	anandamide	45-48	peroxisome proliferator activator receptor delta	Mus musculus	245-259
24644281-4	2014	FABP5 both promotes the hydrolysis of AEA into arachidonic acid and thus reduces brain endocannabinoid levels, and directly shuttles arachidonic acid to the nucleus where it delivers it to PPARbeta/delta, enabling its activation.	Arachidonic Acid	133-149	peroxisome proliferator activator receptor delta	Mus musculus	189-197
24352213-1	2014	Telmisartan, an angiotensin II receptor type 1 blocker (ARB), was recently reported to promote lipolysis in mice by acting as a peroxisome proliferator-activated receptor (PPAR)-delta activator, although in clinical studies, it has also been recognized to activate PPAR-gamma as a major cause of its pleiotropic actions.	Telmisartan	0-11	peroxisome proliferator activator receptor delta	Mus musculus	128-183
24482374-0	2014	Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5" adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor delta pathway.	Metformin	0-9	peroxisome proliferator activator receptor delta	Mus musculus	173-221
24482374-3	2014	We aim to investigate whether PPARdelta is crucial for metformin in ameliorating ER stress and endothelial dysfunction induced by high-fat diet.	Metformin	55-64	peroxisome proliferator activator receptor delta	Mus musculus	30-39
24482374-8	2014	These effects of high-fat diet were reversed by oral treatment with metformin in diet-induced obese PPARdelta wild-type mice but not in diet-induced obese PPARdelta knockout littermates.	Metformin	68-77	peroxisome proliferator activator receptor delta	Mus musculus	100-109
24482374-9	2014	Metformin and PPARdelta agonist GW1516 reversed tunicamycin (ER stress inducer)-induced ER stress, oxidative stress, and impairment of endothelium-dependent relaxation in mouse aortae as well as NO production in mouse aortic endothelial cells.	GW 501516	32-38	peroxisome proliferator activator receptor delta	Mus musculus	14-23
24482374-9	2014	Metformin and PPARdelta agonist GW1516 reversed tunicamycin (ER stress inducer)-induced ER stress, oxidative stress, and impairment of endothelium-dependent relaxation in mouse aortae as well as NO production in mouse aortic endothelial cells.	Tunicamycin	48-59	peroxisome proliferator activator receptor delta	Mus musculus	14-23
24482374-10	2014	Effects of metformin were abolished by cotreatment of GSK0660 (PPARdelta antagonist), whereas effects of GW1516 were unaffected by compound C (AMPK inhibitor).	Metformin	11-20	peroxisome proliferator activator receptor delta	Mus musculus	63-72
24482374-10	2014	Effects of metformin were abolished by cotreatment of GSK0660 (PPARdelta antagonist), whereas effects of GW1516 were unaffected by compound C (AMPK inhibitor).	GSK0660	54-61	peroxisome proliferator activator receptor delta	Mus musculus	63-72
24482374-11	2014	CONCLUSIONS: Metformin restores endothelial function through inhibiting ER stress and oxidative stress and increasing NO bioavailability on activation of AMPK/PPARdelta pathway in obese diabetic mice.	Metformin	13-22	peroxisome proliferator activator receptor delta	Mus musculus	159-168
24158519-0	2014	Peroxisome proliferator-activated receptor delta agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.	GW 501516	57-63	peroxisome proliferator activator receptor delta	Mus musculus	0-48
25520937-11	2014	Consistently, administration of nifedipine markedly reduces fluorescein sodium-induced vessel thrombus formation in mice, which is considerably inhibited when the PPAR-beta/-gamma antagonists are administrated simultaneously.	Nifedipine	32-42	peroxisome proliferator activator receptor delta	Mus musculus	163-172
25520937-11	2014	Consistently, administration of nifedipine markedly reduces fluorescein sodium-induced vessel thrombus formation in mice, which is considerably inhibited when the PPAR-beta/-gamma antagonists are administrated simultaneously.	Fluorescein	60-78	peroxisome proliferator activator receptor delta	Mus musculus	163-172
24864274-8	2014	Similarly, PPARdelta-mediated attenuation of FA synthesis was partially due to AMPK activation, as GW1516 reduced lipogenesis in WT hepatocytes but not AMPKbeta1(-/-) hepatocytes.	GW 501516	99-105	peroxisome proliferator activator receptor delta	Mus musculus	11-20
24486511-10	2014	Most notably, endothelium-specific deletion of the PPAR-delta gene significantly decreased protein expressions of catalase and glutathione peroxidase 1 and resulted in increased levels of H2O2 in the aorta (P &lt; 0.05).	Hydrogen Peroxide	188-192	peroxisome proliferator activator receptor delta	Mus musculus	51-61
24486511-14	2014	We speculate that chronic elevation of H2O2 predisposes PPAR-delta-deficient arteries to oxidative stress and vascular dysfunction.	Hydrogen Peroxide	39-43	peroxisome proliferator activator receptor delta	Mus musculus	56-66
24126710-9	2014	In a mouse model of thrombosis, the administration of nifedipine substantially inhibited fluorescein sodium-induced vessel thrombus formation; however, the antithrombotic effect was considerably reduced in the presence of PPAR-beta/-gamma antagonists.	Nifedipine	54-64	peroxisome proliferator activator receptor delta	Mus musculus	222-231
25016691-9	2014	Interestingly, several genes involved in acyl-CoA synthesis and fatty acid oxidation were also upregulated, such as Ppard, Acsbg1, Ascl3, and Mlycd.	Fatty Acids	64-74	peroxisome proliferator activator receptor delta	Mus musculus	116-121
24186946-8	2014	The elevated RA-responsive gene expression was associated with elevated hepatic triglyceride levels and decreased expression of Ppardelta and its downstream Pdk4 target, suggesting a role for RA in these processes in vivo.	Tretinoin	13-15	peroxisome proliferator activator receptor delta	Mus musculus	128-137
24186946-8	2014	The elevated RA-responsive gene expression was associated with elevated hepatic triglyceride levels and decreased expression of Ppardelta and its downstream Pdk4 target, suggesting a role for RA in these processes in vivo.	Tretinoin	192-194	peroxisome proliferator activator receptor delta	Mus musculus	128-137
24126710-9	2014	In a mouse model of thrombosis, the administration of nifedipine substantially inhibited fluorescein sodium-induced vessel thrombus formation; however, the antithrombotic effect was considerably reduced in the presence of PPAR-beta/-gamma antagonists.	Fluorescein	89-107	peroxisome proliferator activator receptor delta	Mus musculus	222-231
25152753-0	2014	TRPV1 Activation Attenuates High-Salt Diet-Induced Cardiac Hypertrophy and Fibrosis through PPAR-delta Upregulation.	Salts	33-37	peroxisome proliferator activator receptor delta	Mus musculus	92-102
25152753-2	2014	Transient receptor potential vanilloid type 1 (TRPV1), a specific receptor for capsaicin, exerts a protective role in cardiac remodeling that resulted from myocardial infarction, and peroxisome proliferation-activated receptors delta (PPAR-delta) play an important role in metabolic myocardium remodeling.	Capsaicin	79-88	peroxisome proliferator activator receptor delta	Mus musculus	235-245
25152753-3	2014	However, it remains unknown whether activation of TRPV1 could alleviate cardiac hypertrophy and fibrosis and the effect of cross-talk between TRPV1 and PPAR-delta on suppressing high-salt diet-generated oxidative stress.	Salts	183-187	peroxisome proliferator activator receptor delta	Mus musculus	152-162
24153306-8	2013	Unbiased metabolite profiling identifies phosphatidylcholine 18:0/18:1 (PC(18:0/18:1) as a serum lipid regulated by diurnal hepatic PPARdelta activity.	Phosphatidylcholines	41-60	peroxisome proliferator activator receptor delta	Mus musculus	132-141
23499837-0	2013	The PPARdelta agonist GW0742 inhibits neuroinflammation, but does not restore neurogenesis or prevent early delayed hippocampal-dependent cognitive impairment after whole-brain irradiation.	GW0742	22-28	peroxisome proliferator activator receptor delta	Mus musculus	4-13
25006409-0	2013	The peroxisome proliferator-activated receptor beta/delta agonist GW0742 has direct protective effects on right heart hypertrophy.	GW0742	66-72	peroxisome proliferator activator receptor delta	Mus musculus	4-51
25006409-3	2013	PPARbeta/delta is an important receptor in lipid metabolism, athletic performance, and the sensing of prostacyclin.	Epoprostenol	102-114	peroxisome proliferator activator receptor delta	Mus musculus	0-8
25006409-15	2013	In conclusion, the PPARbeta/delta agonist GW0742 has direct protective effects on the right heart in vivo.	GW0742	42-48	peroxisome proliferator activator receptor delta	Mus musculus	19-27
23918045-8	2013	In vitro studies in C2C12 myocytes revealed that linoleate (18:2n6) and not oleate (18:1n9) caused a 3-fold increase in PPARdelta and a 9-fold increase in CPT-1b with a subsequent increase in fat oxidation.	Linoleic Acid	49-58	peroxisome proliferator activator receptor delta	Mus musculus	120-129
23918045-8	2013	In vitro studies in C2C12 myocytes revealed that linoleate (18:2n6) and not oleate (18:1n9) caused a 3-fold increase in PPARdelta and a 9-fold increase in CPT-1b with a subsequent increase in fat oxidation.	Oleic Acid	52-58	peroxisome proliferator activator receptor delta	Mus musculus	120-129
24059847-3	2013	Retinoic acid (RA), the carboxylic acid form of vitamin A, displays agonist activity toward several nuclear hormone receptors, including RA receptors (RARs) and peroxisome proliferator-activated receptor delta (PPARdelta).	Tretinoin	0-13	peroxisome proliferator activator receptor delta	Mus musculus	161-209
24059847-3	2013	Retinoic acid (RA), the carboxylic acid form of vitamin A, displays agonist activity toward several nuclear hormone receptors, including RA receptors (RARs) and peroxisome proliferator-activated receptor delta (PPARdelta).	Tretinoin	0-13	peroxisome proliferator activator receptor delta	Mus musculus	211-220
24059847-3	2013	Retinoic acid (RA), the carboxylic acid form of vitamin A, displays agonist activity toward several nuclear hormone receptors, including RA receptors (RARs) and peroxisome proliferator-activated receptor delta (PPARdelta).	Tretinoin	15-17	peroxisome proliferator activator receptor delta	Mus musculus	161-209
24059847-3	2013	Retinoic acid (RA), the carboxylic acid form of vitamin A, displays agonist activity toward several nuclear hormone receptors, including RA receptors (RARs) and peroxisome proliferator-activated receptor delta (PPARdelta).	Tretinoin	15-17	peroxisome proliferator activator receptor delta	Mus musculus	211-220
24059847-3	2013	Retinoic acid (RA), the carboxylic acid form of vitamin A, displays agonist activity toward several nuclear hormone receptors, including RA receptors (RARs) and peroxisome proliferator-activated receptor delta (PPARdelta).	Carboxylic Acids	24-39	peroxisome proliferator activator receptor delta	Mus musculus	161-209
24059847-3	2013	Retinoic acid (RA), the carboxylic acid form of vitamin A, displays agonist activity toward several nuclear hormone receptors, including RA receptors (RARs) and peroxisome proliferator-activated receptor delta (PPARdelta).	Carboxylic Acids	24-39	peroxisome proliferator activator receptor delta	Mus musculus	211-220
24059847-3	2013	Retinoic acid (RA), the carboxylic acid form of vitamin A, displays agonist activity toward several nuclear hormone receptors, including RA receptors (RARs) and peroxisome proliferator-activated receptor delta (PPARdelta).	Vitamin A	48-57	peroxisome proliferator activator receptor delta	Mus musculus	161-209
24059847-3	2013	Retinoic acid (RA), the carboxylic acid form of vitamin A, displays agonist activity toward several nuclear hormone receptors, including RA receptors (RARs) and peroxisome proliferator-activated receptor delta (PPARdelta).	Vitamin A	48-57	peroxisome proliferator activator receptor delta	Mus musculus	211-220
24069449-9	2013	We conclude that the absence of 5-HT2B receptors leads to the overproduction of prostacyclin, inducing reduced osteoblast differentiation due to PPAR-ss/delta -dependent target regulation and defective cell-cell adhesion and matrix mineralization.	Epoprostenol	80-92	peroxisome proliferator activator receptor delta	Mus musculus	145-158
23605066-5	2013	Chronic dietary capsaicin promoted lipolysis by increasing hepatic phosphorylated hormone-sensitive lipase (phospho-HSL), carnitine palmitoyltransferase 1 (CPT1), and peroxisome proliferator-activated receptor delta (PPARdelta) in wild-type (WT) mice.	Capsaicin	16-25	peroxisome proliferator activator receptor delta	Mus musculus	167-215
23605066-5	2013	Chronic dietary capsaicin promoted lipolysis by increasing hepatic phosphorylated hormone-sensitive lipase (phospho-HSL), carnitine palmitoyltransferase 1 (CPT1), and peroxisome proliferator-activated receptor delta (PPARdelta) in wild-type (WT) mice.	Capsaicin	16-25	peroxisome proliferator activator receptor delta	Mus musculus	217-226
23605066-9	2013	In the in vivo study, TRPV1 activation by dietary capsaicin enhanced hepatic PPARdelta and autophagy-related proteins and reduced hepatic enzymes and inflammatory factor in WT but not TRPV1(-/-) mice.	Capsaicin	50-59	peroxisome proliferator activator receptor delta	Mus musculus	77-86
23605066-10	2013	TRPV1 activation by dietary capsaicin prevents NAFLD through PPARdelta-dependent autophagy enhancement in mice.	Capsaicin	28-37	peroxisome proliferator activator receptor delta	Mus musculus	61-70
23851158-0	2013	PPARbeta/delta modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity.	Ethanol	25-32	peroxisome proliferator activator receptor delta	Mus musculus	0-8
23851158-6	2013	Ethanol fed Pparbeta/delta-null mice exhibited steatosis after short-term treatment compared to controls, the latter effect appeared to be due to increased activity of sterol regulatory element binding protein 1c (SREBP1c).	Ethanol	0-7	peroxisome proliferator activator receptor delta	Mus musculus	12-20
23851158-8	2013	In particular, metabolites associated with arginine and proline metabolism, and glycerolipid metabolism, were markedly different between genotypes suggesting a constitutive role for PPARbeta/delta in the metabolism of these amino acids.	Arginine	43-51	peroxisome proliferator activator receptor delta	Mus musculus	182-190
23851158-8	2013	In particular, metabolites associated with arginine and proline metabolism, and glycerolipid metabolism, were markedly different between genotypes suggesting a constitutive role for PPARbeta/delta in the metabolism of these amino acids.	Proline	56-63	peroxisome proliferator activator receptor delta	Mus musculus	182-190
23851158-8	2013	In particular, metabolites associated with arginine and proline metabolism, and glycerolipid metabolism, were markedly different between genotypes suggesting a constitutive role for PPARbeta/delta in the metabolism of these amino acids.	glycerolipid	80-92	peroxisome proliferator activator receptor delta	Mus musculus	182-190
23851158-9	2013	Interestingly, urinary excretion of taurine was present in ethanol-fed wild-type mice but markedly lower in similarly treated Pparbeta/delta-null mice.	Taurine	36-43	peroxisome proliferator activator receptor delta	Mus musculus	126-134
23851158-10	2013	Evidence suggests that PPARbeta/delta modulates pyridoxal kinase activity by altering Km, consistent with the observed decreased in urinary taurine excretion.	Taurine	140-147	peroxisome proliferator activator receptor delta	Mus musculus	23-31
23851158-11	2013	These data collectively suggest that PPARbeta/delta prevents ethanol-induced hepatic effects by inhibiting hepatic lipogenesis, modulation of amino acid metabolism, and altering pyridoxal kinase activity.	Ethanol	61-68	peroxisome proliferator activator receptor delta	Mus musculus	37-45
24011070-0	2013	The hypoxia-inducible microRNA cluster miR-199a~214 targets myocardial PPARdelta and impairs mitochondrial fatty acid oxidation.	Fatty Acids	107-117	peroxisome proliferator activator receptor delta	Mus musculus	71-80
24011070-6	2013	Taken together, our data suggest a mechanism whereby miR-199a~214 actively represses cardiac PPARdelta expression, facilitating a metabolic shift from predominant reliance on fatty acid utilization in the healthy myocardium toward increased reliance on glucose metabolism at the onset of heart failure.	Fatty Acids	175-185	peroxisome proliferator activator receptor delta	Mus musculus	93-102
24011070-6	2013	Taken together, our data suggest a mechanism whereby miR-199a~214 actively represses cardiac PPARdelta expression, facilitating a metabolic shift from predominant reliance on fatty acid utilization in the healthy myocardium toward increased reliance on glucose metabolism at the onset of heart failure.	Glucose	253-260	peroxisome proliferator activator receptor delta	Mus musculus	93-102
23962686-10	2013	Furthermore, MW treatment permitted the localization of PPARbeta/delta in glutaraldehyde-fixed specimens, which was impossible in the absence of MWI.	Glutaral	74-88	peroxisome proliferator activator receptor delta	Mus musculus	56-64
23605066-0	2013	Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor delta activation.	Capsaicin	8-17	peroxisome proliferator activator receptor delta	Mus musculus	118-166
23977003-3	2013	Endogenous all-trans retinoic acid (ATRA) can activate both receptors depending on specific transport proteins: Fabp5 initiates PPARdelta signaling whereas Crabp2 promotes RAR signaling.	Tretinoin	11-34	peroxisome proliferator activator receptor delta	Mus musculus	128-137
23977003-3	2013	Endogenous all-trans retinoic acid (ATRA) can activate both receptors depending on specific transport proteins: Fabp5 initiates PPARdelta signaling whereas Crabp2 promotes RAR signaling.	Tretinoin	36-40	peroxisome proliferator activator receptor delta	Mus musculus	128-137
23954156-0	2013	Salmonella require the fatty acid regulator PPARdelta for the establishment of a metabolic environment essential for long-term persistence.	Fatty Acids	23-33	peroxisome proliferator activator receptor delta	Mus musculus	44-53
23954156-4	2013	Further, PPARdelta, a eukaryotic transcription factor involved in sustaining fatty acid metabolism, is upregulated in Salmonella-infected macrophages.	Fatty Acids	77-87	peroxisome proliferator activator receptor delta	Mus musculus	9-18
23954156-5	2013	PPARdelta deficiency dramatically inhibits Salmonella replication, which is linked to the metabolic state of macrophages and the level of intracellular glucose available to bacteria.	Glucose	152-159	peroxisome proliferator activator receptor delta	Mus musculus	0-9
23954156-6	2013	Pharmacological activation of PPARdelta increases glucose availability and enhances bacterial replication in macrophages and mice, while Salmonella fail to persist in Ppardelta null mice.	Glucose	50-57	peroxisome proliferator activator receptor delta	Mus musculus	30-39
23499837-3	2013	In this study, we determined if the peroxisomal proliferator-activated receptor (PPAR) delta agonist GW0742 can prevent radiation-induced brain injury in C57Bl/6 wild-type (WT) and PPARdelta knockout (KO) mice.	GW0742	101-107	peroxisome proliferator activator receptor delta	Mus musculus	181-190
23305993-4	2013	In transactivation reporter gene assays LYSO-07 showed a pan partial agonist effect on the three PPAR subtypes (PPARgamma, PPARalpha and PPARbeta/delta).	lyso-07	40-47	peroxisome proliferator activator receptor delta	Mus musculus	137-145
26155222-5	2013	LPS-induced inflammation decrease the expression of peroxisome proliferator-activated receptor alpha (PPARalpha), PPARbeta/delta, PPARgamma, and coactivators PPARgamma co-activator 1 alpha (PGC-1alpha), PGC-1beta messenger RNA (mRNA) in the liver of Balb/c mouse.	lps	0-3	peroxisome proliferator activator receptor delta	Mus musculus	114-122
26155222-6	2013	In addition, LPS-induced inflammation diminishes the protein level of PPARalpha, PPARbeta/delta, and PPARgamma.	lps	13-16	peroxisome proliferator activator receptor delta	Mus musculus	81-89
23811944-1	2013	The peroxisome proliferator-activated receptor-delta (PPARdelta) regulates a multitude of physiological processes associated with glucose and lipid metabolism, inflammation, and proliferation.	Glucose	130-137	peroxisome proliferator activator receptor delta	Mus musculus	4-52
23811944-1	2013	The peroxisome proliferator-activated receptor-delta (PPARdelta) regulates a multitude of physiological processes associated with glucose and lipid metabolism, inflammation, and proliferation.	Glucose	130-137	peroxisome proliferator activator receptor delta	Mus musculus	54-63
23811944-4	2013	Multiparous mice presented with mammary carcinomas after a latency of 12 months, and administration of the PPARdelta ligand GW501516 reduced tumor latency to 5 months.	GW 501516	124-132	peroxisome proliferator activator receptor delta	Mus musculus	107-116
23991366-1	2013	The vitamin A metabolite retinoic acid (RA) regulates gene transcription by activating the nuclear receptors RAR and PPARbeta/delta and their cognate lipid binding proteins CRABP-II, which delivers RA to RAR, and FABP5, which shuttles the hormone to PPARbeta/delta.	Vitamin A	4-13	peroxisome proliferator activator receptor delta	Mus musculus	117-125
23991366-1	2013	The vitamin A metabolite retinoic acid (RA) regulates gene transcription by activating the nuclear receptors RAR and PPARbeta/delta and their cognate lipid binding proteins CRABP-II, which delivers RA to RAR, and FABP5, which shuttles the hormone to PPARbeta/delta.	Vitamin A	4-13	peroxisome proliferator activator receptor delta	Mus musculus	250-258
23991366-1	2013	The vitamin A metabolite retinoic acid (RA) regulates gene transcription by activating the nuclear receptors RAR and PPARbeta/delta and their cognate lipid binding proteins CRABP-II, which delivers RA to RAR, and FABP5, which shuttles the hormone to PPARbeta/delta.	Tretinoin	25-38	peroxisome proliferator activator receptor delta	Mus musculus	117-125
23991366-1	2013	The vitamin A metabolite retinoic acid (RA) regulates gene transcription by activating the nuclear receptors RAR and PPARbeta/delta and their cognate lipid binding proteins CRABP-II, which delivers RA to RAR, and FABP5, which shuttles the hormone to PPARbeta/delta.	Tretinoin	25-38	peroxisome proliferator activator receptor delta	Mus musculus	250-258
23991366-1	2013	The vitamin A metabolite retinoic acid (RA) regulates gene transcription by activating the nuclear receptors RAR and PPARbeta/delta and their cognate lipid binding proteins CRABP-II, which delivers RA to RAR, and FABP5, which shuttles the hormone to PPARbeta/delta.	Tretinoin	40-42	peroxisome proliferator activator receptor delta	Mus musculus	117-125
23991366-1	2013	The vitamin A metabolite retinoic acid (RA) regulates gene transcription by activating the nuclear receptors RAR and PPARbeta/delta and their cognate lipid binding proteins CRABP-II, which delivers RA to RAR, and FABP5, which shuttles the hormone to PPARbeta/delta.	Tretinoin	40-42	peroxisome proliferator activator receptor delta	Mus musculus	250-258
23991366-1	2013	The vitamin A metabolite retinoic acid (RA) regulates gene transcription by activating the nuclear receptors RAR and PPARbeta/delta and their cognate lipid binding proteins CRABP-II, which delivers RA to RAR, and FABP5, which shuttles the hormone to PPARbeta/delta.	Tretinoin	109-111	peroxisome proliferator activator receptor delta	Mus musculus	250-258
23606724-0	2013	Fatty acids regulate perilipin5 in muscle by activating PPARdelta.	Fatty Acids	0-11	peroxisome proliferator activator receptor delta	Mus musculus	56-65
23606724-10	2013	Our analyses demonstrate that FAs require PPARdelta to induce transcription of Plin4 and Plin5.	Fatty Acids	30-33	peroxisome proliferator activator receptor delta	Mus musculus	42-51
23247708-5	2013	RESULTS: In livers from DUhTP mice, we identified significantly higher messenger RNA transcript levels of peroxisome proliferator-activated receptor delta and higher protein levels of sirtuin-1, acetyl-CoA-synthetase, acetyl-CoA-carboxylase, phosphoenolpyruvate carboxykinase, and glutamate-dehydrogenase, suggesting higher gluconeogenesis and lipogenesis in DUhTP mice.	duhtp	24-29	peroxisome proliferator activator receptor delta	Mus musculus	106-154
23247708-5	2013	RESULTS: In livers from DUhTP mice, we identified significantly higher messenger RNA transcript levels of peroxisome proliferator-activated receptor delta and higher protein levels of sirtuin-1, acetyl-CoA-synthetase, acetyl-CoA-carboxylase, phosphoenolpyruvate carboxykinase, and glutamate-dehydrogenase, suggesting higher gluconeogenesis and lipogenesis in DUhTP mice.	duhtp	359-364	peroxisome proliferator activator receptor delta	Mus musculus	106-154
23559003-0	2013	Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARbeta/delta: a potential therapeutic role for CNS autoimmune disease.	baicalein	36-45	peroxisome proliferator activator receptor delta	Mus musculus	64-72
23559003-4	2013	We further observed that inhibition of 12/15-LO with BA led to increased expression of peroxisome proliferator-activated receptor (PPAR)beta/delta in microglia of EAE mice.	baicalein	53-55	peroxisome proliferator activator receptor delta	Mus musculus	131-140
23559003-7	2013	Moreover, among these compounds only 12/15-LO metabolite 12-hydroxyeicosatetraenoic acid was able to reverse BA-mediated upregulation of PPARbeta/delta in BV2 cells.	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid	57-88	peroxisome proliferator activator receptor delta	Mus musculus	137-145
23559003-7	2013	Moreover, among these compounds only 12/15-LO metabolite 12-hydroxyeicosatetraenoic acid was able to reverse BA-mediated upregulation of PPARbeta/delta in BV2 cells.	baicalein	109-111	peroxisome proliferator activator receptor delta	Mus musculus	137-145
23500098-0	2013	A peroxisome proliferator-activated receptor-delta agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson"s disease.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	91-135	peroxisome proliferator activator receptor delta	Mus musculus	2-50
23500098-4	2013	In vitro administration of the PPARdelta antagonist GSK0660 (1 muM) increased the detrimental effect of 1-methyl-4-phenylpyridinium iodide (MPP+) on cell viability, which was reversed by co-treatment with agonist GW0742 (1 muM).	GSK0660	52-59	peroxisome proliferator activator receptor delta	Mus musculus	31-40
23500098-4	2013	In vitro administration of the PPARdelta antagonist GSK0660 (1 muM) increased the detrimental effect of 1-methyl-4-phenylpyridinium iodide (MPP+) on cell viability, which was reversed by co-treatment with agonist GW0742 (1 muM).	MPP+ iodide	104-138	peroxisome proliferator activator receptor delta	Mus musculus	31-40
23500098-4	2013	In vitro administration of the PPARdelta antagonist GSK0660 (1 muM) increased the detrimental effect of 1-methyl-4-phenylpyridinium iodide (MPP+) on cell viability, which was reversed by co-treatment with agonist GW0742 (1 muM).	mangion-purified polysaccharide (Candida albicans)	140-144	peroxisome proliferator activator receptor delta	Mus musculus	31-40
23500098-4	2013	In vitro administration of the PPARdelta antagonist GSK0660 (1 muM) increased the detrimental effect of 1-methyl-4-phenylpyridinium iodide (MPP+) on cell viability, which was reversed by co-treatment with agonist GW0742 (1 muM).	GW0742	213-219	peroxisome proliferator activator receptor delta	Mus musculus	31-40
23500098-7	2013	Striatal PPARdelta levels were increased (over two-fold) immediately after MPTP treatment (30 mg/kg for 5 consecutive days) compared to saline-treated mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	75-79	peroxisome proliferator activator receptor delta	Mus musculus	9-18
23500098-10	2013	These results indicate that agonism of PPARdelta provides protection against MPTP toxicity, in agreement with the effects of other PPAR agonists.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	77-81	peroxisome proliferator activator receptor delta	Mus musculus	39-48
21920965-3	2013	METHODS AND RESULTS: Treatment of EPCs with GW501516, a PPAR-delta agonist, induced specifically matrix metallo-proteinase (MMP)-9 by direct transcriptional activation.	GW 501516	44-52	peroxisome proliferator activator receptor delta	Mus musculus	56-66
23374874-0	2013	Molecular evidence for the involvement of PPAR-delta and PPAR-gamma in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma.	palmidrol	123-144	peroxisome proliferator activator receptor delta	Mus musculus	42-52
23238297-8	2013	The protein levels of PPARdelta, phospho-Akt, phospho-AS160, and Glut4 translocation to the plasma membrane in the skeletal muscle on insulin stimulation were reduced by high-fat diet and were restored by telmisartan administration in wild-type mice.	Telmisartan	205-216	peroxisome proliferator activator receptor delta	Mus musculus	22-31
23103566-7	2013	All of the above effects of HFCS-55 were attenuated by the specific PPAR-delta agonist GW0742.	GW0742	87-93	peroxisome proliferator activator receptor delta	Mus musculus	68-78
23103566-8	2013	Thus, we demonstrate for the first time that the specific PPAR-delta agonist GW0742 attenuates the metabolic abnormalities and the renal dysfunction/inflammation caused by chronic HFCS-55 exposure by preventing upregulation of fructokinase (liver) and activation of the NLRP3 inflammasome (kidney).	GW0742	77-83	peroxisome proliferator activator receptor delta	Mus musculus	58-68
22982594-0	2012	PPARdelta agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice.	GW 501516	18-26	peroxisome proliferator activator receptor delta	Mus musculus	0-9
24107399-1	2013	Peroxisome proliferator-activated receptors gamma (PPARgamma) and delta (PPARdelta) are nuclear receptors that have significant physiological effects on glucose and lipid metabolism.	Glucose	153-160	peroxisome proliferator activator receptor delta	Mus musculus	73-82
23105114-0	2012	Retinoic acid induces neurogenesis by activating both retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta).	Tretinoin	0-13	peroxisome proliferator activator receptor delta	Mus musculus	89-136
23105114-0	2012	Retinoic acid induces neurogenesis by activating both retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta).	Tretinoin	0-13	peroxisome proliferator activator receptor delta	Mus musculus	144-152
23105114-1	2012	Retinoic acid (RA) regulates gene transcription by activating the nuclear receptors retinoic acid receptor (RAR) and peroxisome proliferator-activated receptor (PPAR) beta/delta and their respective cognate lipid-binding proteins CRABP-II and FABP5.	Tretinoin	0-13	peroxisome proliferator activator receptor delta	Mus musculus	117-171
23105114-1	2012	Retinoic acid (RA) regulates gene transcription by activating the nuclear receptors retinoic acid receptor (RAR) and peroxisome proliferator-activated receptor (PPAR) beta/delta and their respective cognate lipid-binding proteins CRABP-II and FABP5.	Tretinoin	15-17	peroxisome proliferator activator receptor delta	Mus musculus	117-171
23105114-3	2012	Here, we show that the RA-induced commitment of P19 stem cells to neuronal progenitors is mediated by the CRABP-II/RAR path and that the FABP5/PPARbeta/delta path can inhibit the process through induction of the RAR repressors SIRT1 and Ajuba.	Tretinoin	23-25	peroxisome proliferator activator receptor delta	Mus musculus	143-151
23105114-5	2012	Hence, RA-induced neuronal differentiation is mediated through RAR in the early stages and through PPARbeta/delta in the late stages of the process.	Tretinoin	7-9	peroxisome proliferator activator receptor delta	Mus musculus	99-107
23861559-3	2013	This study aimed to investigate the signaling pathways activated in the gastrocnemius muscle by chronic administration of the selective PPAR- delta agonist, GW0742 (1 mg/kg/day for 16 weeks), in male C57Bl6/J mice treated for 30 weeks with high-fructose corn syrup (HFCS), the major sweetener in foods and soft-drinks (15% wt/vol in drinking water).	GW0742	157-163	peroxisome proliferator activator receptor delta	Mus musculus	136-147
23861559-6	2013	GW0742 administration induced PPAR- delta upregulation and improvement in glucose and lipid metabolism.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	30-41
23074280-12	2012	We identified the PPARdelta ligand PGI(2) as the most abundant AAMphi-derived eicosanoid and propose a PGI(2)-PPARdelta axis maintains AAMphi during B malayi implantation.	Epoprostenol	35-41	peroxisome proliferator activator receptor delta	Mus musculus	18-27
23074280-12	2012	We identified the PPARdelta ligand PGI(2) as the most abundant AAMphi-derived eicosanoid and propose a PGI(2)-PPARdelta axis maintains AAMphi during B malayi implantation.	Eicosanoids	78-88	peroxisome proliferator activator receptor delta	Mus musculus	18-27
22886847-10	2012	Treatment with PPARdelta ligand GW501516 (2 mg/kg/day) for 14 days significantly increased BH(4) bioavailability and improved endothelium-dependent relaxations in Tg2576 mice aortas.	GW 501516	32-40	peroxisome proliferator activator receptor delta	Mus musculus	15-24
22933110-8	2012	PPARdelta agonist GW1516 restored EDRs in mouse aortae under high-glucose conditions or in db/db mouse aortae ex vivo.	GW 501516	18-24	peroxisome proliferator activator receptor delta	Mus musculus	0-9
22933110-8	2012	PPARdelta agonist GW1516 restored EDRs in mouse aortae under high-glucose conditions or in db/db mouse aortae ex vivo.	edrs	34-38	peroxisome proliferator activator receptor delta	Mus musculus	0-9
22933110-8	2012	PPARdelta agonist GW1516 restored EDRs in mouse aortae under high-glucose conditions or in db/db mouse aortae ex vivo.	Glucose	66-73	peroxisome proliferator activator receptor delta	Mus musculus	0-9
22933110-9	2012	After oral treatment with GW1516, EDRs in aortae and FMDs in mesenteric resistance arteries were improved in obese mice in a PPARdelta-specific manner.	GW 501516	26-32	peroxisome proliferator activator receptor delta	Mus musculus	125-134
22729460-0	2012	Liver X receptor beta and peroxisome proliferator-activated receptor delta regulate cholesterol transport in murine cholangiocytes.	Cholesterol	84-95	peroxisome proliferator activator receptor delta	Mus musculus	26-74
22729460-4	2012	Activation of LXRbeta and/or PPARdelta in cholangiocytes induces ATP-binding cassette cholesterol transporter A1 (ABCA1) and increases cholesterol export at the basolateral compartment in polarized cultured cholangiocytes.	Cholesterol	86-97	peroxisome proliferator activator receptor delta	Mus musculus	29-38
22729460-5	2012	In addition, PPARdelta induces Niemann-Pick C1-like L1 (NPC1L1), which imports cholesterol into cholangiocytes and is expressed on the apical cholangiocyte membrane via specific interaction with a peroxisome proliferator-activated response element (PPRE) within the NPC1L1 promoter.	Cholesterol	79-90	peroxisome proliferator activator receptor delta	Mus musculus	13-22
22982594-2	2012	The role of PPARdelta in metabolism of tetrahydrobiopterin (BH4) has not been studied in the cerebral microvasculature.	sapropterin	39-58	peroxisome proliferator activator receptor delta	Mus musculus	12-21
22982594-2	2012	The role of PPARdelta in metabolism of tetrahydrobiopterin (BH4) has not been studied in the cerebral microvasculature.	sapropterin	60-63	peroxisome proliferator activator receptor delta	Mus musculus	12-21
22982594-4	2012	Wild-type (B6CBA) and hph-1 mice were orally gavaged with a selective PPARdelta activator, GW501516 (2 mg/kg/day) for 14 days, and thereafter, cerebral microvessels were isolated and studied.	GW 501516	91-99	peroxisome proliferator activator receptor delta	Mus musculus	70-79
22982594-6	2012	Attenuation of L-NAME-inhibitable superoxide anion levels by GW501516 demonstrated that activation of PPARdelta might prevent uncoupling of endothelial nitric oxide synthase (eNOS, P&lt;0.05, n=6-9).	NG-Nitroarginine Methyl Ester	15-21	peroxisome proliferator activator receptor delta	Mus musculus	102-111
22982594-6	2012	Attenuation of L-NAME-inhibitable superoxide anion levels by GW501516 demonstrated that activation of PPARdelta might prevent uncoupling of endothelial nitric oxide synthase (eNOS, P&lt;0.05, n=6-9).	Superoxides	34-50	peroxisome proliferator activator receptor delta	Mus musculus	102-111
22982594-6	2012	Attenuation of L-NAME-inhibitable superoxide anion levels by GW501516 demonstrated that activation of PPARdelta might prevent uncoupling of endothelial nitric oxide synthase (eNOS, P&lt;0.05, n=6-9).	GW 501516	61-69	peroxisome proliferator activator receptor delta	Mus musculus	102-111
22982594-8	2012	PPARdelta activation increased the total nitrite and nitrate (NO2+NO3) content in cerebral microvessels (P&lt;0.05, n=6).	Nitrites	41-48	peroxisome proliferator activator receptor delta	Mus musculus	0-9
22982594-8	2012	PPARdelta activation increased the total nitrite and nitrate (NO2+NO3) content in cerebral microvessels (P&lt;0.05, n=6).	Nitrates	53-60	peroxisome proliferator activator receptor delta	Mus musculus	0-9
22982594-8	2012	PPARdelta activation increased the total nitrite and nitrate (NO2+NO3) content in cerebral microvessels (P&lt;0.05, n=6).	no2+no3	62-69	peroxisome proliferator activator receptor delta	Mus musculus	0-9
23093780-6	2012	Analyses of insulin release from isolated PPARbeta/delta-deficient islets revealed an accelerated second phase of glucose-stimulated insulin secretion.	Glucose	114-121	peroxisome proliferator activator receptor delta	Mus musculus	42-50
22607770-8	2012	These changes were accompanied by up-regulation of genes involved in cholesterol efflux such as PPARdelta, LXRalpha, and LXRalpha-targeting genes and down-regulation of pro-inflammatory cytokine and chemokine genes in obese TLR3(-/-) mice.	Cholesterol	69-80	peroxisome proliferator activator receptor delta	Mus musculus	96-105
22750553-0	2012	The antiplatelet activity of magnolol is mediated by PPAR-beta/gamma.	magnolol	29-37	peroxisome proliferator activator receptor delta	Mus musculus	53-62
23046570-0	2012	GW501516-activated PPARbeta/delta promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation.	GW 501516	0-8	peroxisome proliferator activator receptor delta	Mus musculus	19-27
23046570-3	2012	This study investigated whether activation of PPARbeta/delta with the ligand GW501516 influenced the fibrotic response to injury from chronic carbon tetrachloride (CCl4) treatment in mice.	GW 501516	77-85	peroxisome proliferator activator receptor delta	Mus musculus	46-54
22879602-9	2012	Furthermore, gemfibrozil treatment also led to the recruitment of PPAR-beta to the PLP promoter in vivo in the spinal cord of experimental autoimmune encephalomyelitis mice and suppression of experimental autoimmune encephalomyelitis symptoms in PLP-T cell receptor transgenic mice.	Gemfibrozil	13-24	peroxisome proliferator activator receptor delta	Mus musculus	66-75
22750553-8	2012	However, these above effects of magnolol on platelet responses were strongly reduced by simultaneous addition of GSK0660 or GW9662, suggesting that PPAR-beta/gamma-mediated processes may account for magnolol-regulated antiplatelet mechanisms.	magnolol	199-207	peroxisome proliferator activator receptor delta	Mus musculus	148-157
22750553-9	2012	Similarly, administration of PPAR-beta/gamma antagonists remarkably abolished the actions of magnolol in preventing platelet plug formation and prolonging bleeding time in mice.	magnolol	93-101	peroxisome proliferator activator receptor delta	Mus musculus	29-38
22750553-10	2012	Taken together, we demonstrate for the first time that the antiplatelet and anti-thrombotic activities of magnolol are modulated by up-regulation of PPAR-beta/gamma-dependent pathways.	magnolol	106-114	peroxisome proliferator activator receptor delta	Mus musculus	149-158
22750553-3	2012	Magnolol (20-60 muM) dose-dependently enhanced the activity and intracellular level of PPAR-beta/gamma in platelets.	magnolol	0-8	peroxisome proliferator activator receptor delta	Mus musculus	87-96
22750553-4	2012	In the presence of selective PPAR-beta antagonist (GSK0660) or PPAR-gamma antagonist (GW9662), the inhibition of magnolol on collagen-induced platelet aggregation and intracellular Ca(2+) mobilization was significantly reversed.	magnolol	113-121	peroxisome proliferator activator receptor delta	Mus musculus	29-38
22750553-5	2012	Moreover, magnolol-mediated up-regulation of NO/cyclic GMP/PKG pathway and Akt phosphorylation leading to increase of eNOS activity were markedly abolished by blocking PPAR-beta/gamma activity.	magnolol	10-18	peroxisome proliferator activator receptor delta	Mus musculus	168-177
22750553-6	2012	Additionally, magnolol significantly inhibited collagen-induced PKCalpha activation through a PPAR-beta/gamma and PKCalpha interaction manner.	magnolol	14-22	peroxisome proliferator activator receptor delta	Mus musculus	94-103
22750553-8	2012	However, these above effects of magnolol on platelet responses were strongly reduced by simultaneous addition of GSK0660 or GW9662, suggesting that PPAR-beta/gamma-mediated processes may account for magnolol-regulated antiplatelet mechanisms.	magnolol	32-40	peroxisome proliferator activator receptor delta	Mus musculus	148-157
22750553-8	2012	However, these above effects of magnolol on platelet responses were strongly reduced by simultaneous addition of GSK0660 or GW9662, suggesting that PPAR-beta/gamma-mediated processes may account for magnolol-regulated antiplatelet mechanisms.	GSK0660	113-120	peroxisome proliferator activator receptor delta	Mus musculus	148-157
22750553-8	2012	However, these above effects of magnolol on platelet responses were strongly reduced by simultaneous addition of GSK0660 or GW9662, suggesting that PPAR-beta/gamma-mediated processes may account for magnolol-regulated antiplatelet mechanisms.	2-chloro-5-nitrobenzanilide	124-130	peroxisome proliferator activator receptor delta	Mus musculus	148-157
22179221-6	2012	Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Pparbeta/delta-null mice showed increased Tyr705- and Ser727-STAT3 as well as phospho-ERK1/2 levels.	GW 501516	10-18	peroxisome proliferator activator receptor delta	Mus musculus	190-198
22473775-0	2012	Activation of peroxisome proliferator-activated receptor-delta attenuates glutamate-induced neurotoxicity in HT22 mouse hippocampal cells.	Glutamic Acid	74-83	peroxisome proliferator activator receptor delta	Mus musculus	14-62
22473775-2	2012	This study demonstrates that peroxisome proliferator-activated receptor (PPAR)-delta regulates glutamate-induced neurotoxicity in HT22 mouse hippocampal cells.	Glutamic Acid	95-104	peroxisome proliferator activator receptor delta	Mus musculus	29-84
22473775-3	2012	Activation of PPARdelta by GW501516, a specific ligand, significantly inhibited glutamate-induced cell death and reactive oxygen species (ROS) production in HT22 cells.	GW 501516	27-35	peroxisome proliferator activator receptor delta	Mus musculus	14-23
22473775-3	2012	Activation of PPARdelta by GW501516, a specific ligand, significantly inhibited glutamate-induced cell death and reactive oxygen species (ROS) production in HT22 cells.	Glutamic Acid	80-89	peroxisome proliferator activator receptor delta	Mus musculus	14-23
22473775-3	2012	Activation of PPARdelta by GW501516, a specific ligand, significantly inhibited glutamate-induced cell death and reactive oxygen species (ROS) production in HT22 cells.	Reactive Oxygen Species	113-136	peroxisome proliferator activator receptor delta	Mus musculus	14-23
22473775-3	2012	Activation of PPARdelta by GW501516, a specific ligand, significantly inhibited glutamate-induced cell death and reactive oxygen species (ROS) production in HT22 cells.	Reactive Oxygen Species	138-141	peroxisome proliferator activator receptor delta	Mus musculus	14-23
22473775-4	2012	The siRNA-mediated knockdown of PPARdelta abrogated the effects of GW501516 in neuronal toxicity and ROS production induced by glutamate.	GW 501516	67-75	peroxisome proliferator activator receptor delta	Mus musculus	32-41
22473775-4	2012	The siRNA-mediated knockdown of PPARdelta abrogated the effects of GW501516 in neuronal toxicity and ROS production induced by glutamate.	Reactive Oxygen Species	101-104	peroxisome proliferator activator receptor delta	Mus musculus	32-41
22473775-4	2012	The siRNA-mediated knockdown of PPARdelta abrogated the effects of GW501516 in neuronal toxicity and ROS production induced by glutamate.	Glutamic Acid	127-136	peroxisome proliferator activator receptor delta	Mus musculus	32-41
22473775-5	2012	In addition, ligand-activated PPARdelta reduced the glutamate-induced level of intracellular calcium ions (Ca(2+)) by modulating the influx of Ca(2+) from the extracellular space.	Glutamic Acid	52-61	peroxisome proliferator activator receptor delta	Mus musculus	30-39
22473775-5	2012	In addition, ligand-activated PPARdelta reduced the glutamate-induced level of intracellular calcium ions (Ca(2+)) by modulating the influx of Ca(2+) from the extracellular space.	Calcium	93-100	peroxisome proliferator activator receptor delta	Mus musculus	30-39
22473775-7	2012	Taken together, these results suggest that PPARdelta plays an important role in glutamate-induced neurotoxicity by modulating oxidative stress and Ca(2+) influx.	Glutamic Acid	80-89	peroxisome proliferator activator receptor delta	Mus musculus	43-52
22685301-11	2012	Overall, the results indicate that lipolytic products can activate PPARalpha and PPARdelta in brown adipocytes, thereby expanding the oxidative capacity to match enhanced fatty acid supply.	Fatty Acids	171-181	peroxisome proliferator activator receptor delta	Mus musculus	81-90
22521259-0	2012	Peroxisome proliferator-activated receptor beta/delta agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice.	GW0742	62-68	peroxisome proliferator activator receptor delta	Mus musculus	0-47
22521259-0	2012	Peroxisome proliferator-activated receptor beta/delta agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice.	Taurocholic Acid	95-107	peroxisome proliferator activator receptor delta	Mus musculus	0-47
22521259-4	2012	The aim of the present study was to evaluate the influence of PPAR-beta/delta receptor in a model of edematous pancreatitis induced in mice by administration of cerulein at supramaximal doses, as well as in necrohemorrhagic model induced by intraductal administration of sodium taurocholate (STC).	Taurocholic Acid	271-290	peroxisome proliferator activator receptor delta	Mus musculus	62-71
22521259-4	2012	The aim of the present study was to evaluate the influence of PPAR-beta/delta receptor in a model of edematous pancreatitis induced in mice by administration of cerulein at supramaximal doses, as well as in necrohemorrhagic model induced by intraductal administration of sodium taurocholate (STC).	Taurocholic Acid	292-295	peroxisome proliferator activator receptor delta	Mus musculus	62-71
22521259-13	2012	In addition, the pancreatic water content was reduced in mice treated with PPAR-beta/delta agonist.	Water	28-33	peroxisome proliferator activator receptor delta	Mus musculus	75-84
22396202-2	2012	The activity is mediated in part through activation of the nuclear receptors RA receptors (RARs) and peroxisome proliferator-activated receptor beta/delta and their associated binding proteins cellular RA binding protein type II (CRABP-II) and fatty acid binding protein type 5 in adipocytes and skeletal muscle, leading to enhanced lipid oxidation and energy dissipation.	Fatty Acids	244-254	peroxisome proliferator activator receptor delta	Mus musculus	101-148
22387176-9	2012	PPARdelta inhibited NF-kappaB via transrepression by physically interacting with the p65 subunit and prevented activation of the PKCalpha/MEK1/2/ERK1/2/AP-1 pathway by inhibiting the radiation-induced increase in intracellular reactive oxygen species generation.	Reactive Oxygen Species	227-250	peroxisome proliferator activator receptor delta	Mus musculus	0-9
22782371-9	2012	These results suggest that the t10,c12 CLA is responsible for improving endurance exercise capacity by promoting fat oxidation with a reduction of the consumption of stored liver glycogen, potentially mediated via PPARdelta dependent mechanisms.	Glycogen	179-187	peroxisome proliferator activator receptor delta	Mus musculus	214-223
22387176-7	2012	Incubating BV-2 murine microglial cells with the PPARdelta agonist L-165041 prevented the radiation-induced increase in: (i) intracellular reactive oxygen species generation, (ii) Cox-2 and MCP-1 expression, and (iii) IL-1beta and TNF-alpha message levels.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	67-75	peroxisome proliferator activator receptor delta	Mus musculus	49-58
22387176-7	2012	Incubating BV-2 murine microglial cells with the PPARdelta agonist L-165041 prevented the radiation-induced increase in: (i) intracellular reactive oxygen species generation, (ii) Cox-2 and MCP-1 expression, and (iii) IL-1beta and TNF-alpha message levels.	Reactive Oxygen Species	139-162	peroxisome proliferator activator receptor delta	Mus musculus	49-58
22369181-0	2012	(Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPARbeta/delta-selective ligand with inverse agonistic properties.	(z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile	0-75	peroxisome proliferator activator receptor delta	Mus musculus	108-116
22369181-0	2012	(Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPARbeta/delta-selective ligand with inverse agonistic properties.	2-(2-bromophenyl)-3-((4-(1-methylpiperazine)amino)phenyl)acrylonitrile	77-82	peroxisome proliferator activator receptor delta	Mus musculus	108-116
22369181-4	2012	This led to the design of derivative 37, (Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172), a novel PPARbeta/delta-selective ligand showing high binding affinity (IC(50) = 27 nM) and potent inverse agonistic properties.	(z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile	41-116	peroxisome proliferator activator receptor delta	Mus musculus	134-142
22369181-4	2012	This led to the design of derivative 37, (Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172), a novel PPARbeta/delta-selective ligand showing high binding affinity (IC(50) = 27 nM) and potent inverse agonistic properties.	2-(2-bromophenyl)-3-((4-(1-methylpiperazine)amino)phenyl)acrylonitrile	118-123	peroxisome proliferator activator receptor delta	Mus musculus	134-142
21687928-9	2011	We observed that bezafibrate, a dual ligand for the peroxisome proliferator-activated receptors alpha (PPARalpha) and PPARdelta, significantly attenuated the palmitate-induced cytotoxicity as determined by the MTT assay and inhibited the palmitate-induced apoptosis as determined by a flow cytometry assay using Annexin V-FITC/PI and assessment of the activity of caspase-3.	Bezafibrate	17-28	peroxisome proliferator activator receptor delta	Mus musculus	118-127
21685825-0	2012	GW0742, a high-affinity PPAR-delta agonist, mediates protection in an organotypic model of spinal cord damage.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	24-34
21685825-2	2012	OBJECTIVE: To clarify the protective mechanism of PPAR-delta agonist GW0742 in the injured spinal cord using an in vitro model.	GW0742	69-75	peroxisome proliferator activator receptor delta	Mus musculus	50-60
21685825-10	2012	CONCLUSION: GW0742 reduces the cellular and molecular changes occurring in SCI by targeting different downstream pathways modulating PPAR-delta receptors.	GW0742	12-18	peroxisome proliferator activator receptor delta	Mus musculus	133-143
21940900-1	2012	The ligand-activated transcription factor peroxisome proliferator-activated receptor (PPAR)-delta is highly expressed in colonic epithelial cells; however, the role of PPARdelta ligands, such as fatty acids, in mucosal inflammation and malignant transformation has not been clarified.	Fatty Acids	195-206	peroxisome proliferator activator receptor delta	Mus musculus	42-97
21940900-2	2012	Recent evidence suggests that the anti-inflammatory/chemoprotective properties of fish oil (FO)-derived n-3 polyunsaturated fatty acids (PUFAs) may be partly mediated by PPARdelta.	Fish Oils	92-94	peroxisome proliferator activator receptor delta	Mus musculus	170-179
21940900-2	2012	Recent evidence suggests that the anti-inflammatory/chemoprotective properties of fish oil (FO)-derived n-3 polyunsaturated fatty acids (PUFAs) may be partly mediated by PPARdelta.	Fatty Acids, Omega-3	104-135	peroxisome proliferator activator receptor delta	Mus musculus	170-179
21940900-2	2012	Recent evidence suggests that the anti-inflammatory/chemoprotective properties of fish oil (FO)-derived n-3 polyunsaturated fatty acids (PUFAs) may be partly mediated by PPARdelta.	Fatty Acids, Unsaturated	137-142	peroxisome proliferator activator receptor delta	Mus musculus	170-179
22104958-11	2011	In early-stage cachexia, rosiglitazone normalized PDK4 and PPAR-delta mRNA in quadriceps muscle and rescued the decrease in insulin-stimulated glucose disappearance in mice with tumors.	Rosiglitazone	25-38	peroxisome proliferator activator receptor delta	Mus musculus	59-69
22916190-6	2012	Because in peripheral tissues, expression of PPARdelta increases lipid oxidative genes and opposes inflammation, we hypothesized that CNS PPARdelta protects against the development of DIO.	3,3'-Dioctadecyloxacarbocyanine perchlorate	184-187	peroxisome proliferator activator receptor delta	Mus musculus	45-54
22916190-6	2012	Because in peripheral tissues, expression of PPARdelta increases lipid oxidative genes and opposes inflammation, we hypothesized that CNS PPARdelta protects against the development of DIO.	3,3'-Dioctadecyloxacarbocyanine perchlorate	184-187	peroxisome proliferator activator receptor delta	Mus musculus	138-147
22606335-7	2012	Here, we report that three selective PPAR beta/delta antagonists, GSK0660, compound 3 h, and GSK3787 can be formulated for topical application to the skin and that their skin concentration can be accurately quantified using ultra-high performance liquid chromatography (UPLC)/mass spectrometry.	GSK0660	66-73	peroxisome proliferator activator receptor delta	Mus musculus	37-46
22606335-7	2012	Here, we report that three selective PPAR beta/delta antagonists, GSK0660, compound 3 h, and GSK3787 can be formulated for topical application to the skin and that their skin concentration can be accurately quantified using ultra-high performance liquid chromatography (UPLC)/mass spectrometry.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	93-100	peroxisome proliferator activator receptor delta	Mus musculus	37-46
22606335-9	2012	PPAR beta/delta antagonists GSK0660 and compound 3 do not exhibit systemic drug accumulation after prolonged application to the skin, nor do they induce inflammatory or irritant changes.	GSK0660	28-35	peroxisome proliferator activator receptor delta	Mus musculus	0-9
22606335-10	2012	Significantly, the irreversible PPAR beta/delta antagonist (GSK3787) retains efficacy when applied topically only three times per week which could be of practical clinical usefulness.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	60-67	peroxisome proliferator activator receptor delta	Mus musculus	32-41
22135324-3	2011	Transcriptional profiling revealed that the lactate dehydrogenase b (Ldhb)/Ldha gene expression ratio is increased in MCK-PPARbeta/delta muscle, an isoenzyme shift that diverts pyruvate into the mitochondrion for the final steps of glucose oxidation.	Pyruvic Acid	177-185	peroxisome proliferator activator receptor delta	Mus musculus	122-130
22135324-3	2011	Transcriptional profiling revealed that the lactate dehydrogenase b (Ldhb)/Ldha gene expression ratio is increased in MCK-PPARbeta/delta muscle, an isoenzyme shift that diverts pyruvate into the mitochondrion for the final steps of glucose oxidation.	Glucose	232-239	peroxisome proliferator activator receptor delta	Mus musculus	122-130
22135324-5	2011	MCK-PPARbeta/delta muscle was shown to have high glycogen stores, increased levels of GLUT4, and augmented capacity for mitochondrial pyruvate oxidation, suggesting a broad reprogramming of glucose utilization pathways.	Glycogen	49-57	peroxisome proliferator activator receptor delta	Mus musculus	4-12
22135324-5	2011	MCK-PPARbeta/delta muscle was shown to have high glycogen stores, increased levels of GLUT4, and augmented capacity for mitochondrial pyruvate oxidation, suggesting a broad reprogramming of glucose utilization pathways.	Glucose	190-197	peroxisome proliferator activator receptor delta	Mus musculus	4-12
21687928-9	2011	We observed that bezafibrate, a dual ligand for the peroxisome proliferator-activated receptors alpha (PPARalpha) and PPARdelta, significantly attenuated the palmitate-induced cytotoxicity as determined by the MTT assay and inhibited the palmitate-induced apoptosis as determined by a flow cytometry assay using Annexin V-FITC/PI and assessment of the activity of caspase-3.	Palmitates	158-167	peroxisome proliferator activator receptor delta	Mus musculus	118-127
21426320-4	2011	PPARdelta KI mice displayed a small decrease of high-density lipoprotein-cholesterol whereas other lipid parameters were unaltered.	Cholesterol	73-84	peroxisome proliferator activator receptor delta	Mus musculus	0-9
21894990-11	2011	We propose that marked activation of PPAR-delta is the primary mechanism mediating the antiobesogenic effect of soybean and that PPAR-delta has multiple actions: induction of thermogenesis in muscle, reduction of fatty acid synthesis in adipose tissue, and reduction of fatty acid uptake in intestinal tissue.	Fatty Acids	213-223	peroxisome proliferator activator receptor delta	Mus musculus	129-139
21894990-11	2011	We propose that marked activation of PPAR-delta is the primary mechanism mediating the antiobesogenic effect of soybean and that PPAR-delta has multiple actions: induction of thermogenesis in muscle, reduction of fatty acid synthesis in adipose tissue, and reduction of fatty acid uptake in intestinal tissue.	Fatty Acids	270-280	peroxisome proliferator activator receptor delta	Mus musculus	129-139
21511721-2	2011	In particular, maternal prostacyclin (PGI(2)) is critical for embryo implantation and the action of PGI(2) is not mediated via its G-protein-coupled membrane receptor, IP, but its nuclear receptor, peroxisome-proliferator-activated receptor delta (PPARdelta).	Epoprostenol	24-36	peroxisome proliferator activator receptor delta	Mus musculus	198-246
21511721-2	2011	In particular, maternal prostacyclin (PGI(2)) is critical for embryo implantation and the action of PGI(2) is not mediated via its G-protein-coupled membrane receptor, IP, but its nuclear receptor, peroxisome-proliferator-activated receptor delta (PPARdelta).	Epoprostenol	24-36	peroxisome proliferator activator receptor delta	Mus musculus	248-257
21511721-7	2011	Carbaprostacyclin (a stable analogue of PGI(2)) and GW501516 (a PPARdelta selective agonist) significantly accelerated blastocyst hatching but did not increase total cell number of cultured blastocysts.	GW 501516	52-60	peroxisome proliferator activator receptor delta	Mus musculus	64-73
21426320-5	2011	Plasma metabolic parameters were similar in wild-type and PPARdelta KI mice when fed chow or HFD, and following physiological (fasting) and pharmacological (GW0742 compound) activation of PPARdelta.	GW0742	157-163	peroxisome proliferator activator receptor delta	Mus musculus	188-197
21798999-5	2011	We report that PPARbeta activation with GW0742 induces a rapid (2 h) and sustained down-regulation of gamma3-AMPK expression both in mouse skeletal muscles and in culture myotubes.	GW0742	40-46	peroxisome proliferator activator receptor delta	Mus musculus	15-23
21843327-5	2011	The metabolic effects of the receptors were readily distinguished, with PPARgamma activation characterized by increased fat storage, synthesis and elongation, while PPARdelta activation caused increased fatty acid beta-oxidation, tricarboxylic acid cycle rate and oxidation of extracellular branch chain amino acids.	Fatty Acids	203-213	peroxisome proliferator activator receptor delta	Mus musculus	165-174
21843327-5	2011	The metabolic effects of the receptors were readily distinguished, with PPARgamma activation characterized by increased fat storage, synthesis and elongation, while PPARdelta activation caused increased fatty acid beta-oxidation, tricarboxylic acid cycle rate and oxidation of extracellular branch chain amino acids.	Tricarboxylic Acids	230-248	peroxisome proliferator activator receptor delta	Mus musculus	165-174
21725906-7	2011	In the present study, we used L-165041 as PPARdelta agonist to treat the high fat diet (HFD) fed mice.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	30-38	peroxisome proliferator activator receptor delta	Mus musculus	42-51
20477906-3	2011	Administration of telmisartan up-regulated levels of PPAR-delta and phospho-AMPKalpha in cultured myotubes.	Telmisartan	18-29	peroxisome proliferator activator receptor delta	Mus musculus	53-63
22466297-1	2011	The peroxisome proliferator-activated receptor (PPAR) subtype specificity of GW501516, a well-known PPARdelta-specific agonist, was studied by examining its effects on the expression of endogenous genes in primary hepatocytes and the liver of wild-type and PPARalpha-null mice.	GW 501516	77-85	peroxisome proliferator activator receptor delta	Mus musculus	100-109
21631112-5	2011	Similarly, in the murine ear edema model, 12-O-tetradecanoylphorbol-13-acetate-induced inflammation was inhibited by mogrosides by down-regulating COX-2 and IL-6 and up-regulating PARP1, BCL2l1, TRP53, MAPK9, and PPARdelta gene expression.	Tetradecanoylphorbol Acetate	42-78	peroxisome proliferator activator receptor delta	Mus musculus	213-222
21631112-5	2011	Similarly, in the murine ear edema model, 12-O-tetradecanoylphorbol-13-acetate-induced inflammation was inhibited by mogrosides by down-regulating COX-2 and IL-6 and up-regulating PARP1, BCL2l1, TRP53, MAPK9, and PPARdelta gene expression.	mogrosides	117-127	peroxisome proliferator activator receptor delta	Mus musculus	213-222
20477906-5	2011	Chronic administration of telmisartan remarkably prevented weight gain, enhanced running endurance and post-exercise oxygen consumption, and increased slow-twitch skeletal muscle fibres in wild-type mice, but these effects were absent in PPAR-delta-deficient mice.	Telmisartan	26-37	peroxisome proliferator activator receptor delta	Mus musculus	238-248
21765606-0	2011	Administration of PPARbeta/delta agonist reduces copper-induced liver damage in mice: possible implications in clinical practice.	Copper	49-55	peroxisome proliferator activator receptor delta	Mus musculus	18-26
21765606-1	2011	In this study we investigated if peroxisome proliferator-activated receptor beta/delta activation protects from copper-induced acute liver damage.	Copper	112-118	peroxisome proliferator activator receptor delta	Mus musculus	33-80
21765606-3	2011	Mice treated with copper and peroxisome proliferator-activated receptor beta/delta agonist GW0742 had significantly less body weight loss, less serum alanine aminotransferase increase, less tumor necrosis factor alpha, macrophage inflammatory protein-2 and 8-hydroxy-2"-deoxyguanosine upregulation than copper treated mice.	GW0742	91-97	peroxisome proliferator activator receptor delta	Mus musculus	29-76
21765606-3	2011	Mice treated with copper and peroxisome proliferator-activated receptor beta/delta agonist GW0742 had significantly less body weight loss, less serum alanine aminotransferase increase, less tumor necrosis factor alpha, macrophage inflammatory protein-2 and 8-hydroxy-2"-deoxyguanosine upregulation than copper treated mice.	8-ohdg	257-284	peroxisome proliferator activator receptor delta	Mus musculus	29-76
21765606-3	2011	Mice treated with copper and peroxisome proliferator-activated receptor beta/delta agonist GW0742 had significantly less body weight loss, less serum alanine aminotransferase increase, less tumor necrosis factor alpha, macrophage inflammatory protein-2 and 8-hydroxy-2"-deoxyguanosine upregulation than copper treated mice.	Copper	303-309	peroxisome proliferator activator receptor delta	Mus musculus	29-76
21765606-4	2011	The opposite effect was observed in mice treated with copper and peroxisome proliferator-activated receptor beta/delta antagonist GSK0660.	GSK0660	130-137	peroxisome proliferator activator receptor delta	Mus musculus	65-112
21765606-5	2011	In vitro, copper induced reactive oxygen species, which was lower in cells treated with GW0742 or transfected with peroxisome proliferator-activated receptor beta/delta expression vector; together, transfection and GW0742 had an additive reactive oxygen species-reducing effect.	Copper	10-16	peroxisome proliferator activator receptor delta	Mus musculus	115-162
21765606-5	2011	In vitro, copper induced reactive oxygen species, which was lower in cells treated with GW0742 or transfected with peroxisome proliferator-activated receptor beta/delta expression vector; together, transfection and GW0742 had an additive reactive oxygen species-reducing effect.	Reactive Oxygen Species	25-48	peroxisome proliferator activator receptor delta	Mus musculus	115-162
21765606-5	2011	In vitro, copper induced reactive oxygen species, which was lower in cells treated with GW0742 or transfected with peroxisome proliferator-activated receptor beta/delta expression vector; together, transfection and GW0742 had an additive reactive oxygen species-reducing effect.	Reactive Oxygen Species	238-261	peroxisome proliferator activator receptor delta	Mus musculus	115-162
21765606-7	2011	In conclusion, peroxisome proliferator-activated receptor beta/delta activation reduced copper-induced reactive oxygen species, pro-inflammatory and acute phase reaction cytokines in mice liver.	Copper	88-94	peroxisome proliferator activator receptor delta	Mus musculus	15-62
21765606-7	2011	In conclusion, peroxisome proliferator-activated receptor beta/delta activation reduced copper-induced reactive oxygen species, pro-inflammatory and acute phase reaction cytokines in mice liver.	Reactive Oxygen Species	103-126	peroxisome proliferator activator receptor delta	Mus musculus	15-62
21765606-8	2011	Peroxisome proliferator-activated receptor beta/delta agonists could become useful in the management of copper-induced liver damage.	Copper	104-110	peroxisome proliferator activator receptor delta	Mus musculus	0-47
21499286-10	2011	These effects could be blocked by AMPK inhibitor compound C (5 mumol/L), or the PPARbeta inhibitor GSK0660 (0.5 mumol/L), but not by the PPARalpha inhibitor MK886 (10 mumol/L).	GSK0660	99-106	peroxisome proliferator activator receptor delta	Mus musculus	80-88
21617181-4	2011	RESULTS: First, we observed that the PPAR-beta/-delta agonist GW501516 prevented both IL-6-dependent reduction in insulin-stimulated Akt phosphorylation and glucose uptake in adipocytes.	GW 501516	62-70	peroxisome proliferator activator receptor delta	Mus musculus	37-46
21617181-4	2011	RESULTS: First, we observed that the PPAR-beta/-delta agonist GW501516 prevented both IL-6-dependent reduction in insulin-stimulated Akt phosphorylation and glucose uptake in adipocytes.	Glucose	157-164	peroxisome proliferator activator receptor delta	Mus musculus	37-46
21143191-9	2011	In conclusion, we show for the first time that the myocardial protection afforded by rIPC is mediated via the PI3K/Akt/GSK3beta signalling pathway, activation of which is associated with nuclear accumulation of beta-catenin and the up-regulation of its downstream targets E-cadherin and PPARdelta involved in cell survival.	ripc	85-89	peroxisome proliferator activator receptor delta	Mus musculus	287-296
21272187-0	2011	A new, highly selective murine peroxisome proliferator-activated receptor delta agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice.	Glucose	140-147	peroxisome proliferator activator receptor delta	Mus musculus	31-79
21272187-1	2011	AIM: We investigated how GW800644, the first pharmacologically selective murine peroxisome proliferator-activated receptor delta (PPARdelta) agonist, affects energy balance, glucose homeostasis and fuel utilization by muscle in obese mice.	2-(2-methyl-4-((1-(6-(4-(trifluoromethyl)phenyl)-2-pyridinyl)pentyl)oxy)phenoxy)acetic acid	25-33	peroxisome proliferator activator receptor delta	Mus musculus	80-128
21272187-1	2011	AIM: We investigated how GW800644, the first pharmacologically selective murine peroxisome proliferator-activated receptor delta (PPARdelta) agonist, affects energy balance, glucose homeostasis and fuel utilization by muscle in obese mice.	2-(2-methyl-4-((1-(6-(4-(trifluoromethyl)phenyl)-2-pyridinyl)pentyl)oxy)phenoxy)acetic acid	25-33	peroxisome proliferator activator receptor delta	Mus musculus	130-139
21272187-6	2011	RESULTS: GW800644 activated murine PPARdelta (EC(50) 2 nM), but caused little to no activation of PPARalpha or PPARgamma up to 10 microM.	2-(2-methyl-4-((1-(6-(4-(trifluoromethyl)phenyl)-2-pyridinyl)pentyl)oxy)phenoxy)acetic acid	9-17	peroxisome proliferator activator receptor delta	Mus musculus	35-44
21272187-13	2011	CONCLUSIONS: PPARdelta agonism reduced food intake and independently elicited metabolic effects that included increased responsiveness to beta(3)-adrenoceptor stimulation, increased glucose utilization and fat oxidation in soleus muscle of Lep(ob)/Lep(ob) but not lean mice and increased glucose utilization in vivo in Lep(ob)/Lep(ob) mice.	Glucose	182-189	peroxisome proliferator activator receptor delta	Mus musculus	13-22
21272187-13	2011	CONCLUSIONS: PPARdelta agonism reduced food intake and independently elicited metabolic effects that included increased responsiveness to beta(3)-adrenoceptor stimulation, increased glucose utilization and fat oxidation in soleus muscle of Lep(ob)/Lep(ob) but not lean mice and increased glucose utilization in vivo in Lep(ob)/Lep(ob) mice.	Glucose	288-295	peroxisome proliferator activator receptor delta	Mus musculus	13-22
21363937-0	2011	The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation.	GW 501516	29-37	peroxisome proliferator activator receptor delta	Mus musculus	4-12
21363937-0	2011	The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation.	Fatty Acids	186-196	peroxisome proliferator activator receptor delta	Mus musculus	4-12
21458563-0	2011	Peroxisome proliferator-activated receptor delta downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice.	Streptozocin	178-192	peroxisome proliferator activator receptor delta	Mus musculus	0-48
21458563-3	2011	Streptozotocin-induced diabetic mice (STZ mice) were injected with a PPARdelta agonist, L-165041 (5 muM/kg, intraperitoneal) once daily for 10 days and high glucose-treated cultured HEK cells were also used.	Streptozocin	0-14	peroxisome proliferator activator receptor delta	Mus musculus	69-78
21499286-12	2011	CONCLUSION: Bezafibrate stimulates proliferation and differentiation of MC3T3-E1 cells, mainly via a PPARbeta-dependent mechanism.	Bezafibrate	12-23	peroxisome proliferator activator receptor delta	Mus musculus	101-109
21270242-0	2011	Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice.	Streptozocin	72-86	peroxisome proliferator activator receptor delta	Mus musculus	14-62
21270242-3	2011	Here, we report the renoprotective effects of PPARdelta activation in a model of streptozotocin-induced diabetic nephropathy.	Streptozocin	81-95	peroxisome proliferator activator receptor delta	Mus musculus	46-55
21059653-3	2011	We demonstrate here that adenovirus-mediated liver-restricted PPARdelta activation reduces fasting glucose levels in chow- and high fat-fed mice.	Glucose	99-106	peroxisome proliferator activator receptor delta	Mus musculus	62-71
21059653-6	2011	Assessment of the lipid composition reveals that PPARdelta increases the production of monounsaturated fatty acids, which are PPAR activators, and reduces that of saturated FAs.	Fatty Acids, Monounsaturated	87-114	peroxisome proliferator activator receptor delta	Mus musculus	49-58
21059653-6	2011	Assessment of the lipid composition reveals that PPARdelta increases the production of monounsaturated fatty acids, which are PPAR activators, and reduces that of saturated FAs.	Fatty Acids, Monounsaturated	87-114	peroxisome proliferator activator receptor delta	Mus musculus	49-53
21059653-8	2011	The altered substrate utilization by PPARdelta also results in a secondary effect on AMP-activated protein kinase activation, which likely contributes to the glucose-lowering activity.	Glucose	158-165	peroxisome proliferator activator receptor delta	Mus musculus	37-46
21059653-9	2011	Collectively, our data suggest that PPARdelta controls hepatic energy substrate homeostasis by coordinated regulation of glucose and fatty acid metabolism, which provide a molecular basis for developing PPARdelta agonists to manage hyperglycemia and insulin resistance.	Glucose	121-128	peroxisome proliferator activator receptor delta	Mus musculus	36-45
21059653-9	2011	Collectively, our data suggest that PPARdelta controls hepatic energy substrate homeostasis by coordinated regulation of glucose and fatty acid metabolism, which provide a molecular basis for developing PPARdelta agonists to manage hyperglycemia and insulin resistance.	Glucose	121-128	peroxisome proliferator activator receptor delta	Mus musculus	203-212
21059653-9	2011	Collectively, our data suggest that PPARdelta controls hepatic energy substrate homeostasis by coordinated regulation of glucose and fatty acid metabolism, which provide a molecular basis for developing PPARdelta agonists to manage hyperglycemia and insulin resistance.	Fatty Acids	133-143	peroxisome proliferator activator receptor delta	Mus musculus	36-45
21059653-9	2011	Collectively, our data suggest that PPARdelta controls hepatic energy substrate homeostasis by coordinated regulation of glucose and fatty acid metabolism, which provide a molecular basis for developing PPARdelta agonists to manage hyperglycemia and insulin resistance.	Fatty Acids	133-143	peroxisome proliferator activator receptor delta	Mus musculus	203-212
21966476-0	2011	GW501516, a PPARdelta agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFkappaB pathway in mice.	GW 501516	0-8	peroxisome proliferator activator receptor delta	Mus musculus	12-21
21750705-11	2011	Global metabolite profiling identified HL/VLDL released fatty acids including oleic acid and palmitoleic acid that were capable of recapitulating PPARdelta activation and ADRP gene regulation in vitro.	Fatty Acids	56-67	peroxisome proliferator activator receptor delta	Mus musculus	146-155
21750705-11	2011	Global metabolite profiling identified HL/VLDL released fatty acids including oleic acid and palmitoleic acid that were capable of recapitulating PPARdelta activation and ADRP gene regulation in vitro.	Oleic Acid	78-88	peroxisome proliferator activator receptor delta	Mus musculus	146-155
21750705-11	2011	Global metabolite profiling identified HL/VLDL released fatty acids including oleic acid and palmitoleic acid that were capable of recapitulating PPARdelta activation and ADRP gene regulation in vitro.	palmitoleic acid	93-109	peroxisome proliferator activator receptor delta	Mus musculus	146-155
21750705-12	2011	CONCLUSIONS: These data define a novel pathway involving HL hydrolysis of VLDL that activates PPARdelta through generation of specific monounsaturated fatty acids.	Fatty Acids, Monounsaturated	135-162	peroxisome proliferator activator receptor delta	Mus musculus	94-103
21904539-7	2011	The present study demonstrates that cardiomyocyte-restricted deletion of PPARbeta/delta in PPARalpha-null mice causes impaired mitochondrial biogenesis and defense, but no further depression of fatty acid oxidation.	Fatty Acids	194-204	peroxisome proliferator activator receptor delta	Mus musculus	73-81
20693380-9	2010	All the observed beneficial effects of GW0742 were attenuated by the PPAR-beta/delta antagonist GSK0660.	GW0742	39-45	peroxisome proliferator activator receptor delta	Mus musculus	69-78
20693380-9	2010	All the observed beneficial effects of GW0742 were attenuated by the PPAR-beta/delta antagonist GSK0660.	GSK0660	96-103	peroxisome proliferator activator receptor delta	Mus musculus	69-78
21297860-6	2011	The transgenic mammary gland also expressed higher levels of PPARdelta and a gene expression profile resembling wild-type mice maintained on a diet containing the PPARdelta agonist, GW501516.	GW 501516	182-190	peroxisome proliferator activator receptor delta	Mus musculus	163-172
21297860-9	2011	GW501516-treated transgenic mice expressed higher levels of fatty acid and phospholipid metabolites than treated wild-type mice, suggesting the involvement of PDK1 in enhancing PPARdelta-driven energy metabolism.	GW 501516	0-8	peroxisome proliferator activator receptor delta	Mus musculus	177-186
21159610-4	2010	Ligand activation of PPARbeta/delta with GW0742 caused a PPARbeta/delta-dependent delay in the onset of tumor formation.	GW0742	41-47	peroxisome proliferator activator receptor delta	Mus musculus	21-29
21159610-4	2010	Ligand activation of PPARbeta/delta with GW0742 caused a PPARbeta/delta-dependent delay in the onset of tumor formation.	GW0742	41-47	peroxisome proliferator activator receptor delta	Mus musculus	57-65
21159610-6	2010	Combining ligand activation of PPARbeta/delta with dietary nimesulide resulted in a further decrease of tumor multiplicity (58%) in wild-type mice but not in Pparbeta/delta-null mice.	nimesulide	59-69	peroxisome proliferator activator receptor delta	Mus musculus	158-166
21159610-8	2010	Increased levels and activity of PPARbeta/delta by nimesulide were also observed.	nimesulide	51-61	peroxisome proliferator activator receptor delta	Mus musculus	33-41
21966476-3	2011	Thus, we examined the renoprotective effect of GW501516, a PPARdelta agonist, in a protein-overload mouse nephropathy model and identified its molecular mechanism.	GW 501516	47-55	peroxisome proliferator activator receptor delta	Mus musculus	59-68
20516370-0	2010	Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	113-120	peroxisome proliferator activator receptor delta	Mus musculus	48-95
20709805-4	2010	We demonstrated that administration of GW0742, a specific PPARdelta ligand, provided beneficial effects to rats subjected to cecal ligation and puncture, as shown by reduced systemic release of pro-inflammatory cytokines and neutrophil infiltration in lung, liver, and cecum, when compared with vehicle treatment.	GW0742	39-45	peroxisome proliferator activator receptor delta	Mus musculus	58-67
20709805-8	2010	RNA silencing of PPARdelta abrogated the inhibitory effects of GW0742 on TNFalpha production.	GW0742	63-69	peroxisome proliferator activator receptor delta	Mus musculus	17-26
21244753-0	2010	GW0742, a high affinity PPAR-beta/delta agonist reduces lung inflammation induced by bleomycin instillation in mice.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	24-33
21244753-5	2010	Therefore, the aim of this study is to investigate the effects of GW0742, a synthetic high affinity PPAR beta/delta agonist, and its possible role in preventing the advance of inflammatory and apoptotic processes induced by bleomycin, that long-term leads to the appearance of pulmonary fibrosis.	GW0742	66-72	peroxisome proliferator activator receptor delta	Mus musculus	100-109
21244753-5	2010	Therefore, the aim of this study is to investigate the effects of GW0742, a synthetic high affinity PPAR beta/delta agonist, and its possible role in preventing the advance of inflammatory and apoptotic processes induced by bleomycin, that long-term leads to the appearance of pulmonary fibrosis.	Bleomycin	224-233	peroxisome proliferator activator receptor delta	Mus musculus	100-109
20516370-2	2010	In this study, a new PPARbeta/delta antagonist, 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), was characterized using in vivo and in vitro models.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	48-117	peroxisome proliferator activator receptor delta	Mus musculus	21-29
20516370-2	2010	In this study, a new PPARbeta/delta antagonist, 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), was characterized using in vivo and in vitro models.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	119-126	peroxisome proliferator activator receptor delta	Mus musculus	21-29
20516370-3	2010	Orally administered GSK3787 caused antagonism of 4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethylsulfanyl]-2-methyl-phenoxy}-acetic acid (GW0742)-induced up-regulation of Angptl4 and Adrp mRNA expression in wild-type mouse colon but not in Pparbeta/delta-null mouse colon.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	20-27	peroxisome proliferator activator receptor delta	Mus musculus	260-268
20516370-6	2010	Time-resolved fluorescence resonance energy transfer assays confirmed the ability of GSK3787 to modulate the association of both PPARbeta/delta and PPARgamma coregulator peptides in response to ligand activation, consistent with reporter assays.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	85-92	peroxisome proliferator activator receptor delta	Mus musculus	129-137
20624891-1	2010	Peroxisome proliferator-activated receptors (PPARs; PPAR-alpha, PPAR-delta, and PPAR-gamma) comprise a family of nuclear receptors that sense fatty acid levels and translate this information into altered gene transcription.	Fatty Acids	142-152	peroxisome proliferator activator receptor delta	Mus musculus	64-74
20378851-0	2010	Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress.	Fatty Acids	40-51	peroxisome proliferator activator receptor delta	Mus musculus	67-114
20516370-7	2010	In vivo and in vitro analysis indicates that the efficacy of GSK3787 to modulate PPARgamma activity is markedly lower than the efficacy of GSK3787 to act as a PPARbeta/delta antagonist.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	139-146	peroxisome proliferator activator receptor delta	Mus musculus	159-167
20516370-10	2010	Results from these studies demonstrate that GSK3787 can antagonize PPARbeta/delta in vivo, thus providing a new strategy to delineate the functional role of a receptor with great potential as a therapeutic target for the treatment and prevention of disease.	4-chloro-N-(2-((5-trifluoromethyl-2-pyridyl)sulfonyl)ethyl)benzamide	44-51	peroxisome proliferator activator receptor delta	Mus musculus	67-75
20406305-8	2010	In this study we show that the PPARdelta agonists GW501516 and L165041 ameliorate MOGp35-55-induced EAE in C57BL/6 mice by blocking interferon (IFN)-gamma and interleukin (IL)-17 production by T helper type 1 (Th1) and Th17 cells.	GW 501516	50-58	peroxisome proliferator activator receptor delta	Mus musculus	31-40
20406305-8	2010	In this study we show that the PPARdelta agonists GW501516 and L165041 ameliorate MOGp35-55-induced EAE in C57BL/6 mice by blocking interferon (IFN)-gamma and interleukin (IL)-17 production by T helper type 1 (Th1) and Th17 cells.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	63-70	peroxisome proliferator activator receptor delta	Mus musculus	31-40
20430778-0	2010	GW0742, a selective PPAR-beta/delta agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	20-29
20430778-6	2010	This study investigated the effects of GW0742, a potent and selective PPAR-beta/delta agonist, on tissue injury, caused in a mouse model of SAO shock.	GW0742	39-45	peroxisome proliferator activator receptor delta	Mus musculus	70-79
20378851-0	2010	Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress.	Fatty Acids	40-50	peroxisome proliferator activator receptor delta	Mus musculus	67-114
20378851-6	2010	Consistent with these data, linolenic acid stimulated binding of PPARbeta/delta but not PPARalpha to the Angptl4 gene.	alpha-Linolenic Acid	28-42	peroxisome proliferator activator receptor delta	Mus musculus	65-73
20190170-1	2010	Peroxisome proliferator-activated receptor delta promotes fatty acid catabolism and energy expenditure in skeletal muscle and adipose tissues.	Fatty Acids	58-68	peroxisome proliferator activator receptor delta	Mus musculus	0-48
20190170-3	2010	Polyunsaturated fatty acids are potential ligands for PPARdelta activation.	Fatty Acids, Unsaturated	0-27	peroxisome proliferator activator receptor delta	Mus musculus	54-63
20190170-8	2010	Adipose tissue expression of genes involved in adipogenesis (i.e., lipoprotein lipase and adipocyte fatty acid-binding protein) was decreased in transgenic mice fed fish oil or the PPARdelta ligand.	Fatty Acids	100-110	peroxisome proliferator activator receptor delta	Mus musculus	181-190
19538467-3	2010	Here, we demonstrate that administration of GW501516, a specific PPARdelta ligand, significantly promoted wound closure in the experimental mouse and had a profound effect on the expression of collagen types I and III, alpha-smooth muscle actin, pSmad3 and TGF-beta1, which play a pivotal role in wound healing processes.	GW 501516	44-52	peroxisome proliferator activator receptor delta	Mus musculus	65-74
20504373-0	2010	Vaticanol C, a resveratrol tetramer, activates PPARalpha and PPARbeta/delta in vitro and in vivo.	vaticanol C	0-11	peroxisome proliferator activator receptor delta	Mus musculus	61-69
20504373-0	2010	Vaticanol C, a resveratrol tetramer, activates PPARalpha and PPARbeta/delta in vitro and in vivo.	Resveratrol	15-26	peroxisome proliferator activator receptor delta	Mus musculus	61-69
20504373-7	2010	RESULTS: We show that vaticanol C activates PPARalpha and PPARbeta/delta in cell-based reporter assays, but does not activate SIRT1.	vaticanol C	22-33	peroxisome proliferator activator receptor delta	Mus musculus	58-66
20504373-9	2010	Eight-week intake of vaticanol C with a high fat diet upregulates hepatic expression of PPARalpha-responsive genes such as cyp4a10, cyp4a14 and FABP1, and skeletal muscle expression of PPARbeta/delta-responsive genes, such as UCP3 and PDK4 (pyruvate dehydrogenase kinase, isoform 4), in wild-type, but not PPARalpha-knockout mice.	vaticanol C	21-32	peroxisome proliferator activator receptor delta	Mus musculus	185-193
20504373-10	2010	CONCLUSION: Vaticanol C, a resveratrol tetramer, activated PPARalpha and PPARbeta/delta in vitro and in vivo.	vaticanol C	12-23	peroxisome proliferator activator receptor delta	Mus musculus	73-81
20504373-11	2010	These findings indicate that activation of PPARalpha and PPARbeta/delta by vaticanol C may be a novel mechanism, affording beneficial effects against lifestyle-related diseases.	vaticanol C	75-86	peroxisome proliferator activator receptor delta	Mus musculus	57-65
20445066-3	2010	Here we report for the first time that PPARdelta is significantly reduced in oxygen-glucose deprivation (OGD)-induced mouse CEC death.	oxygen-glucose	77-91	peroxisome proliferator activator receptor delta	Mus musculus	39-48
20445066-5	2010	To explore the molecular mechanisms, we have identified that upregulation of PPARdelta can alleviate ODG-activated microRNA-15a (miR-15a) expression in CECs.	BMP15 protein, human	101-104	peroxisome proliferator activator receptor delta	Mus musculus	77-86
20185762-4	2010	In C2C12 skeletal muscle cells, the PPARdelta agonist GW501516 prevented phosphorylation of insulin receptor substrate-1 at Ser(307) and the inhibition of insulin-stimulated Akt phosphorylation caused by exposure to the saturated fatty acid palmitate.	saturated fatty acid palmitate	220-250	peroxisome proliferator activator receptor delta	Mus musculus	36-45
20176685-11	2010	30 min before treatment with GW0742) significantly blocked the effect of the PPAR-beta/delta agonist and thus abolished the protective effect.	GW0742	29-35	peroxisome proliferator activator receptor delta	Mus musculus	77-86
20185762-5	2010	This latter effect was reversed by the PPARdelta antagonist GSK0660.	GSK0660	60-67	peroxisome proliferator activator receptor delta	Mus musculus	39-48
20185762-6	2010	Treatment with the PPARdelta agonist enhanced the expression of two well known PPARdelta target genes involved in fatty acid oxidation, carnitine palmitoyltransferase-1 and pyruvate dehydrogenase kinase 4 and increased the phosphorylation of AMP-activated protein kinase, preventing the reduction in fatty acid oxidation caused by palmitate exposure.	Fatty Acids	114-124	peroxisome proliferator activator receptor delta	Mus musculus	19-28
20185762-6	2010	Treatment with the PPARdelta agonist enhanced the expression of two well known PPARdelta target genes involved in fatty acid oxidation, carnitine palmitoyltransferase-1 and pyruvate dehydrogenase kinase 4 and increased the phosphorylation of AMP-activated protein kinase, preventing the reduction in fatty acid oxidation caused by palmitate exposure.	Fatty Acids	114-124	peroxisome proliferator activator receptor delta	Mus musculus	79-88
20185762-6	2010	Treatment with the PPARdelta agonist enhanced the expression of two well known PPARdelta target genes involved in fatty acid oxidation, carnitine palmitoyltransferase-1 and pyruvate dehydrogenase kinase 4 and increased the phosphorylation of AMP-activated protein kinase, preventing the reduction in fatty acid oxidation caused by palmitate exposure.	Fatty Acids	300-310	peroxisome proliferator activator receptor delta	Mus musculus	19-28
20185762-6	2010	Treatment with the PPARdelta agonist enhanced the expression of two well known PPARdelta target genes involved in fatty acid oxidation, carnitine palmitoyltransferase-1 and pyruvate dehydrogenase kinase 4 and increased the phosphorylation of AMP-activated protein kinase, preventing the reduction in fatty acid oxidation caused by palmitate exposure.	Fatty Acids	300-310	peroxisome proliferator activator receptor delta	Mus musculus	79-88
20185762-9	2010	Consistent with these findings, PPARdelta activation by GW501516 blocked palmitate-induced NF-kappaB DNA-binding activity.	GW 501516	56-64	peroxisome proliferator activator receptor delta	Mus musculus	32-41
20185762-9	2010	Consistent with these findings, PPARdelta activation by GW501516 blocked palmitate-induced NF-kappaB DNA-binding activity.	Palmitates	73-82	peroxisome proliferator activator receptor delta	Mus musculus	32-41
20185762-11	2010	These findings indicate that PPARdelta attenuates fatty acid-induced NF-kappaB activation and the subsequent development of insulin resistance in skeletal muscle cells by reducing DAG accumulation.	Fatty Acids	50-60	peroxisome proliferator activator receptor delta	Mus musculus	29-38
20185762-11	2010	These findings indicate that PPARdelta attenuates fatty acid-induced NF-kappaB activation and the subsequent development of insulin resistance in skeletal muscle cells by reducing DAG accumulation.	Diglycerides	180-183	peroxisome proliferator activator receptor delta	Mus musculus	29-38
20176998-0	2010	Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways.	Telmisartan	0-11	peroxisome proliferator activator receptor delta	Mus musculus	67-115
20176998-2	2010	In the present study we tested the hypothesis that telmisartan prevents adipogenesis in vitro and weight gain in vivo through activation of peroxisome proliferator-activated receptor (PPAR)-delta-dependent pathways in several tissues.	Telmisartan	51-62	peroxisome proliferator activator receptor delta	Mus musculus	140-195
20176998-8	2010	Telmisartan-associated reduction of adipogenesis in preadipocytes was significantly blocked after PPAR-delta gene knockout.	Telmisartan	0-11	peroxisome proliferator activator receptor delta	Mus musculus	98-108
20176998-10	2010	We conclude that telmisartan prevents adipogenesis and weight gain through activation of PPAR-delta-dependent lipolytic pathways and energy uncoupling in several tissues.	Telmisartan	17-28	peroxisome proliferator activator receptor delta	Mus musculus	89-99
20300524-11	2010	Key transcriptional programs activated in psoriasis, including IL1-related signalling and cholesterol biosynthesis, are replicated in the mouse model, suggesting that PPARbeta/delta regulates these transcriptional changes in psoriasis.	Cholesterol	90-101	peroxisome proliferator activator receptor delta	Mus musculus	167-175
20407409-0	2010	GW0742, a high-affinity PPAR -beta/delta agonist, inhibits acute lung injury in mice.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	24-34
20407409-2	2010	The aim of this study was to investigate the effects of a high-affinity PPAR-beta/delta agonist, GW0742, in a mouse model of carrageenan (CAR)-induced pleurisy.	GW0742	97-103	peroxisome proliferator activator receptor delta	Mus musculus	72-81
20407409-7	2010	Thus, based on these findings, we propose that a PPAR-beta/delta agonist such as GW0742 may be useful in the treatment of various inflammatory diseases.	GW0742	81-87	peroxisome proliferator activator receptor delta	Mus musculus	49-58
20009009-6	2010	Pathways downregulated by PPARbeta/delta deletion included lipoprotein metabolism and various pathways related to glucose utilization, which correlated with elevated plasma glucose and triglycerides and reduced plasma cholesterol in PPARbeta/delta-/- mice.	Glucose	114-121	peroxisome proliferator activator receptor delta	Mus musculus	26-34
20009009-6	2010	Pathways downregulated by PPARbeta/delta deletion included lipoprotein metabolism and various pathways related to glucose utilization, which correlated with elevated plasma glucose and triglycerides and reduced plasma cholesterol in PPARbeta/delta-/- mice.	Glucose	114-121	peroxisome proliferator activator receptor delta	Mus musculus	233-241
20009009-6	2010	Pathways downregulated by PPARbeta/delta deletion included lipoprotein metabolism and various pathways related to glucose utilization, which correlated with elevated plasma glucose and triglycerides and reduced plasma cholesterol in PPARbeta/delta-/- mice.	Glucose	173-180	peroxisome proliferator activator receptor delta	Mus musculus	26-34
20009009-6	2010	Pathways downregulated by PPARbeta/delta deletion included lipoprotein metabolism and various pathways related to glucose utilization, which correlated with elevated plasma glucose and triglycerides and reduced plasma cholesterol in PPARbeta/delta-/- mice.	Triglycerides	185-198	peroxisome proliferator activator receptor delta	Mus musculus	26-34
20009009-6	2010	Pathways downregulated by PPARbeta/delta deletion included lipoprotein metabolism and various pathways related to glucose utilization, which correlated with elevated plasma glucose and triglycerides and reduced plasma cholesterol in PPARbeta/delta-/- mice.	Triglycerides	185-198	peroxisome proliferator activator receptor delta	Mus musculus	233-241
20009009-6	2010	Pathways downregulated by PPARbeta/delta deletion included lipoprotein metabolism and various pathways related to glucose utilization, which correlated with elevated plasma glucose and triglycerides and reduced plasma cholesterol in PPARbeta/delta-/- mice.	Cholesterol	218-229	peroxisome proliferator activator receptor delta	Mus musculus	26-34
20009009-6	2010	Pathways downregulated by PPARbeta/delta deletion included lipoprotein metabolism and various pathways related to glucose utilization, which correlated with elevated plasma glucose and triglycerides and reduced plasma cholesterol in PPARbeta/delta-/- mice.	Cholesterol	218-229	peroxisome proliferator activator receptor delta	Mus musculus	233-241
20009009-9	2010	Our data indicate that PPARbeta/delta governs glucose utilization and lipoprotein metabolism and has an important anti-inflammatory role in liver.	Glucose	46-53	peroxisome proliferator activator receptor delta	Mus musculus	23-31
19903700-5	2010	METHODS AND RESULTS: En face confocal microscopy of murine aortas demonstrated that the PPARdelta-selective ligand GW501516 induced endothelial haem oxygenase-1 expression.	GW 501516	115-123	peroxisome proliferator activator receptor delta	Mus musculus	88-97
20042001-0	2010	Retinoic acid activation of peroxisome proliferation-activated receptor delta represses obesity and insulin resistance.	Tretinoin	0-13	peroxisome proliferator activator receptor delta	Mus musculus	28-77
20075336-2	2010	Long-term cardiomyocyte-restricted PPARdelta deficiency in mice leads to depressed myocardial fatty acid oxidation, bioenergetics, and premature death with lipotoxic cardiomyopathy.	Fatty Acids	94-104	peroxisome proliferator activator receptor delta	Mus musculus	35-44
20075336-7	2010	Rates of palmitate and glucose oxidation were markedly depressed in cardiomyocytes of PPARdelta knockout hearts.	Palmitates	9-18	peroxisome proliferator activator receptor delta	Mus musculus	86-95
19998413-11	2010	Furthermore, maturation of hepatic-like tissue and mitochondriogenesis in hepatocyte could be efficiently stimulated by PPAR-beta specific agonist L165041 and abolished by PPAR-beta specific antagonist GSK0660, but not affected by PPAR-gamma specific agonist GW1929.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	147-154	peroxisome proliferator activator receptor delta	Mus musculus	120-129
19998413-11	2010	Furthermore, maturation of hepatic-like tissue and mitochondriogenesis in hepatocyte could be efficiently stimulated by PPAR-beta specific agonist L165041 and abolished by PPAR-beta specific antagonist GSK0660, but not affected by PPAR-gamma specific agonist GW1929.	GSK0660	202-209	peroxisome proliferator activator receptor delta	Mus musculus	172-181
19998413-11	2010	Furthermore, maturation of hepatic-like tissue and mitochondriogenesis in hepatocyte could be efficiently stimulated by PPAR-beta specific agonist L165041 and abolished by PPAR-beta specific antagonist GSK0660, but not affected by PPAR-gamma specific agonist GW1929.	GW 1929	259-265	peroxisome proliferator activator receptor delta	Mus musculus	120-129
19998413-11	2010	Furthermore, maturation of hepatic-like tissue and mitochondriogenesis in hepatocyte could be efficiently stimulated by PPAR-beta specific agonist L165041 and abolished by PPAR-beta specific antagonist GSK0660, but not affected by PPAR-gamma specific agonist GW1929.	GW 1929	259-265	peroxisome proliferator activator receptor delta	Mus musculus	172-181
19675577-4	2010	Treatment of fetal rat explants with the PPARdelta ligand, GW 610742X, accelerates permeability barrier development, evidenced by a decrease in transepidermal water loss and an enhanced outside-in barrier function, attributable to the presence of more mature lamellar membranes in the SC and enhanced expression of loricrin and involucrin.	glycyltryptophan	59-61	peroxisome proliferator activator receptor delta	Mus musculus	41-50
20185762-0	2010	Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.	GW 501516	68-76	peroxisome proliferator activator receptor delta	Mus musculus	14-63
20185762-0	2010	Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.	Fatty Acids	86-96	peroxisome proliferator activator receptor delta	Mus musculus	14-63
20185762-4	2010	In C2C12 skeletal muscle cells, the PPARdelta agonist GW501516 prevented phosphorylation of insulin receptor substrate-1 at Ser(307) and the inhibition of insulin-stimulated Akt phosphorylation caused by exposure to the saturated fatty acid palmitate.	GW 501516	54-62	peroxisome proliferator activator receptor delta	Mus musculus	36-45
20185762-4	2010	In C2C12 skeletal muscle cells, the PPARdelta agonist GW501516 prevented phosphorylation of insulin receptor substrate-1 at Ser(307) and the inhibition of insulin-stimulated Akt phosphorylation caused by exposure to the saturated fatty acid palmitate.	Serine	124-127	peroxisome proliferator activator receptor delta	Mus musculus	36-45
20167109-0	2010	Role of PPAR-delta in the development of zymosan-induced multiple organ failure: an experiment mice study.	Zymosan	41-48	peroxisome proliferator activator receptor delta	Mus musculus	8-18
20167109-3	2010	Saturated and polyunsaturated fatty acids activate PPAR-beta/delta, but physiological ligands have not yet been identified.	saturated and polyunsaturated fatty acids	0-41	peroxisome proliferator activator receptor delta	Mus musculus	51-60
20167109-11	2010	The PPAR-beta/delta agonist, GW0742, at the dose of 0,3 mg/kg in 10% DMSO, also attenuated the multiple organ dysfunction syndrome caused by zymosan.	GW0742	29-35	peroxisome proliferator activator receptor delta	Mus musculus	4-13
20167109-11	2010	The PPAR-beta/delta agonist, GW0742, at the dose of 0,3 mg/kg in 10% DMSO, also attenuated the multiple organ dysfunction syndrome caused by zymosan.	Dimethyl Sulfoxide	69-73	peroxisome proliferator activator receptor delta	Mus musculus	4-13
20167109-11	2010	The PPAR-beta/delta agonist, GW0742, at the dose of 0,3 mg/kg in 10% DMSO, also attenuated the multiple organ dysfunction syndrome caused by zymosan.	Zymosan	141-148	peroxisome proliferator activator receptor delta	Mus musculus	4-13
20001953-4	2010	We show that effects of GW0742 are mediated through PPARdelta since no amelioration of EAE clinical scores was observed in PPARdelta-null mice.	GW0742	24-30	peroxisome proliferator activator receptor delta	Mus musculus	52-61
19928766-0	2010	Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.	bisaryl substituted thiazoles	6-35	peroxisome proliferator activator receptor delta	Mus musculus	80-128
19928766-0	2010	Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.	Oxazoles	40-48	peroxisome proliferator activator receptor delta	Mus musculus	80-128
19928766-4	2010	A (2-methylphenoxy)acetic acid headgroup, a flexible linker, and a five-membered heteroaromatic center ring with two hydrophobic aryl substituents were required for efficient and selective PPARdelta activation.	(2-methylphenoxy)acetic acid	2-30	peroxisome proliferator activator receptor delta	Mus musculus	189-198
20042001-1	2010	Retinoic acid (RA) was found to be a ligand for peroxisome proliferation-activated receptor delta (PPARdelta) as well as the classical RA receptor (RAR).	Tretinoin	0-13	peroxisome proliferator activator receptor delta	Mus musculus	48-97
20042001-1	2010	Retinoic acid (RA) was found to be a ligand for peroxisome proliferation-activated receptor delta (PPARdelta) as well as the classical RA receptor (RAR).	Tretinoin	0-13	peroxisome proliferator activator receptor delta	Mus musculus	99-108
20042001-1	2010	Retinoic acid (RA) was found to be a ligand for peroxisome proliferation-activated receptor delta (PPARdelta) as well as the classical RA receptor (RAR).	Tretinoin	15-17	peroxisome proliferator activator receptor delta	Mus musculus	48-97
20042001-1	2010	Retinoic acid (RA) was found to be a ligand for peroxisome proliferation-activated receptor delta (PPARdelta) as well as the classical RA receptor (RAR).	Tretinoin	15-17	peroxisome proliferator activator receptor delta	Mus musculus	99-108
20042001-2	2010	Carrier proteins that move the RA from the cytosol into the nucleus are the fatty acid-binding protein 5 (FABP5), activating PPARdelta, and the cellular retinoic acid-binding protein II (CRABPII), activating RAR.	Tretinoin	31-33	peroxisome proliferator activator receptor delta	Mus musculus	125-134
20042001-4	2010	By activating PPARdelta, RA was found to induce expression of genes affecting lipid and glucose homeostasis, in particular, leading to expression of the insulin-signaling gene PDK1 and improvement of insulin action.	Tretinoin	25-27	peroxisome proliferator activator receptor delta	Mus musculus	14-23
20042001-7	2010	RA implantation into obese mice has caused upregulation of levels of PPARdelta and consequent weight loss as well as increased expression of PPARdelta target genes, including the insulin-signaling gene PDK1.	Tretinoin	0-2	peroxisome proliferator activator receptor delta	Mus musculus	69-78
20042001-7	2010	RA implantation into obese mice has caused upregulation of levels of PPARdelta and consequent weight loss as well as increased expression of PPARdelta target genes, including the insulin-signaling gene PDK1.	Tretinoin	0-2	peroxisome proliferator activator receptor delta	Mus musculus	141-150
19818749-3	2010	Whether PPARdelta is involved in the regulation of glucose metabolism is not completely understood.	Glucose	51-58	peroxisome proliferator activator receptor delta	Mus musculus	8-17
19748995-7	2010	Interestingly, the combined treatment of GW0742 and nimesulide increased the efficacy of the decrease in papilloma multiplicity for 6 weeks in wild-type mice, but this effect was not found at later time points and was not found in similarly treated Pparbeta/delta-null mice.	GW0742	41-47	peroxisome proliferator activator receptor delta	Mus musculus	249-257
19818749-7	2010	Following intravenous glucose (1g/kg), glucose tolerance was improved after PPARdelta activation (K(G) 1.3+/-0.6 vs. -0.05+/-0.7 %/min, P=0.048).	Glucose	22-29	peroxisome proliferator activator receptor delta	Mus musculus	76-85
19818749-11	2010	This suggests that activation of PPARdelta improves glucose metabolism and may therefore potentially be target for treatment of type 2 diabetes.	Glucose	52-59	peroxisome proliferator activator receptor delta	Mus musculus	33-42
21318167-1	2010	Peroxisome proliferator-activated receptordelta (PPARdelta) regulates a multiplicity of physiological processes associated with glucose and lipid metabolism, inflammation, and proliferation.	Glucose	128-135	peroxisome proliferator activator receptor delta	Mus musculus	0-47
21318167-1	2010	Peroxisome proliferator-activated receptordelta (PPARdelta) regulates a multiplicity of physiological processes associated with glucose and lipid metabolism, inflammation, and proliferation.	Glucose	128-135	peroxisome proliferator activator receptor delta	Mus musculus	49-58
21318167-3	2010	In the present study, we describe a new gastric tumor mouse model that is dependent on the potent and highly selective PPARdelta agonist GW501516 following carcinogen administration.	GW 501516	137-145	peroxisome proliferator activator receptor delta	Mus musculus	119-128
19748995-7	2010	Interestingly, the combined treatment of GW0742 and nimesulide increased the efficacy of the decrease in papilloma multiplicity for 6 weeks in wild-type mice, but this effect was not found at later time points and was not found in similarly treated Pparbeta/delta-null mice.	nimesulide	52-62	peroxisome proliferator activator receptor delta	Mus musculus	249-257
19968882-8	2009	RESULTS: Analysis by multivariate statistics demonstrated that PPARdelta activation profoundly affected glycolysis, gluconeogenesis, the TCA cycle and linoleic acid and alpha-linolenic acid essential fatty acid pathways.	Trichloroacetic Acid	137-140	peroxisome proliferator activator receptor delta	Mus musculus	63-72
19968882-8	2009	RESULTS: Analysis by multivariate statistics demonstrated that PPARdelta activation profoundly affected glycolysis, gluconeogenesis, the TCA cycle and linoleic acid and alpha-linolenic acid essential fatty acid pathways.	Linoleic Acid	151-164	peroxisome proliferator activator receptor delta	Mus musculus	63-72
19968882-8	2009	RESULTS: Analysis by multivariate statistics demonstrated that PPARdelta activation profoundly affected glycolysis, gluconeogenesis, the TCA cycle and linoleic acid and alpha-linolenic acid essential fatty acid pathways.	alpha-linolenic acid essential fatty acid	169-210	peroxisome proliferator activator receptor delta	Mus musculus	63-72
19968882-9	2009	CONCLUSIONS: Although activation of both PPARdelta and PPARgamma lead to increased insulin sensitivity and glucose tolerance, PPARdelta activation was functionally distinct from PPARgamma activation, and was characterized by increased hepatic and peripheral fatty acid oxidative metabolism, demonstrating the distinctive catabolic role of this receptor compared with PPARgamma.	Glucose	107-114	peroxisome proliferator activator receptor delta	Mus musculus	41-50
19968882-9	2009	CONCLUSIONS: Although activation of both PPARdelta and PPARgamma lead to increased insulin sensitivity and glucose tolerance, PPARdelta activation was functionally distinct from PPARgamma activation, and was characterized by increased hepatic and peripheral fatty acid oxidative metabolism, demonstrating the distinctive catabolic role of this receptor compared with PPARgamma.	Fatty Acids	258-268	peroxisome proliferator activator receptor delta	Mus musculus	126-135
19744959-5	2009	GW501516, a PPARbeta/delta agonist, was found to stimulate utrophin A mRNA levels in C2C12 muscle cells through an element in the utrophin A promoter.	GW 501516	0-8	peroxisome proliferator activator receptor delta	Mus musculus	12-20
19805517-0	2009	Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver.	Fatty Acids, Nonesterified	108-123	peroxisome proliferator activator receptor delta	Mus musculus	0-53
19805517-0	2009	Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver.	Fatty Acids, Nonesterified	108-123	peroxisome proliferator activator receptor delta	Mus musculus	55-63
19805517-6	2009	Binding of PPARbeta/delta to the Lpin2 and St3gal5 genes followed the plasma free fatty acid (FFA) concentration, consistent with activation of PPARbeta/delta by plasma FFAs.	Fatty Acids, Nonesterified	77-92	peroxisome proliferator activator receptor delta	Mus musculus	11-19
19805517-6	2009	Binding of PPARbeta/delta to the Lpin2 and St3gal5 genes followed the plasma free fatty acid (FFA) concentration, consistent with activation of PPARbeta/delta by plasma FFAs.	Fatty Acids, Nonesterified	94-97	peroxisome proliferator activator receptor delta	Mus musculus	11-19
19577662-0	2009	A pan-PPAR ligand induces hepatic fatty acid oxidation in PPARalpha-/- mice possibly through PGC-1 mediated PPARdelta coactivation.	Fatty Acids	34-44	peroxisome proliferator activator receptor delta	Mus musculus	108-117
19766624-0	2009	PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	17-25	peroxisome proliferator activator receptor delta	Mus musculus	0-9
19587222-3	2009	BPS concentration dependently induced the p21/p27 promoter- and consensus cAMP-responsive element (CRE)-driven luciferase activities, which were significantly suppressed by blocking PPARdelta activation.	Cyclic AMP	74-78	peroxisome proliferator activator receptor delta	Mus musculus	182-191
19577614-4	2009	Cell culture experiments revealed that CACT mRNA abundance was higher in liver cells treated with either WY-14,643 or PPARdelta agonist GW0742, but not with PPARgamma agonist troglitazone (TGZ) than in control cells (P&lt;0.05).	GW0742	136-142	peroxisome proliferator activator receptor delta	Mus musculus	118-127
19577614-8	2009	The upregulation of CACT by PPARalpha and PPARdelta, which are both important for the regulation of fatty acid oxidation in tissues during fasting, may increase the import of acylcarnitine into the mitochondrial matrix during fasting.	Fatty Acids	100-110	peroxisome proliferator activator receptor delta	Mus musculus	42-51
19577614-8	2009	The upregulation of CACT by PPARalpha and PPARdelta, which are both important for the regulation of fatty acid oxidation in tissues during fasting, may increase the import of acylcarnitine into the mitochondrial matrix during fasting.	acylcarnitine	175-188	peroxisome proliferator activator receptor delta	Mus musculus	42-51
19439761-0	2009	Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux.	Cholesterol	95-106	peroxisome proliferator activator receptor delta	Mus musculus	0-48
19439761-2	2009	Activation of PPARdelta markedly increases fecal neutral sterol secretion, the last step in reverse cholesterol transport.	Cholesterol	100-111	peroxisome proliferator activator receptor delta	Mus musculus	14-23
19439761-4	2009	To test the hypothesis that PPARdelta activation leads to stimulation of transintestinal cholesterol efflux (TICE), we quantified it by intestine perfusions in FVB mice treated with PPARdelta agonist GW610742.	Cholesterol	89-100	peroxisome proliferator activator receptor delta	Mus musculus	28-37
19439761-4	2009	To test the hypothesis that PPARdelta activation leads to stimulation of transintestinal cholesterol efflux (TICE), we quantified it by intestine perfusions in FVB mice treated with PPARdelta agonist GW610742.	GW 610742	200-208	peroxisome proliferator activator receptor delta	Mus musculus	28-37
19439761-4	2009	To test the hypothesis that PPARdelta activation leads to stimulation of transintestinal cholesterol efflux (TICE), we quantified it by intestine perfusions in FVB mice treated with PPARdelta agonist GW610742.	GW 610742	200-208	peroxisome proliferator activator receptor delta	Mus musculus	182-191
19439761-8	2009	Interestingly, expression of Rab9 and LIMPII, encoding proteins involved in intracellular cholesterol trafficking, was increased upon PPARdelta activation.	Cholesterol	90-101	peroxisome proliferator activator receptor delta	Mus musculus	134-143
19439761-10	2009	These data show that activation of PPARdelta stimulates fecal cholesterol excretion in mice, primarily by the two-fold increase in TICE, indicating that this pathway provides an interesting target for the development of drugs aiming at the prevention of atherosclerosis.	Cholesterol	62-73	peroxisome proliferator activator receptor delta	Mus musculus	35-44
19595695-1	2009	Peroxisome proliferator-activated receptor delta (PPARdelta) is an essential determinant of basal myocardial fatty acid oxidation (FAO) and bioenergetics.	Fatty Acids	109-119	peroxisome proliferator activator receptor delta	Mus musculus	0-48
19595695-1	2009	Peroxisome proliferator-activated receptor delta (PPARdelta) is an essential determinant of basal myocardial fatty acid oxidation (FAO) and bioenergetics.	Fatty Acids	109-119	peroxisome proliferator activator receptor delta	Mus musculus	50-59
19461048-6	2009	Administration of a PPARdelta ligand GW501516 to mice also suppressed elastase-induced cell death of aortic VSMCs.	GW 501516	37-45	peroxisome proliferator activator receptor delta	Mus musculus	20-29
19435887-0	2009	PPAR{delta} agonism activates fatty acid oxidation via PGC-1{alpha} but does not increase mitochondrial gene expression and function.	Fatty Acids	30-40	peroxisome proliferator activator receptor delta	Mus musculus	0-10
19435887-1	2009	PPARdelta (peroxisome proliferator-activated receptor delta) is a regulator of lipid metabolism and has been shown to induce fatty acid oxidation (FAO).	Fatty Acids	125-135	peroxisome proliferator activator receptor delta	Mus musculus	0-9
19435887-1	2009	PPARdelta (peroxisome proliferator-activated receptor delta) is a regulator of lipid metabolism and has been shown to induce fatty acid oxidation (FAO).	Fatty Acids	125-135	peroxisome proliferator activator receptor delta	Mus musculus	11-59
19435887-3	2009	In this study, we determined the effect of selective PPARdelta agonism with the synthetic ligand, GW501516, on FAO and mitochondrial gene expression in vitro and in vivo.	GW 501516	98-106	peroxisome proliferator activator receptor delta	Mus musculus	53-62
19435887-4	2009	Our results show that activation of PPARdelta by GW501516 led to a robust increase in mRNA levels of key lipid metabolism genes.	GW 501516	49-57	peroxisome proliferator activator receptor delta	Mus musculus	36-45
19236478-6	2009	By contrast, a PPARbeta/delta activator (GW501516) normalized only the expression of involucrin and filaggrin but not loricrin.	GW 501516	41-49	peroxisome proliferator activator receptor delta	Mus musculus	15-23
19389799-4	2009	Using intravital microscopy in the mouse cremasteric microcirculation, we have shown that activation of PPARbeta/delta by its selective ligand GW501516 inhibits TNF-alpha-induced leukocyte rolling flux, adhesion, and emigration in a dose-dependant manner.	GW 501516	143-151	peroxisome proliferator activator receptor delta	Mus musculus	104-112
19513536-3	2009	The PPARdelta agonist GW501516 exerted similar effects on protein synthesis to IL15.	GW 501516	22-30	peroxisome proliferator activator receptor delta	Mus musculus	4-13
18593727-0	2008	PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742.	GW0742	115-121	peroxisome proliferator activator receptor delta	Mus musculus	22-32
19364826-1	2009	Many biological activities of all-trans-retinoic acid (RA) are mediated by the ligand-activated transcription factors termed retinoic acid receptors (RARs), but this hormone can also activate the nuclear receptor peroxisome proliferation-activated receptor beta/delta (PPARbeta/delta).	2-octenal	34-40	peroxisome proliferator activator receptor delta	Mus musculus	269-277
19364826-1	2009	Many biological activities of all-trans-retinoic acid (RA) are mediated by the ligand-activated transcription factors termed retinoic acid receptors (RARs), but this hormone can also activate the nuclear receptor peroxisome proliferation-activated receptor beta/delta (PPARbeta/delta).	Tretinoin	40-53	peroxisome proliferator activator receptor delta	Mus musculus	269-277
19364826-1	2009	Many biological activities of all-trans-retinoic acid (RA) are mediated by the ligand-activated transcription factors termed retinoic acid receptors (RARs), but this hormone can also activate the nuclear receptor peroxisome proliferation-activated receptor beta/delta (PPARbeta/delta).	Tretinoin	55-57	peroxisome proliferator activator receptor delta	Mus musculus	269-277
19364826-2	2009	We show here that adipocyte differentiation is accompanied by a shift in RA signaling which, in mature adipocytes, allows RA to activate both RARs and PPARbeta/delta, thereby enhancing lipolysis and depleting lipid stores.	Tretinoin	73-75	peroxisome proliferator activator receptor delta	Mus musculus	151-165
19364826-4	2009	RA treatment of obese mice induced expression of PPARbeta/delta and RAR target genes involved in regulation of lipid homeostasis, leading to weight loss and improved insulin responsiveness.	Tretinoin	0-2	peroxisome proliferator activator receptor delta	Mus musculus	49-57
19364826-5	2009	RA treatment also restored adipose PPARbeta/delta expression.	Tretinoin	0-2	peroxisome proliferator activator receptor delta	Mus musculus	35-43
19364826-6	2009	The data indicate that suppression of obesity and insulin resistance by RA is largely mediated by PPARbeta/delta and is further enhanced by activation of RARs.	Tretinoin	72-74	peroxisome proliferator activator receptor delta	Mus musculus	98-106
19101649-3	2009	Since COX-2-derived prostanoids can activate the nuclear receptor PPARdelta, we crossed Ppardelta(-/-) mice with COX-2 transgenic mice in the FVB/N background.	Prostaglandins	20-31	peroxisome proliferator activator receptor delta	Mus musculus	66-75
19101649-7	2009	We postulate that activation of the nuclear receptor PPARdelta by COX-2-derived prostanoids may be involved in the proliferation of mammary epithelial cells and therefore contribute to mammary cancer development.	Prostaglandins	80-91	peroxisome proliferator activator receptor delta	Mus musculus	53-62
19197156-0	2009	PPARdelta agonist-mediated ROS stimulates mouse embryonic stem cell proliferation through cooperation of p38 MAPK and Wnt/beta-catenin.	Reactive Oxygen Species	27-30	peroxisome proliferator activator receptor delta	Mus musculus	0-9
19197156-4	2009	PPARdelta increased biphasic reactive oxygen species (ROS) production at 15 min and at 120 min incubation.	Reactive Oxygen Species	29-52	peroxisome proliferator activator receptor delta	Mus musculus	0-9
19197156-4	2009	PPARdelta increased biphasic reactive oxygen species (ROS) production at 15 min and at 120 min incubation.	Reactive Oxygen Species	54-57	peroxisome proliferator activator receptor delta	Mus musculus	0-9
19197156-5	2009	PPARdelta significantly increased [(3)H] thymidine incorporation levels at various concentrations (10(-8) M to 10(-6) M) and incubation times (12 to 48 hr), and this activity was blocked by antioxidants.	(3)h] thymidine	35-50	peroxisome proliferator activator receptor delta	Mus musculus	0-9
19197156-7	2009	PPARdelta increased the protein levels of cell cycle regulators, and these levels were abolished by antioxidants, bisindolymaleimide I, SB203580 and beta-catenin specific siRNA.	bisindolymaleimide i	114-134	peroxisome proliferator activator receptor delta	Mus musculus	0-9
19197156-7	2009	PPARdelta increased the protein levels of cell cycle regulators, and these levels were abolished by antioxidants, bisindolymaleimide I, SB203580 and beta-catenin specific siRNA.	SB 203580	136-144	peroxisome proliferator activator receptor delta	Mus musculus	0-9
19197156-8	2009	In addition, the effect of PPARdelta on increased [(3)H] thymidine incorporation was blocked by bisindolymaleimide I, SB203580 and beta-catenin specific siRNA.	[(3)h] thymidine	50-66	peroxisome proliferator activator receptor delta	Mus musculus	27-36
19197156-8	2009	In addition, the effect of PPARdelta on increased [(3)H] thymidine incorporation was blocked by bisindolymaleimide I, SB203580 and beta-catenin specific siRNA.	bisindolymaleimide i	96-116	peroxisome proliferator activator receptor delta	Mus musculus	27-36
19197156-8	2009	In addition, the effect of PPARdelta on increased [(3)H] thymidine incorporation was blocked by bisindolymaleimide I, SB203580 and beta-catenin specific siRNA.	SB 203580	118-126	peroxisome proliferator activator receptor delta	Mus musculus	27-36
19197156-9	2009	In conclusion, PPARdelta agonist enhanced mouse ES cells proliferation through ROS-mediated p38 MAPK and Wnt/beta-catenin activation.	Reactive Oxygen Species	79-82	peroxisome proliferator activator receptor delta	Mus musculus	15-24
18997443-2	2009	PPARdelta regulates lipid oxidation in skeletal muscle and is activated by several physiological ligands including fatty acids.	Fatty Acids	115-126	peroxisome proliferator activator receptor delta	Mus musculus	0-9
19266055-0	2009	The PPARdelta ligand GW501516 reduces growth but not apoptosis in mouse inner medullary collecting duct cells.	GW 501516	21-29	peroxisome proliferator activator receptor delta	Mus musculus	4-13
18727927-3	2008	In transient transactivation assay, PAR-5359 (3-(4-(2[4-(4chloro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-ethoxy)-phenyl)-(2S)-ethoxy-propionic acid) significantly activated human and mouse PPARalpha and gamma without activating PPARdelta.	(3-(4-(2(4-(4chloro-phenyl)-3,6-dihydro-2H-pyridin-1-yl)-ethoxy)-phenyl)-(2S)-ethoxy-propionic acid)	36-44	peroxisome proliferator activator receptor delta	Mus musculus	225-234
18599600-3	2008	PPARbeta/delta agonist 4-[3-[4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid (L165,041) and PPARgamma agonists ciglitazone and troglitazone, but not rosiglitazone, potently induced VEGF mRNA and protein expression from cultured keratinocytes.	4-[3-[4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid	23-91	peroxisome proliferator activator receptor delta	Mus musculus	0-8
18599600-3	2008	PPARbeta/delta agonist 4-[3-[4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid (L165,041) and PPARgamma agonists ciglitazone and troglitazone, but not rosiglitazone, potently induced VEGF mRNA and protein expression from cultured keratinocytes.	2-amino-1-(4-chlorophenyl)ethanone Hydrochloride	93-97	peroxisome proliferator activator receptor delta	Mus musculus	0-8
18622026-0	2008	Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.	Carbon Tetrachloride	103-123	peroxisome proliferator activator receptor delta	Mus musculus	21-74
18622026-0	2008	Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.	Carbon Tetrachloride	103-123	peroxisome proliferator activator receptor delta	Mus musculus	76-84
18622026-1	2008	Peroxisome proliferator-activated receptor (PPAR) beta/delta-null mice exhibit exacerbated hepatotoxicity in response to administration of carbon tetrachloride (CCl(4)).	Carbon Tetrachloride	139-159	peroxisome proliferator activator receptor delta	Mus musculus	0-54
18622026-1	2008	Peroxisome proliferator-activated receptor (PPAR) beta/delta-null mice exhibit exacerbated hepatotoxicity in response to administration of carbon tetrachloride (CCl(4)).	Cefaclor	161-164	peroxisome proliferator activator receptor delta	Mus musculus	0-54
18622026-3	2008	Biomarkers of liver toxicity, including serum alanine aminotransferase (ALT) and hepatic tumor necrosis factor (TNF) alpha mRNA, were significantly higher in CCl(4)-treated PPARbeta/delta-null mice compared to wild-type mice.	Cefaclor	158-161	peroxisome proliferator activator receptor delta	Mus musculus	173-181
18622026-4	2008	Hepatic expression of TNF-like weak inducer of apoptosis receptor (TWEAKr) and S100 calcium-binding protein A6 (S100A6/calcyclin), genes involved in nuclear factor kappa B signaling, was higher in the CCl(4)-treated PPARbeta/delta-null mice compared to wild-type mice.	Cefaclor	201-204	peroxisome proliferator activator receptor delta	Mus musculus	216-224
18622026-5	2008	GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl(4)-induced TNF-alpha, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARbeta/delta-null mice.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	231-239
20169010-0	2009	Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol.	Cholesterol	105-116	peroxisome proliferator activator receptor delta	Mus musculus	9-57
20169010-0	2009	Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol.	Cholesterol	186-197	peroxisome proliferator activator receptor delta	Mus musculus	9-57
20169010-1	2009	Peroxisome proliferator-activated receptor delta (PPARdelta) agonism increases HDL cholesterol and has therefore the potential to stimulate macrophage-to-feces reverse cholesterol transport (RCT).	Cholesterol	83-94	peroxisome proliferator activator receptor delta	Mus musculus	0-48
20169010-1	2009	Peroxisome proliferator-activated receptor delta (PPARdelta) agonism increases HDL cholesterol and has therefore the potential to stimulate macrophage-to-feces reverse cholesterol transport (RCT).	Cholesterol	83-94	peroxisome proliferator activator receptor delta	Mus musculus	50-59
20169010-1	2009	Peroxisome proliferator-activated receptor delta (PPARdelta) agonism increases HDL cholesterol and has therefore the potential to stimulate macrophage-to-feces reverse cholesterol transport (RCT).	Cholesterol	168-179	peroxisome proliferator activator receptor delta	Mus musculus	0-48
20169010-1	2009	Peroxisome proliferator-activated receptor delta (PPARdelta) agonism increases HDL cholesterol and has therefore the potential to stimulate macrophage-to-feces reverse cholesterol transport (RCT).	Cholesterol	168-179	peroxisome proliferator activator receptor delta	Mus musculus	50-59
20169010-3	2009	PPARdelta agonist GW0742 (10 mg/kg per day) did not change 3H-tracer plasma appearance, but increased fecal 3H-free sterols excretion by 103% ( p &lt; 0.005) over 48 hours.	GW0742	18-24	peroxisome proliferator activator receptor delta	Mus musculus	0-9
20169010-9	2009	In conclusion, PPARdelta activation enhances excretion of macrophage or HDL-derived cholesterol in feces through reduced NPC1L1 expression in mice, comparable to the effect of ezetimibe.	Cholesterol	84-95	peroxisome proliferator activator receptor delta	Mus musculus	15-24
18239600-4	2008	RESULTS: ATRA treatment triggered a dose-dependent increase in the muscle mRNA expression levels of selected enzymes, transporters and transcription factors involved in fatty-acid oxidation, respiration, and thermogenesis namely: muscle-type carnitine palmitoyltransferase 1, acyl CoA oxidase 1, subunit II of cytochrome oxidase, uncoupling protein 3, peroxisome proliferator-activated receptor-gamma co-activator -1alpha and peroxisome proliferator-activated receptor-delta (PPARdelta).	Tretinoin	9-13	peroxisome proliferator activator receptor delta	Mus musculus	426-474
18627005-9	2008	Knockdown of endogenous Insig-1 attenuated the suppressive effect of GW0742 on SREBP-1 and its target genes, indicating PPARdelta inhibited SREBP-1 activation via induction of Insig-1.	GW0742	69-75	peroxisome proliferator activator receptor delta	Mus musculus	120-129
18622687-0	2008	Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta/delta ligand GW0742.	GW0742	123-129	peroxisome proliferator activator receptor delta	Mus musculus	101-109
18622687-1	2008	OBJECTIVE: To define the anti-inflammatory effects of PPARbeta/delta activation by use of the selective PPARbeta/delta ligand (GW0742) in a model of lipopolysaccharide (LPS)-induced pulmonary inflammation.	GW0742	127-133	peroxisome proliferator activator receptor delta	Mus musculus	54-62
18622687-1	2008	OBJECTIVE: To define the anti-inflammatory effects of PPARbeta/delta activation by use of the selective PPARbeta/delta ligand (GW0742) in a model of lipopolysaccharide (LPS)-induced pulmonary inflammation.	GW0742	127-133	peroxisome proliferator activator receptor delta	Mus musculus	104-112
18622687-2	2008	METHODS: Male BALB/c mice were pretreated for three days with the PPARbeta/delta agonist, GW0742, prior to induction of LPS-mediated pulmonary inflammation.	GW0742	90-96	peroxisome proliferator activator receptor delta	Mus musculus	66-74
18711014-6	2008	These actions by PPAR-delta activation in EPCs were dependent on the phosphatidylinositol 3-kinase/Akt pathway.	Phosphatidylinositols	69-89	peroxisome proliferator activator receptor delta	Mus musculus	17-27
18684227-0	2008	Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.	GW 501516	58-66	peroxisome proliferator activator receptor delta	Mus musculus	0-48
18684227-0	2008	Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.	Glutamic Acid	137-148	peroxisome proliferator activator receptor delta	Mus musculus	0-48
18407349-0	2008	Cyclooxygenase-2 derived PGE2 and PGI2 play an important role via EP2 and PPARdelta receptors in early steps of oil induced decidualization in mice.	Dinoprostone	25-29	peroxisome proliferator activator receptor delta	Mus musculus	74-83
18407349-0	2008	Cyclooxygenase-2 derived PGE2 and PGI2 play an important role via EP2 and PPARdelta receptors in early steps of oil induced decidualization in mice.	Oils	112-115	peroxisome proliferator activator receptor delta	Mus musculus	74-83
18407349-3	2008	Previous reports described that cyclooxygenase-2 (COX2) derived prostacyclin (PGI2) plays an important role via peroxisome proliferator activated receptor (PPARdelta) nuclear receptor in implantation and decidualization.	Epoprostenol	64-76	peroxisome proliferator activator receptor delta	Mus musculus	156-165
18407349-6	2008	COX2, mPGES-1, PGIS, EP2 and PPARdelta immunostaining are strongly observed at 24 h and 48 h in oil-induced horn and than significantly reduced at 72 h and 120 h and absent in non-infused horn.	Oils	96-99	peroxisome proliferator activator receptor delta	Mus musculus	29-38
18407349-10	2008	Our data suggest that COX2 derived both PGE2 and PGI2 mediate its function via EP2 and PPARdelta receptors in early steps of decidualization in mice.	Dinoprostone	40-44	peroxisome proliferator activator receptor delta	Mus musculus	87-96
18239600-4	2008	RESULTS: ATRA treatment triggered a dose-dependent increase in the muscle mRNA expression levels of selected enzymes, transporters and transcription factors involved in fatty-acid oxidation, respiration, and thermogenesis namely: muscle-type carnitine palmitoyltransferase 1, acyl CoA oxidase 1, subunit II of cytochrome oxidase, uncoupling protein 3, peroxisome proliferator-activated receptor-gamma co-activator -1alpha and peroxisome proliferator-activated receptor-delta (PPARdelta).	Tretinoin	9-13	peroxisome proliferator activator receptor delta	Mus musculus	476-485
18239600-6	2008	Skeletal muscle protein levels of PPARdelta and retinoid X receptor gamma, a partner for many nuclear receptors involved in lipid metabolism, were increased after ATRA treatment.	Tretinoin	163-167	peroxisome proliferator activator receptor delta	Mus musculus	34-43
17878286-7	2008	Adipocyte differentiation in myoblasts coexpressing PPARdelta and mutated PPARgamma was greater than in myoblasts coexpressing PPARdelta and wild type PPARgamma, confirming that Ser 112 is important for the function of PPARgamma.	Serine	178-181	peroxisome proliferator activator receptor delta	Mus musculus	52-61
18096720-0	2008	High-glucose-induced prostaglandin E(2) and peroxisome proliferator-activated receptor delta promote mouse embryonic stem cell proliferation.	high-glucose	0-12	peroxisome proliferator activator receptor delta	Mus musculus	21-92
18096720-7	2008	Subsequently, high glucose-induced PGE(2) stimulated PPARdelta expression directly or through Akt phosphorylation indirectly through the E type prostaglandin receptor receptors.	Glucose	19-26	peroxisome proliferator activator receptor delta	Mus musculus	53-62
18096720-7	2008	Subsequently, high glucose-induced PGE(2) stimulated PPARdelta expression directly or through Akt phosphorylation indirectly through the E type prostaglandin receptor receptors.	Prostaglandins E	35-38	peroxisome proliferator activator receptor delta	Mus musculus	53-62
18096720-8	2008	The PPARdelta antagonist inhibited the 25 mM glucose-induced DNA synthesis.	Glucose	45-52	peroxisome proliferator activator receptor delta	Mus musculus	4-13
18096720-9	2008	Moreover, transfection with a pool of PPARdelta-specific small interfering RNA inhibited the 25 mM glucose-induced DNA synthesis and G1/S phase progression.	Glucose	99-106	peroxisome proliferator activator receptor delta	Mus musculus	38-47
18096720-10	2008	Twenty-five millimolar glucose also increased the level of the cell cycle regulatory proteins (cyclin E/cyclin-dependent kinase [CDK] 2 and cyclin D1/CDK 4) and decreased p21(WAF1/Cip1) and p27(Kip1), which were blocked by the inhibition of the cPLA(2), COX-2, or PPARdelta pathways.	Glucose	23-30	peroxisome proliferator activator receptor delta	Mus musculus	264-273
18096720-11	2008	In conclusion, high glucose promotes mouse ESC growth in part through the cPLA(2)-mediated PGE(2) synthesis and in part through PPARdelta pathways.	Glucose	20-27	peroxisome proliferator activator receptor delta	Mus musculus	128-137
18007025-4	2008	The PPARdelta activator GW501516 upregulates TGF-beta1 expression in a dose- and time-dependent manner.	GW 501516	24-32	peroxisome proliferator activator receptor delta	Mus musculus	4-13
18007025-5	2008	This induction is attenuated significantly by the presence of small interfering RNA against PPARdelta or GW9662, an inhibitor of PPARdelta.	2-chloro-5-nitrobenzanilide	105-111	peroxisome proliferator activator receptor delta	Mus musculus	129-138
17620284-8	2008	Beraprost-mediated protection in a murine model of balloon angioplasty was significantly attenuated by 13S-HODE, a PPARdelta antagonist.	13-hydroxy-9,11-octadecadienoic acid	103-111	peroxisome proliferator activator receptor delta	Mus musculus	115-124
17620284-9	2008	Taken together, the results suggest that the causal relationship between PPARdelta and iNOS contributes to the vasoprotective action of beraprost in RASMCs.	rasmcs	149-155	peroxisome proliferator activator receptor delta	Mus musculus	73-82
17713572-6	2008	Although basal permeability barrier function was normal, PPARbeta/delta knockout (KO) mice show a significant delay in barrier recovery rates following acute barrier disruption by either acetone treatment or tape-stripping.	Acetone	187-194	peroxisome proliferator activator receptor delta	Mus musculus	57-65
17713572-8	2008	Finally, PPARbeta/delta KO mice displayed increased inflammation in response to 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment.	Tetradecanoylphorbol Acetate	80-116	peroxisome proliferator activator receptor delta	Mus musculus	9-17
17713572-8	2008	Finally, PPARbeta/delta KO mice displayed increased inflammation in response to 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment.	Tetradecanoylphorbol Acetate	118-121	peroxisome proliferator activator receptor delta	Mus musculus	9-17
17893232-6	2008	Inhibition of COX2 by nimesulide attenuated colon cancer and ligand activation of PPARbeta/delta by GW0742 had inhibitory effects.	GW0742	100-106	peroxisome proliferator activator receptor delta	Mus musculus	82-90
18038451-1	2008	UNLABELLED: Potential functional roles for the peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in skeletal muscle fatty acid catabolism and epithelial carcinogenesis have recently been described.	Fatty Acids	137-147	peroxisome proliferator activator receptor delta	Mus musculus	47-94
18038451-1	2008	UNLABELLED: Potential functional roles for the peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in skeletal muscle fatty acid catabolism and epithelial carcinogenesis have recently been described.	Fatty Acids	137-147	peroxisome proliferator activator receptor delta	Mus musculus	102-110
17878286-7	2008	Adipocyte differentiation in myoblasts coexpressing PPARdelta and mutated PPARgamma was greater than in myoblasts coexpressing PPARdelta and wild type PPARgamma, confirming that Ser 112 is important for the function of PPARgamma.	Serine	178-181	peroxisome proliferator activator receptor delta	Mus musculus	127-136
18528523-3	2008	In particular, a study of the chemopreventive effect of two isomers of NO-aspirin on intestinal neoplasia in Min mice showed that, compared to wild-type controls, PPARdelta is overexpressed in the intestinal mucosa of Min mice; PPARdelta responds to m- and p-NO-ASA proportionally to their antitumor effect (p- &gt; m-).	Aspirin	74-81	peroxisome proliferator activator receptor delta	Mus musculus	163-172
18038451-5	2008	Exacerbated carbon tetrachloride (CCl(4)) hepatoxicity was also observed in PPARbeta/delta-null as compared with wild-type mice.	Carbon Tetrachloride	12-32	peroxisome proliferator activator receptor delta	Mus musculus	76-84
19009042-4	2008	The lipid content alteration observed in PPARbeta null brains and the positive action of PPARbeta agonists on oligodendrocyte differentiation, a process characterized by lipid accumulation, suggest that PPARbeta acts on the fatty acids and/or cholesterol metabolisms in the brain.	Fatty Acids	224-235	peroxisome proliferator activator receptor delta	Mus musculus	41-49
19009042-4	2008	The lipid content alteration observed in PPARbeta null brains and the positive action of PPARbeta agonists on oligodendrocyte differentiation, a process characterized by lipid accumulation, suggest that PPARbeta acts on the fatty acids and/or cholesterol metabolisms in the brain.	Fatty Acids	224-235	peroxisome proliferator activator receptor delta	Mus musculus	89-97
19009042-4	2008	The lipid content alteration observed in PPARbeta null brains and the positive action of PPARbeta agonists on oligodendrocyte differentiation, a process characterized by lipid accumulation, suggest that PPARbeta acts on the fatty acids and/or cholesterol metabolisms in the brain.	Fatty Acids	224-235	peroxisome proliferator activator receptor delta	Mus musculus	89-97
19009042-4	2008	The lipid content alteration observed in PPARbeta null brains and the positive action of PPARbeta agonists on oligodendrocyte differentiation, a process characterized by lipid accumulation, suggest that PPARbeta acts on the fatty acids and/or cholesterol metabolisms in the brain.	Cholesterol	243-254	peroxisome proliferator activator receptor delta	Mus musculus	89-97
19009042-4	2008	The lipid content alteration observed in PPARbeta null brains and the positive action of PPARbeta agonists on oligodendrocyte differentiation, a process characterized by lipid accumulation, suggest that PPARbeta acts on the fatty acids and/or cholesterol metabolisms in the brain.	Cholesterol	243-254	peroxisome proliferator activator receptor delta	Mus musculus	89-97
18038451-5	2008	Exacerbated carbon tetrachloride (CCl(4)) hepatoxicity was also observed in PPARbeta/delta-null as compared with wild-type mice.	Cefaclor	34-37	peroxisome proliferator activator receptor delta	Mus musculus	76-84
18038451-8	2008	CONCLUSION: Results from these studies show that PPARbeta/delta is protective against liver toxicity induced by AOM and CCl(4), suggesting that this receptor is hepatoprotective against environmental chemicals that are metabolized in this tissue.	Cefaclor	120-123	peroxisome proliferator activator receptor delta	Mus musculus	49-57
17951219-6	2008	In contrast, the PPARalpha antagonist MK886 decreased cardiomyogenesis, whereas the PPARbeta agonist L-165,041 as well as the PPARgamma agonist GW1929 were without effects.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	101-110	peroxisome proliferator activator receptor delta	Mus musculus	84-92
18528523-3	2008	In particular, a study of the chemopreventive effect of two isomers of NO-aspirin on intestinal neoplasia in Min mice showed that, compared to wild-type controls, PPARdelta is overexpressed in the intestinal mucosa of Min mice; PPARdelta responds to m- and p-NO-ASA proportionally to their antitumor effect (p- &gt; m-).	Aspirin	262-265	peroxisome proliferator activator receptor delta	Mus musculus	163-172
18528523-4	2008	This effect is accompanied by the induction of epithelial cell death, which correlates with the antineoplastic effect of NO-aspirin; and NO-aspirin"s effect on PPARdelta is specific (no changes in PPARalpha or PPARgamma).	Aspirin	140-147	peroxisome proliferator activator receptor delta	Mus musculus	160-169
17631136-9	2007	In contrast to the beneficial effect of fenofibrate, the PPARdelta ligand GW0742 accelerated the onset of colitis in IL-10(-/-) mice.	GW0742	74-80	peroxisome proliferator activator receptor delta	Mus musculus	57-66
18037994-7	2007	In reporter assays, we showed that PPARbeta/delta and PPARalpha exerted differential transcriptional control of the GLUT4 promoter, which may explain the observed isotype-specific effects on glucose uptake.	Glucose	191-198	peroxisome proliferator activator receptor delta	Mus musculus	35-43
17404849-7	2007	These studies demonstrate that PPARbeta/delta expression in the colonic epithelium inhibits inflammation and protects against DSS-induced colitis through a ligand-independent mechanism.	dss	126-129	peroxisome proliferator activator receptor delta	Mus musculus	31-39
17404849-5	2007	PPARbeta/delta-null mice exhibited increased sensitivity to DSS-induced colitis, as shown by marked differences in body weight loss, colon length, colonic morphology, myeloperoxidase activity and increased expression of mRNAs encoding the inflammatory markers interferon gamma, tumor necrosis factor-alpha, and interleukin-6 compared to similarly treated wild-type mice.	dss	60-63	peroxisome proliferator activator receptor delta	Mus musculus	0-8
17466944-2	2007	PPARalpha and PPARbeta isotypes are known to regulate muscle fatty acid oxidation and a reciprocal compensation of their function has been proposed.	Fatty Acids	61-71	peroxisome proliferator activator receptor delta	Mus musculus	14-22
17382197-0	2007	The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).	4-hydroxy-2-nonenal	30-46	peroxisome proliferator activator receptor delta	Mus musculus	154-162
17333240-1	2007	Peroxisome proliferator-activated receptor-delta (PPAR-delta) is known as a transcription factor involved in the regulation of fatty acid oxidation and mitochondrial biogenesis in several tissues, such as skeletal muscle, liver and adipose tissues.	Fatty Acids	127-137	peroxisome proliferator activator receptor delta	Mus musculus	0-48
17333240-1	2007	Peroxisome proliferator-activated receptor-delta (PPAR-delta) is known as a transcription factor involved in the regulation of fatty acid oxidation and mitochondrial biogenesis in several tissues, such as skeletal muscle, liver and adipose tissues.	Fatty Acids	127-137	peroxisome proliferator activator receptor delta	Mus musculus	50-60
17382197-6	2007	In support, oxidized-VLDL and constituents including 13-S-hydroxyoctadecadienoic acid (13-S-HODE) and 4-HNE are PPARbeta/delta ligands.	13-hydroxy-9,11-octadecadienoic acid	53-85	peroxisome proliferator activator receptor delta	Mus musculus	112-120
17382197-6	2007	In support, oxidized-VLDL and constituents including 13-S-hydroxyoctadecadienoic acid (13-S-HODE) and 4-HNE are PPARbeta/delta ligands.	13-hydroxy-9,11-octadecadienoic acid	87-96	peroxisome proliferator activator receptor delta	Mus musculus	112-120
17382197-6	2007	In support, oxidized-VLDL and constituents including 13-S-hydroxyoctadecadienoic acid (13-S-HODE) and 4-HNE are PPARbeta/delta ligands.	4-hydroxy-2-nonenal	102-107	peroxisome proliferator activator receptor delta	Mus musculus	112-120
17382197-7	2007	A structure-activity relationship was established where 4-HNE and 4-hydroperoxynonenal (4-HpNE) enhanced the activity of the PPARbeta/delta subtype while 4-hyroxyhexenal (4-HHE), 4-oxo-2-Nonenal (4-ONE), and trans-4,5-epoxy-2(E)-decenal did not activate this receptor.	4-hydroxy-2-nonenal	56-61	peroxisome proliferator activator receptor delta	Mus musculus	125-133
17382197-7	2007	A structure-activity relationship was established where 4-HNE and 4-hydroperoxynonenal (4-HpNE) enhanced the activity of the PPARbeta/delta subtype while 4-hyroxyhexenal (4-HHE), 4-oxo-2-Nonenal (4-ONE), and trans-4,5-epoxy-2(E)-decenal did not activate this receptor.	4-Hydroperoxy-2-nonenal	66-86	peroxisome proliferator activator receptor delta	Mus musculus	125-133
17382197-7	2007	A structure-activity relationship was established where 4-HNE and 4-hydroperoxynonenal (4-HpNE) enhanced the activity of the PPARbeta/delta subtype while 4-hyroxyhexenal (4-HHE), 4-oxo-2-Nonenal (4-ONE), and trans-4,5-epoxy-2(E)-decenal did not activate this receptor.	4-Hydroperoxy-2-nonenal	88-94	peroxisome proliferator activator receptor delta	Mus musculus	125-133
17382197-7	2007	A structure-activity relationship was established where 4-HNE and 4-hydroperoxynonenal (4-HpNE) enhanced the activity of the PPARbeta/delta subtype while 4-hyroxyhexenal (4-HHE), 4-oxo-2-Nonenal (4-ONE), and trans-4,5-epoxy-2(E)-decenal did not activate this receptor.	4-oxo-2-nonenal	179-194	peroxisome proliferator activator receptor delta	Mus musculus	125-133
17382197-7	2007	A structure-activity relationship was established where 4-HNE and 4-hydroperoxynonenal (4-HpNE) enhanced the activity of the PPARbeta/delta subtype while 4-hyroxyhexenal (4-HHE), 4-oxo-2-Nonenal (4-ONE), and trans-4,5-epoxy-2(E)-decenal did not activate this receptor.	4-oxo-2-nonenal	196-201	peroxisome proliferator activator receptor delta	Mus musculus	125-133
17382197-7	2007	A structure-activity relationship was established where 4-HNE and 4-hydroperoxynonenal (4-HpNE) enhanced the activity of the PPARbeta/delta subtype while 4-hyroxyhexenal (4-HHE), 4-oxo-2-Nonenal (4-ONE), and trans-4,5-epoxy-2(E)-decenal did not activate this receptor.	3-(3-pentyloxiran-2-yl)prop-2-enal	208-236	peroxisome proliferator activator receptor delta	Mus musculus	125-133
17382197-8	2007	Increasing PPARbeta/delta activity with a synthetic agonist decreased sensitivity of hepatocytes to 4-HNE and other toxic agents, whereas inhibition of this receptor had the opposite result.	4-hydroxy-2-nonenal	100-105	peroxisome proliferator activator receptor delta	Mus musculus	11-19
17328923-10	2007	Our results suggest that PGI(2) may affect blastomeres number via the so called hypothesis of PPARdelta nuclear receptor in autocrine manner.	Epoprostenol	25-31	peroxisome proliferator activator receptor delta	Mus musculus	94-103
17710237-7	2007	GW9135, a PPARpan agonist with weak activity at PPARdelta, induced weight loss initially followed by rebound weight gain reaching vehicle control levels by the end of the experiment.	gw9135	0-6	peroxisome proliferator activator receptor delta	Mus musculus	48-57
17167170-7	2007	Moreover, the PPARdelta agonists also significantly attenuated MPTP-induced depletion of striatal dopamine and related metabolite contents in mouse brain.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	63-67	peroxisome proliferator activator receptor delta	Mus musculus	14-23
17167170-7	2007	Moreover, the PPARdelta agonists also significantly attenuated MPTP-induced depletion of striatal dopamine and related metabolite contents in mouse brain.	Dopamine	98-106	peroxisome proliferator activator receptor delta	Mus musculus	14-23
17148604-4	2006	Here, we present genetic and pharmacologic evidence demonstrating that deletion of PPARdelta decreases intestinal adenoma growth in Apc(Min/+) mice and inhibits tumor-promoting effects of a PPARdelta agonist GW501516.	GW 501516	208-216	peroxisome proliferator activator receptor delta	Mus musculus	83-92
17047030-6	2007	PFOA significantly increased mouse and human PPARalpha and mouse PPARbeta/delta activity relative to vehicle.	perfluorooctanoic acid	0-4	peroxisome proliferator activator receptor delta	Mus musculus	65-73
17047030-7	2007	PFOS significantly increased activation of mouse PPARalpha and PPARbeta/delta isoforms.	perfluorooctane sulfonic acid	0-4	peroxisome proliferator activator receptor delta	Mus musculus	63-71
17148604-4	2006	Here, we present genetic and pharmacologic evidence demonstrating that deletion of PPARdelta decreases intestinal adenoma growth in Apc(Min/+) mice and inhibits tumor-promoting effects of a PPARdelta agonist GW501516.	GW 501516	208-216	peroxisome proliferator activator receptor delta	Mus musculus	190-199
16890607-2	2006	Peroxisome proliferator-activated receptor beta (PPARbeta) is a nuclear hormone receptor activated by fatty acids and is highly expressed in the digestive tract.	Fatty Acids	102-113	peroxisome proliferator activator receptor delta	Mus musculus	0-47
16931011-0	2006	3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists.	3,4,5-trisubstituted isoxazoles	0-31	peroxisome proliferator activator receptor delta	Mus musculus	41-50
16931011-3	2006	Isoxazole LCI765 (17d) was found to be a potent and selective PPARdelta agonist with good in vivo PK properties in mouse (C(max)=5.1 microM, t(1/2)=3.1 h).	Isoxazoles	0-9	peroxisome proliferator activator receptor delta	Mus musculus	62-71
16931011-3	2006	Isoxazole LCI765 (17d) was found to be a potent and selective PPARdelta agonist with good in vivo PK properties in mouse (C(max)=5.1 microM, t(1/2)=3.1 h).	lci765	10-16	peroxisome proliferator activator receptor delta	Mus musculus	62-71
16943204-5	2006	[Ru(CO)(3)Cl(2)](2) activated PPARdelta transcriptional activity via the MEK5/ERK5 signaling pathway.	[ru(co)(3)cl(2)](2)	0-19	peroxisome proliferator activator receptor delta	Mus musculus	30-39
16857752-9	2006	The murine UCP3 promoter is activated by fatty acids through either PPARalpha or PPARdelta but not by PPARgamma or retinoid X receptor alone.	Fatty Acids	41-52	peroxisome proliferator activator receptor delta	Mus musculus	81-90
16890607-2	2006	Peroxisome proliferator-activated receptor beta (PPARbeta) is a nuclear hormone receptor activated by fatty acids and is highly expressed in the digestive tract.	Fatty Acids	102-113	peroxisome proliferator activator receptor delta	Mus musculus	49-57
16890607-8	2006	Importantly, PPARbeta acts on Paneth cell homeostasis by down-regulating the expression of Ihh, an effect that can be mimicked by cyclopamine, a known inhibitor of the hedgehog signaling pathway.	cyclopamine	130-141	peroxisome proliferator activator receptor delta	Mus musculus	13-21
16418176-2	2006	It was further suggested that inhibition of COX2-derived prostaglandins by NSAIDs could reduce levels of putative endogenous ligands of peroxisome proliferator-activated receptor-beta (PPARbeta), and these ligands could potentiate tumorigenesis.	Prostaglandins	57-71	peroxisome proliferator activator receptor delta	Mus musculus	136-183
16418176-2	2006	It was further suggested that inhibition of COX2-derived prostaglandins by NSAIDs could reduce levels of putative endogenous ligands of peroxisome proliferator-activated receptor-beta (PPARbeta), and these ligands could potentiate tumorigenesis.	Prostaglandins	57-71	peroxisome proliferator activator receptor delta	Mus musculus	185-193
16418176-6	2006	Significant inhibition of chemically induced skin carcinogenesis was observed in both wild-type and PPARbeta-null mice, and this was associated with a marked decrease in the concentration of skin prostaglandins including PGE(2) and PGI(2).	Prostaglandins	196-210	peroxisome proliferator activator receptor delta	Mus musculus	100-108
16418176-6	2006	Significant inhibition of chemically induced skin carcinogenesis was observed in both wild-type and PPARbeta-null mice, and this was associated with a marked decrease in the concentration of skin prostaglandins including PGE(2) and PGI(2).	Prostaglandins E	221-224	peroxisome proliferator activator receptor delta	Mus musculus	100-108
16418176-6	2006	Significant inhibition of chemically induced skin carcinogenesis was observed in both wild-type and PPARbeta-null mice, and this was associated with a marked decrease in the concentration of skin prostaglandins including PGE(2) and PGI(2).	Prostaglandins I	232-235	peroxisome proliferator activator receptor delta	Mus musculus	100-108
16574099-7	2006	These results suggest that (a) bezafibrate (especially) and GW501516 might improve hepatic steatosis via an improvement in fatty acid beta-oxidation and a direct prevention of inflammation, (b) treatment with a PPARdelta agonist might improve non-alcholic steatohepatitis, (c) bezafibrate may improve non-alcholic steatohepatitis via activation not only of PPARalpha but also of PPARdelta, because bezafibrate is a PPAR pan-agonist.	Bezafibrate	31-42	peroxisome proliferator activator receptor delta	Mus musculus	211-220
16574099-7	2006	These results suggest that (a) bezafibrate (especially) and GW501516 might improve hepatic steatosis via an improvement in fatty acid beta-oxidation and a direct prevention of inflammation, (b) treatment with a PPARdelta agonist might improve non-alcholic steatohepatitis, (c) bezafibrate may improve non-alcholic steatohepatitis via activation not only of PPARalpha but also of PPARdelta, because bezafibrate is a PPAR pan-agonist.	Bezafibrate	31-42	peroxisome proliferator activator receptor delta	Mus musculus	379-388
16574099-7	2006	These results suggest that (a) bezafibrate (especially) and GW501516 might improve hepatic steatosis via an improvement in fatty acid beta-oxidation and a direct prevention of inflammation, (b) treatment with a PPARdelta agonist might improve non-alcholic steatohepatitis, (c) bezafibrate may improve non-alcholic steatohepatitis via activation not only of PPARalpha but also of PPARdelta, because bezafibrate is a PPAR pan-agonist.	GW 501516	60-68	peroxisome proliferator activator receptor delta	Mus musculus	211-220
16574099-7	2006	These results suggest that (a) bezafibrate (especially) and GW501516 might improve hepatic steatosis via an improvement in fatty acid beta-oxidation and a direct prevention of inflammation, (b) treatment with a PPARdelta agonist might improve non-alcholic steatohepatitis, (c) bezafibrate may improve non-alcholic steatohepatitis via activation not only of PPARalpha but also of PPARdelta, because bezafibrate is a PPAR pan-agonist.	Fatty Acids	123-133	peroxisome proliferator activator receptor delta	Mus musculus	211-220
16618765-3	2006	This hypothesis was examined by treating wild-type (Pparb+/+) and Pparb-/- with azoxymethane, coupled with a highly specific PPARbeta ligand, GW0742.	Azoxymethane	80-92	peroxisome proliferator activator receptor delta	Mus musculus	66-71
16618765-3	2006	This hypothesis was examined by treating wild-type (Pparb+/+) and Pparb-/- with azoxymethane, coupled with a highly specific PPARbeta ligand, GW0742.	GW0742	142-148	peroxisome proliferator activator receptor delta	Mus musculus	125-133
16618765-4	2006	Ligand activation of PPARbeta in Pparb+/+ mice caused an increase in the expression of mRNA encoding adipocyte differentiation-related protein, fatty acid-binding protein, and cathepsin E.	Fatty Acids	144-154	peroxisome proliferator activator receptor delta	Mus musculus	21-29
16618765-4	2006	Ligand activation of PPARbeta in Pparb+/+ mice caused an increase in the expression of mRNA encoding adipocyte differentiation-related protein, fatty acid-binding protein, and cathepsin E.	Fatty Acids	144-154	peroxisome proliferator activator receptor delta	Mus musculus	33-38
16141240-0	2006	NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis.	Aspirin	12-19	peroxisome proliferator activator receptor delta	Mus musculus	85-95
16492734-0	2006	PPARdelta regulates glucose metabolism and insulin sensitivity.	Glucose	20-27	peroxisome proliferator activator receptor delta	Mus musculus	0-9
16492734-4	2006	Euglycemic-hyperinsulinemic-clamp experiments further demonstrate that a PPARdelta-specific agonist suppresses hepatic glucose output, increases glucose disposal, and inhibits free fatty acid release from adipocytes.	Glucose	119-126	peroxisome proliferator activator receptor delta	Mus musculus	73-82
16492734-4	2006	Euglycemic-hyperinsulinemic-clamp experiments further demonstrate that a PPARdelta-specific agonist suppresses hepatic glucose output, increases glucose disposal, and inhibits free fatty acid release from adipocytes.	Fatty Acids, Nonesterified	176-191	peroxisome proliferator activator receptor delta	Mus musculus	73-82
16492734-5	2006	Unexpectedly, gene array and functional analyses suggest that PPARdelta ameliorates hyperglycemia by increasing glucose flux through the pentose phosphate pathway and enhancing fatty acid synthesis.	Glucose	112-119	peroxisome proliferator activator receptor delta	Mus musculus	62-71
16492734-5	2006	Unexpectedly, gene array and functional analyses suggest that PPARdelta ameliorates hyperglycemia by increasing glucose flux through the pentose phosphate pathway and enhancing fatty acid synthesis.	Pentosephosphates	137-154	peroxisome proliferator activator receptor delta	Mus musculus	62-71
16492734-5	2006	Unexpectedly, gene array and functional analyses suggest that PPARdelta ameliorates hyperglycemia by increasing glucose flux through the pentose phosphate pathway and enhancing fatty acid synthesis.	Fatty Acids	177-187	peroxisome proliferator activator receptor delta	Mus musculus	62-71
16492734-6	2006	Coupling increased hepatic carbohydrate catabolism with its ability to promote beta-oxidation in muscle allows PPARdelta to regulate metabolic homeostasis and enhance insulin action by complementary effects in distinct tissues.	Carbohydrates	27-39	peroxisome proliferator activator receptor delta	Mus musculus	111-120
16293616-2	2006	More specifically, we have shown that prostaglandin E2 (PGE2) promotes cell proliferation and invasion through transactivation of the epidermal growth factor receptor, initiates immune evasion through induction of decay accelerating factor, and transactivates peroxisome proliferator-activated receptor delta, leading to increased polyp size and multiplicity.	Dinoprostone	38-54	peroxisome proliferator activator receptor delta	Mus musculus	260-308
16293616-2	2006	More specifically, we have shown that prostaglandin E2 (PGE2) promotes cell proliferation and invasion through transactivation of the epidermal growth factor receptor, initiates immune evasion through induction of decay accelerating factor, and transactivates peroxisome proliferator-activated receptor delta, leading to increased polyp size and multiplicity.	Dinoprostone	56-60	peroxisome proliferator activator receptor delta	Mus musculus	260-308
16141240-0	2006	NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis.	Aspirin	12-19	peroxisome proliferator activator receptor delta	Mus musculus	204-213
16141240-4	2006	We studied histochemically the effect of the meta and para positional isomers of NO-ASA on PPARdelta expression in Min (multiple intestinal neoplasia) and wild-type mice, and on cell proliferation and apoptosis.	Aspirin	84-87	peroxisome proliferator activator receptor delta	Mus musculus	91-100
16141240-6	2006	para NO-ASA inhibited intestinal tumor incidence (59%) and PPARdelta expression (55.3%) more than meta NO-ASA (38 and 41.5%, respectively).	para no-asa	0-11	peroxisome proliferator activator receptor delta	Mus musculus	59-68
16141240-6	2006	para NO-ASA inhibited intestinal tumor incidence (59%) and PPARdelta expression (55.3%) more than meta NO-ASA (38 and 41.5%, respectively).	Aspirin	8-11	peroxisome proliferator activator receptor delta	Mus musculus	59-68
16141240-10	2006	Our data suggest that NO-ASA suppresses intestinal tumorigenesis possibly in part through its inhibitory effect on PPARdelta, the expression of which may contribute to intestinal carcinogenesis.	nitroxy-butyl-acetylsalicylic acid	22-28	peroxisome proliferator activator receptor delta	Mus musculus	115-124
15939051-0	2005	The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice.	GW0742	22-29	peroxisome proliferator activator receptor delta	Mus musculus	4-13
16021179-2	2006	By using of a highly specific ligand (GW0742) and the PPARbeta-null mouse model, activation of PPARbeta was found to selectively induce keratinocyte terminal differentiation and inhibit keratinocyte proliferation.	GW0742	38-44	peroxisome proliferator activator receptor delta	Mus musculus	95-103
17259670-5	2006	Similarly, pretreatment of WT mice with the PPARdelta agonist L-783483 or the PPARgamma agonist L-805645 caused 54 +/- 1% and 38 +/- 8% reduction in carrageenan-induced paw edema, respectively.	L-783483	62-70	peroxisome proliferator activator receptor delta	Mus musculus	44-53
17259670-5	2006	Similarly, pretreatment of WT mice with the PPARdelta agonist L-783483 or the PPARgamma agonist L-805645 caused 54 +/- 1% and 38 +/- 8% reduction in carrageenan-induced paw edema, respectively.	Carrageenan	149-160	peroxisome proliferator activator receptor delta	Mus musculus	44-53
16098614-3	2005	We show that oral administration of the selective PPARdelta agonist GW0742 reduced clinical symptoms in C57BL/6 mice that had been immunized with encephalitogenic myelin oligodendrocyte glycoprotein (MOG) peptide.	GW0742	68-74	peroxisome proliferator activator receptor delta	Mus musculus	50-59
16083348-6	2005	PPARbeta/delta activation also prevents the development of obesity and improves cholesterol homeostasis in obesity-prone mouse models.	Cholesterol	80-91	peroxisome proliferator activator receptor delta	Mus musculus	0-8
15939051-2	2005	Administration of synthetic PPARdelta agonists to obese rhesus monkeys elevates serum high-density lipoprotein (HDL) cholesterol as a result of increased reverse cholesterol transport whilst in vitro studies have suggested a role for PPARdelta in lipid uptake into macrophages.	Cholesterol	117-128	peroxisome proliferator activator receptor delta	Mus musculus	28-37
15939051-2	2005	Administration of synthetic PPARdelta agonists to obese rhesus monkeys elevates serum high-density lipoprotein (HDL) cholesterol as a result of increased reverse cholesterol transport whilst in vitro studies have suggested a role for PPARdelta in lipid uptake into macrophages.	Cholesterol	162-173	peroxisome proliferator activator receptor delta	Mus musculus	28-37
15939051-4	2005	We demonstrate here that the PPARdelta agonist, GW0742X has potent anti-atherogenic activity in the LDLR(-/-) mouse, decreasing lesion area by up to 50%.	GW0742	48-55	peroxisome proliferator activator receptor delta	Mus musculus	29-38
15866483-0	2005	Agonist-induced activation releases peroxisome proliferator-activated receptor beta/delta from its inhibition by palmitate-induced nuclear factor-kappaB in skeletal muscle cells.	Palmitates	113-122	peroxisome proliferator activator receptor delta	Mus musculus	36-83
15867396-5	2005	In contrast, animals treated with the PPARdelta agonist GW501516 showed accelerated tumor formation.	GW 501516	56-64	peroxisome proliferator activator receptor delta	Mus musculus	38-47
15866483-4	2005	Here, we report that exposure of C2C12 skeletal muscle cells to 0.75 mM palmitate reduced (74%, P&lt;0.01) the mRNA levels of the PPARbeta/delta-target gene pyruvatedehydrogenase kinase 4 (PDK-4), which is involved in fatty acid utilization.	Palmitates	72-81	peroxisome proliferator activator receptor delta	Mus musculus	130-138
15866483-4	2005	Here, we report that exposure of C2C12 skeletal muscle cells to 0.75 mM palmitate reduced (74%, P&lt;0.01) the mRNA levels of the PPARbeta/delta-target gene pyruvatedehydrogenase kinase 4 (PDK-4), which is involved in fatty acid utilization.	Fatty Acids	218-228	peroxisome proliferator activator receptor delta	Mus musculus	130-138
15604518-3	2005	Effects of PPARdelta activation by GW610742 were evaluated in wild-type and Abca1-deficient (Abca1(-/-)) mice that lack HDL.	GW 610742	35-43	peroxisome proliferator activator receptor delta	Mus musculus	11-20
15793256-2	2005	Recently, a specific PPARdelta activator (GW501516) was reported to attenuate plasma glucose and insulin levels when administered to genetically obese ob/ob mice.	GW 501516	42-50	peroxisome proliferator activator receptor delta	Mus musculus	21-30
15793256-2	2005	Recently, a specific PPARdelta activator (GW501516) was reported to attenuate plasma glucose and insulin levels when administered to genetically obese ob/ob mice.	Glucose	85-92	peroxisome proliferator activator receptor delta	Mus musculus	21-30
15632134-3	2005	Intracellular phosphorylation analysis showed that phosphorylated PKCalpha and other kinases were lower in wild-type mouse skin treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) as compared with PPARbeta-null mouse skin.	Tetradecanoylphorbol Acetate	141-177	peroxisome proliferator activator receptor delta	Mus musculus	201-209
15632134-3	2005	Intracellular phosphorylation analysis showed that phosphorylated PKCalpha and other kinases were lower in wild-type mouse skin treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) as compared with PPARbeta-null mouse skin.	Tetradecanoylphorbol Acetate	179-182	peroxisome proliferator activator receptor delta	Mus musculus	201-209
15632134-5	2005	Lower ubiquitination of PKCalpha was found in TPA-treated PPARbeta-null skin as compared with wild-type, and inhibition of ubiquitin-dependent proteasome degradation prevented TPA-induced down-regulation of PKCalpha.	Tetradecanoylphorbol Acetate	46-49	peroxisome proliferator activator receptor delta	Mus musculus	58-66
15632134-5	2005	Lower ubiquitination of PKCalpha was found in TPA-treated PPARbeta-null skin as compared with wild-type, and inhibition of ubiquitin-dependent proteasome degradation prevented TPA-induced down-regulation of PKCalpha.	Tetradecanoylphorbol Acetate	176-179	peroxisome proliferator activator receptor delta	Mus musculus	58-66
15632134-6	2005	The activity of PKCalpha and downstream signaling kinases is enhanced, and expression of cyclooxygenase-2 (COX-2) is significantly greater, in PPARbeta-null mouse skin in response to TPA compared with wild-type mouse skin.	Tetradecanoylphorbol Acetate	183-186	peroxisome proliferator activator receptor delta	Mus musculus	143-151
15632134-7	2005	Inhibition of PKCalpha or COX-2 reduced cell proliferation in TPA-treated PPARbeta-null keratinocytes in a dose-dependent manner, whereas it only slightly influenced cell proliferation in wild-type keratinocytes.	Tetradecanoylphorbol Acetate	62-65	peroxisome proliferator activator receptor delta	Mus musculus	74-82
15866483-7	2005	Increased NF-kappaB activity after palmitate exposure was associated with enhanced protein-protein interaction between PPARbeta/delta and p65.	Palmitates	35-44	peroxisome proliferator activator receptor delta	Mus musculus	119-127
15866483-8	2005	Interestingly, treatment with the PPARbeta/delta agonist L-165041 completely abolished this interaction.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	57-65	peroxisome proliferator activator receptor delta	Mus musculus	34-42
15866483-9	2005	These results indicate that palmitate may reduce fatty acid utilization in skeletal muscle cells by reducing PPARbeta/delta signaling through increased NF-kappaB activity.	Palmitates	28-37	peroxisome proliferator activator receptor delta	Mus musculus	109-117
15866483-9	2005	These results indicate that palmitate may reduce fatty acid utilization in skeletal muscle cells by reducing PPARbeta/delta signaling through increased NF-kappaB activity.	Fatty Acids	49-59	peroxisome proliferator activator receptor delta	Mus musculus	109-117
15604518-0	2005	Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1.	Cholesterol	8-19	peroxisome proliferator activator receptor delta	Mus musculus	36-45
15604518-2	2005	Activation of PPARdelta may have antiatherogenic effects through the increase of plasma HDL, theoretically promoting reverse cholesterol transport from peripheral tissues toward the liver for removal via bile and feces.	Cholesterol	125-136	peroxisome proliferator activator receptor delta	Mus musculus	14-23
15604518-6	2005	Unexpectedly, PPARdelta activation led to enhanced fecal neutral sterol loss in both groups without any changes in intestinal Abca1, Abcg5, Abcg8, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression.	Sterols	65-71	peroxisome proliferator activator receptor delta	Mus musculus	14-23
15604518-8	2005	PPARdelta activation is associated with increased plasma HDL and reduced intestinal cholesterol absorption efficiency that may be related to decreased intestinal Npc1l1 expression.	Cholesterol	84-95	peroxisome proliferator activator receptor delta	Mus musculus	0-9
15539957-5	2004	These findings implicate PPARdelta as a focal point of cross-talk between the Wnt and prostaglandin signaling pathways.	Prostaglandins	86-99	peroxisome proliferator activator receptor delta	Mus musculus	25-34
15713628-3	2005	Interestingly, PPARbeta/delta- and Akt1-deficient mice exhibit similar retardation of postnatal hair follicle morphogenesis, particularly at the hair peg stage, revealing a new important function for both factors in the growth of early hair follicles.	Polyethylene Glycols	150-153	peroxisome proliferator activator receptor delta	Mus musculus	15-23
15713628-5	2005	Subsequent PPARbeta/delta-mediated temporal activation of the antiapoptotic Akt1 pathway in vivo protects keratinocytes from hair pegs against apoptosis, which is required for normal hair follicle development.	pegs	130-134	peroxisome proliferator activator receptor delta	Mus musculus	11-19
15803109-4	2005	However, functions of PPARdelta are uncompletely known to date, but some recent data enlight its role in the regulation of fatty acid oxidation in several tissues, such as skeletal muscle and adipose tissue.	Fatty Acids	123-133	peroxisome proliferator activator receptor delta	Mus musculus	22-31
15803109-8	2005	These data strongly suggest that PPARdelta play a major role in the metabolic adaptations to western diet characterized by an excessive amount of saturated fat.	saturated fat	146-159	peroxisome proliferator activator receptor delta	Mus musculus	33-42
15001550-1	2004	We previously showed that peroxisome proliferator-activated receptor delta (PPARdelta) is crucial for embryo implantation as a receptor for cyclooxygenase-2-derived prostacyclin in mice.	Epoprostenol	165-177	peroxisome proliferator activator receptor delta	Mus musculus	26-74
15475963-0	2004	Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy.	Fatty Acids	103-113	peroxisome proliferator activator receptor delta	Mus musculus	25-73
15310864-5	2004	Similarly, a range in the trans-activation of mouse PPARbeta by phthalate monoesters was also observed, but this effect was not found with human PPARbeta.	phthalic acid	64-73	peroxisome proliferator activator receptor delta	Mus musculus	52-60
15310864-8	2004	These studies also show that mouse PPARalpha and PPARbeta are generally activated at lower concentrations of phthalate monoesters than human PPARalpha and PPARbeta, and that both mouse and human PPARgamma exhibit similar sensitivity to phthalate monoesters.	phthalic acid	109-118	peroxisome proliferator activator receptor delta	Mus musculus	49-57
15380519-3	2004	Here we report that PGE(2) indirectly transactivates PPARdelta through PI3K/Akt signaling, which promotes cell survival and intestinal adenoma formation.	Prostaglandins E	20-24	peroxisome proliferator activator receptor delta	Mus musculus	53-62
15380519-4	2004	We also found that PGE(2) treatment of Apc(min) mice dramatically increased intestinal adenoma burden, which was negated in Apc(min) mice lacking PPARdelta.	Prostaglandins E	19-22	peroxisome proliferator activator receptor delta	Mus musculus	146-155
15380519-5	2004	We demonstrate that PPARdelta is a focal point of crosstalk between the prostaglandin and Wnt signaling pathways which results in a shift from cell death to cell survival, leading to increased tumor growth.	Prostaglandins	72-85	peroxisome proliferator activator receptor delta	Mus musculus	20-29
15380519-0	2004	Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta.	Dinoprostone	0-18	peroxisome proliferator activator receptor delta	Mus musculus	89-137
15001550-1	2004	We previously showed that peroxisome proliferator-activated receptor delta (PPARdelta) is crucial for embryo implantation as a receptor for cyclooxygenase-2-derived prostacyclin in mice.	Epoprostenol	165-177	peroxisome proliferator activator receptor delta	Mus musculus	76-85
14676330-0	2003	Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome.	Fatty Acids	71-81	peroxisome proliferator activator receptor delta	Mus musculus	14-62
14758356-2	2004	Exposure of Apc(min) mice to the PPAR-delta ligand GW501516 resulted in a significant increase in the number and size of intestinal polyps.	GW 501516	51-59	peroxisome proliferator activator receptor delta	Mus musculus	33-43
14684157-0	2004	Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes.	Fatty Acids	59-69	peroxisome proliferator activator receptor delta	Mus musculus	0-48
14684157-4	2004	In this study, we tested the hypothesis that PPARdelta activates fatty acids oxidation in cardiomyocytes through transcriptional activation that are independent of PPARalpha.	Fatty Acids	65-76	peroxisome proliferator activator receptor delta	Mus musculus	45-54
14684157-6	2004	Palmitate oxidation rates were significantly increased in both neonatal and adult cardiomyocytes after treatment of a PPARdelta-selective ligand (GW0742).	Palmitates	0-9	peroxisome proliferator activator receptor delta	Mus musculus	118-127
14684157-6	2004	Palmitate oxidation rates were significantly increased in both neonatal and adult cardiomyocytes after treatment of a PPARdelta-selective ligand (GW0742).	GW0742	146-152	peroxisome proliferator activator receptor delta	Mus musculus	118-127
14684157-7	2004	Further increases of fatty acid oxidation were evident when the treatment was applied to cardiomyocytes overexpressing a wild type PPARdelta, but not a mutant PPARdelta that lacks the intact carboxyl ligand-binding domain.	Fatty Acids	21-31	peroxisome proliferator activator receptor delta	Mus musculus	131-140
14684157-11	2004	We conclude that PPARdelta may play a key role in cardiac energy balance and may serve as a "sensor" of fatty acid of other endogenous ligands in controlling fatty acids oxidation levels in the hearts under normal and pathological conditions.	Fatty Acids	104-114	peroxisome proliferator activator receptor delta	Mus musculus	17-26
14684157-11	2004	We conclude that PPARdelta may play a key role in cardiac energy balance and may serve as a "sensor" of fatty acid of other endogenous ligands in controlling fatty acids oxidation levels in the hearts under normal and pathological conditions.	Fatty Acids	158-169	peroxisome proliferator activator receptor delta	Mus musculus	17-26
15033975-3	2004	The onset of tumor formation, tumor size, and tumor multiplicity induced from a two-stage carcinogen bioassay (7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate) were significantly enhanced in PPARbeta-null mice compared with wild-type mice.	7,12-dimethylbenz[a	111-130	peroxisome proliferator activator receptor delta	Mus musculus	211-219
15033975-3	2004	The onset of tumor formation, tumor size, and tumor multiplicity induced from a two-stage carcinogen bioassay (7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate) were significantly enhanced in PPARbeta-null mice compared with wild-type mice.	Tetradecanoylphorbol Acetate	142-178	peroxisome proliferator activator receptor delta	Mus musculus	211-219
15001574-3	2004	PPARbeta-null mice maintained on either normal chow or a 10-week high fat (HF) diet, a condition that has been shown to induce insulin resistance and obesity in mice, have elevated levels of serum triglycerides primarily associated with very low density lipoprotein (VLDL) with no difference in either total cholesterol or phospholipids.	Triglycerides	197-210	peroxisome proliferator activator receptor delta	Mus musculus	0-8
15001574-3	2004	PPARbeta-null mice maintained on either normal chow or a 10-week high fat (HF) diet, a condition that has been shown to induce insulin resistance and obesity in mice, have elevated levels of serum triglycerides primarily associated with very low density lipoprotein (VLDL) with no difference in either total cholesterol or phospholipids.	Cholesterol	308-319	peroxisome proliferator activator receptor delta	Mus musculus	0-8
15001574-3	2004	PPARbeta-null mice maintained on either normal chow or a 10-week high fat (HF) diet, a condition that has been shown to induce insulin resistance and obesity in mice, have elevated levels of serum triglycerides primarily associated with very low density lipoprotein (VLDL) with no difference in either total cholesterol or phospholipids.	Phospholipids	323-336	peroxisome proliferator activator receptor delta	Mus musculus	0-8
15001574-8	2004	Together, these results indicate a clear role for PPARbeta in regulating levels of serum triglycerides in mice on a high fat Western diet by modulating both VLDL production and LPL-mediated catabolism of VLDL-triglycerides and also suggest a potential therapeutic role for PPARbeta in the improvement of serum lipids in the setting of metabolic syndrome.	Triglycerides	89-102	peroxisome proliferator activator receptor delta	Mus musculus	50-58
15001574-8	2004	Together, these results indicate a clear role for PPARbeta in regulating levels of serum triglycerides in mice on a high fat Western diet by modulating both VLDL production and LPL-mediated catabolism of VLDL-triglycerides and also suggest a potential therapeutic role for PPARbeta in the improvement of serum lipids in the setting of metabolic syndrome.	Triglycerides	89-102	peroxisome proliferator activator receptor delta	Mus musculus	273-281
15001574-8	2004	Together, these results indicate a clear role for PPARbeta in regulating levels of serum triglycerides in mice on a high fat Western diet by modulating both VLDL production and LPL-mediated catabolism of VLDL-triglycerides and also suggest a potential therapeutic role for PPARbeta in the improvement of serum lipids in the setting of metabolic syndrome.	Triglycerides	209-222	peroxisome proliferator activator receptor delta	Mus musculus	50-58
15068509-12	2004	In addition to ERs, daidzein transactivated not only peroxisome proliferator-activate receptor gamma (PPARgamma), but also PPARalpha and PPARdelta at micromolar concentrations.	daidzein	20-28	peroxisome proliferator activator receptor delta	Mus musculus	137-146
15102088-4	2004	This study demonstrated that topical treatment of mice with a selective PPAR-beta/delta agonist (GW1514) in vivo had pro-differentiating effects, was anti-inflammatory, improved barrier homeostasis, and stimulated differentiation in a disease model of epidermal hyperproliferation [corrected].	gw1514	97-103	peroxisome proliferator activator receptor delta	Mus musculus	72-81
15102088-7	2004	Furthermore, in vitro PPAR-beta/delta activation, aside from stimulating differentiation-related genes, additionally induced adipose differentiation-related protein (ADRP) and fasting induced adipose factor (FIAF) mRNA in cultures keratinocytes, which was paralleled by increased oil red O staining indicative of lipid accumulation, the bulk of which were triglycerides (TG).	oil red O	280-289	peroxisome proliferator activator receptor delta	Mus musculus	22-31
15102088-7	2004	Furthermore, in vitro PPAR-beta/delta activation, aside from stimulating differentiation-related genes, additionally induced adipose differentiation-related protein (ADRP) and fasting induced adipose factor (FIAF) mRNA in cultures keratinocytes, which was paralleled by increased oil red O staining indicative of lipid accumulation, the bulk of which were triglycerides (TG).	Triglycerides	356-369	peroxisome proliferator activator receptor delta	Mus musculus	22-31
15102088-7	2004	Furthermore, in vitro PPAR-beta/delta activation, aside from stimulating differentiation-related genes, additionally induced adipose differentiation-related protein (ADRP) and fasting induced adipose factor (FIAF) mRNA in cultures keratinocytes, which was paralleled by increased oil red O staining indicative of lipid accumulation, the bulk of which were triglycerides (TG).	Triglycerides	371-373	peroxisome proliferator activator receptor delta	Mus musculus	22-31
15102088-9	2004	Together, these studies indicate that PPAR-beta/delta activation stimulates keratinocyte differentiation, is anti-inflammatory, improves barrier homeostasis, and stimulates TG accumulation in keratinocytes.	Triglycerides	173-175	peroxisome proliferator activator receptor delta	Mus musculus	38-47
14676330-2	2003	Analysis of rat L6 myotubes treated with the PPARdelta subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARdelta controls fatty acid oxidation by regulating genes involved in fatty acid transport, beta-oxidation, and mitochondrial respiration.	GW 501516	82-90	peroxisome proliferator activator receptor delta	Mus musculus	45-54
14676330-2	2003	Analysis of rat L6 myotubes treated with the PPARdelta subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARdelta controls fatty acid oxidation by regulating genes involved in fatty acid transport, beta-oxidation, and mitochondrial respiration.	GW 501516	82-90	peroxisome proliferator activator receptor delta	Mus musculus	152-161
14676330-2	2003	Analysis of rat L6 myotubes treated with the PPARdelta subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARdelta controls fatty acid oxidation by regulating genes involved in fatty acid transport, beta-oxidation, and mitochondrial respiration.	Oligonucleotides	110-125	peroxisome proliferator activator receptor delta	Mus musculus	45-54
14676330-2	2003	Analysis of rat L6 myotubes treated with the PPARdelta subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARdelta controls fatty acid oxidation by regulating genes involved in fatty acid transport, beta-oxidation, and mitochondrial respiration.	Oligonucleotides	110-125	peroxisome proliferator activator receptor delta	Mus musculus	152-161
14676330-2	2003	Analysis of rat L6 myotubes treated with the PPARdelta subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARdelta controls fatty acid oxidation by regulating genes involved in fatty acid transport, beta-oxidation, and mitochondrial respiration.	Fatty Acids	171-181	peroxisome proliferator activator receptor delta	Mus musculus	45-54
14676330-2	2003	Analysis of rat L6 myotubes treated with the PPARdelta subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARdelta controls fatty acid oxidation by regulating genes involved in fatty acid transport, beta-oxidation, and mitochondrial respiration.	Fatty Acids	171-181	peroxisome proliferator activator receptor delta	Mus musculus	152-161
14676330-2	2003	Analysis of rat L6 myotubes treated with the PPARdelta subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARdelta controls fatty acid oxidation by regulating genes involved in fatty acid transport, beta-oxidation, and mitochondrial respiration.	Fatty Acids	224-234	peroxisome proliferator activator receptor delta	Mus musculus	45-54
14676330-2	2003	Analysis of rat L6 myotubes treated with the PPARdelta subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARdelta controls fatty acid oxidation by regulating genes involved in fatty acid transport, beta-oxidation, and mitochondrial respiration.	Fatty Acids	224-234	peroxisome proliferator activator receptor delta	Mus musculus	152-161
14676330-3	2003	Similar PPARdelta-mediated gene activation was observed in the skeletal muscle of GW501516-treated mice.	GW 501516	82-90	peroxisome proliferator activator receptor delta	Mus musculus	8-17
14676330-7	2003	These data suggest that PPARdelta is pivotal to control the program for fatty acid oxidation in the skeletal muscle, thereby ameliorating obesity and insulin resistance through its activation in obese animals.	Fatty Acids	72-82	peroxisome proliferator activator receptor delta	Mus musculus	24-33
14670086-9	2003	CONCLUSIONS: These data collectively demonstrate that PPARdelta plays a fundamental role in mediating a subset of cellular effects of phorbol ester and supports observations from mouse knockout models that PPARdelta is involved in macrophage-mediated inflammatory responses.	Phorbol Esters	134-147	peroxisome proliferator activator receptor delta	Mus musculus	54-63
14670086-9	2003	CONCLUSIONS: These data collectively demonstrate that PPARdelta plays a fundamental role in mediating a subset of cellular effects of phorbol ester and supports observations from mouse knockout models that PPARdelta is involved in macrophage-mediated inflammatory responses.	Phorbol Esters	134-147	peroxisome proliferator activator receptor delta	Mus musculus	206-215
14677574-2	2003	Investigators found that PPAR(delta) activation by such transfer leads to up-regulation of energy expenditure by fatty acid oxidation.	Fatty Acids	113-123	peroxisome proliferator activator receptor delta	Mus musculus	25-36
14677574-3	2003	PPAR(delta) activation also results in lowered serum triglyceride and free fatty acid levels and decreased lipid accumulation.	Triglycerides	53-65	peroxisome proliferator activator receptor delta	Mus musculus	0-11
14677574-3	2003	PPAR(delta) activation also results in lowered serum triglyceride and free fatty acid levels and decreased lipid accumulation.	Fatty Acids, Nonesterified	70-85	peroxisome proliferator activator receptor delta	Mus musculus	0-11
14677574-4	2003	In vivo activation of PPAR(delta) in adipose tissue protects against obesity and fatty liver in mice fed a high-calorie diet.	calorie	112-119	peroxisome proliferator activator receptor delta	Mus musculus	22-33